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ABSTRACT
The spread of Burkholderia cepacia within the cystic fibrosis (CF) population has
become a major cause of concern for patients and their carers and represents a significant
medical and scientific challenge. B. cepacia was originally believed to be an
environmentally ubiquitous organism and of little importance as a human pathogen and
therefore our knowledge of the pathogenic potential of this organism is limited. This
thesis considers biological properties and potential virulence factors of B. cepacia that
may be important in pulmonary colonisation and the immune response in CF patients.
The studies have focused on a highly transmissible, epidemic strain of B. cepacia isolated
in Edinburgh in 1989 and subsequently responsible for colonisation of CF patients in
other regional CF centres.
Prior to this study, environmental B. cepacia in culture collections often comprised
strains that may have originated as contaminants from colonised patients. To obtain 'true'
environmental strains for comparative studies and to test for the ubiquity of B. cepacia an
environmental survey was undertaken. B. cepacia was cultured from a minority of sites
and further characterisation of the isolates revealed them to be distinct from CF strains
suggesting that environmental strains do not pose a major risk to CF patients.
Representative strains of B. cepacia were investigated for biological properties, in
particular expression of cell-associated and extracellular virulence factors. The ability to
survive in unfavourable environments, including antiseptics was also examined. The
epidemic strain was distinct from the majority of B. cepacia strains in several aspects
including the production of melanin, expression of R-LPS and poor motility.
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Culture of B. cepacia from the oral cavity and saliva of colonised CF patients suggested
that the upper respiratory tract may act as a reservoir, both preceding colonisation of the
lower respiratory tract and also contributing to the transmissibility of this strain.
Comparative studies of the ability of clinical and environmental isolates of B. cepacia to
adhere to buccal epithelial cells and respiratory mucin performed by fluorescent labelling,
flow cytometry and ELISA showed that the most pronounced binding was observed with
the epidemic strain.
The humoral immune response in CF patients colonised with B. cepacia was investigated
by ELISA, incorporating B. cepacia R-LPS, and immunoblotting against LPS, flagella
and outer membrane antigens. Elevated levels of specific anti-fi. cepacia IgG, IgA and
IgM were observed in serum from CF patients chronically colonised by B. cepacia,
especially in those patients colonised by the epidemic strain. The detection of anti-5.
cepacia antibodies prior to laboratory isolation of B. cepacia in some patients may aid in
the early diagnosis of B. cepacia colonisation. Concentrations of one or more IgG
subclasses were raised in CF patients, with substantial individual variation. Following
chronic colonisation by B. cepacia, the specific anti-5. cepacia-R-LPS antibody response
comprised mainly IgG2 and IgG3. Chemiluminescent opsonophagocytosis assays
indicated that CF sera may non-specifically inhibit phagocytosis of B. cepacia.
Resistance of B. cepacia to the bactericidal activity of normal human serum appeared to
be determined by the expression of S-LPS, in particular a full O-side chain. The epidemic
strain, which expresses R-LPS was serum sensitive; paradoxically, this strain is associated
with bacteraemia in CF patients.
x
The relevance and significance of these results to the understanding of the pathogenesis,
transmissibility and management of B. cepacia in CF patients is discussed
xi
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Cystic fibrosis (CF) was first described as a clinical entity in 1938 as "Fibrocystic
disease of the Pancreas" (Anderson, 1938), although descriptions of similar clinical
syndromes in children can be found in earlier literature. In the 1940's and 1950's, the
term mucoviscidosis was applied to CF following descriptions of thick, sticky
intestinal secretions (Farber, 1945). At that time few patients survived beyond infancy
but advances in the management of CF have increased the present median survival age
to 30 years (Shale, 1991). Today, CF is the most common lethal autosomal recessive
genetic disease amongst Caucasian populations with an incidence of 1 in 2000 live
births and a carrier frequency of around 1 in 22. World-wide there are 50,000 CF
patients, in the UK 2 million people are carriers of the CF gene and there are currently
approximately 6000 CF patients.
1.1.2 Clinical Features
CF presents with a broad spectrum of symptoms primarily affecting the lungs and
gastrointestinal tract (GIT) with variable clinical severity (Boat et al., 1989). Clinical
features commonly present in infancy, though detection may be considerably delayed
in cases where symptoms are relatively mild (Hunt & Geddes, 1985; Dibble &
Savedra, 1988). Defective chloride ion transport across affected epithelia is the
hallmark of the disease accompanied by accumulation of dehydrated mucus resulting
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in blockage of exocrine glands affecting most of the body's major organ systems.
Symptoms related to the GIT include meconium ileus, or obstruction of the bowel in
the new-born with inspissated meconium, which occurs in 5-10% of CF cases. In the
adult bowel, obstruction (meconium ileus equivalent) may be due to incompletely
digested contents. Pancreatic insufficiency is present in most CF patients from birth,
although 10-15% of CF patients have some residual pancreatic function (Kubesch et
al., 1993). The absence of pancreatic secretions is a consequence of obstruction of
the pancreatic ducts with inspissated mucus leading to acinar cell degradation and
fibrosis of the pancreas. The resulting lack of pancreatic digestive enzymes and the
formation of fibrotic cysts leads to a variety of disorders including malabsorption,
steatorrhoea, diabetes mellitus and a general failure to thrive. Similarly, blockage of
the hepatic ducts may lead to cirrhosis of the liver. Reproductive potential in male CF
patients is greatly reduced; Wolffian duct structure is altered in up to 95% of patients,
with vas deferens, epidydimis and seminal vesicles being atrophic, fibrotic or absent
(Taussig et al., 1972). In contrast, fertility in CF females is virtually normal although
thickened cervical mucus and poor health may delay conception; in one study 75% of
CF pregnancies were completed (Cohen et al., 1980). The most important symptom
and the principle cause of premature mortality in CF patients is pulmonary failure
following chronic lung infection due to a range of opportunistic pathogens.
Overproduction of abnormally viscid, dehydrated tracheobronchial mucus results in
impaired mucociliary clearance and chronic bacterial colonisation of the major
airways. The ensuing cycle of pulmonary inflammation, infection, and mucus
hypersecretion causes irreversible lung injury (Boat et al., 1989).
Diagnosis of CF is often indicated by the symptoms and confirmed by the pilocarpine-
stimulated sweat test (Gibson & Cooke 1959), which relies on the fact that levels of
sodium and chloride in the sweat of children with CF are usually abnormally high (>60
meq/L). In the 1-2% of cases where sweat chloride levels are not elevated, or in
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neonates where it is difficult to obtain sufficient quantities of sweat, additional
diagnostic approaches are now available, for example the immunoreactive trypsin test
and most recently the direct identification of a mutant CF gene.
In the 1940's and 1950's CF patients seldom survived infancy. The increased life
expectancy of today's CF patients is attributable to multiple factors; improved and
earlier diagnosis, the development of more potent antibiotics and enzyme
supplements, advances in surgical procedures and greater attention to the importance
of physiotherapy and regular clinical check-ups. Recent advances in our
understanding of the basic defect in CF has also led to the development of new
therapeutic strategies including amiloride treatment which blocks sodium ion channels
resulting in improved mucociliary clearance, steroids to treat inflammation,
antiproteinases to combat the destructive potential of both host and bacterial enzymes
and DNAse treatment which reduces the viscosity of CF tracheobronchial secretions.
Achieving increased longevity is not without a price however and in recent years a
range of formidable longer term problems for CF patients has become evident,
including profound changes in the homeostasis of the immune response and an array
of new immunological syndromes.
1.1.3 The Cystic Fibrosis Gene - Discovery to Gene Therapy
In 1985, localisation of the CF gene on the long arm of chromosome 7 was
determined by linkage analysis using the polymorphic markers met and D7S8 (White
et al., 1985). Four years of intensive collaborative research followed, utilising novel
cloning strategies including chromosome walking and jumping, and complementary
DNA hybridisation, and in 1989 the CF gene, comprising 250 kb of DNA, was
identified (Riordan et al., 1989; Rommens et al., 1989). Confirmation that this was
indeed the CF gene was demonstrated by the fact that the mutant forms of the gene
were present in patients with CF but not in normal individuals and that expression of a
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6.5 kb mRNA transcript was higher in tissues severely affected in CF including the
lungs and pancreas (Riordan et al., 1989). Further genetic analysis indicated that a
single mutation, a three base pair (phenylalanine) deletion at position 508 of the
proposed protein (the AF508 mutation), was present in approximately 70% of CF
chromosomes (Kerem et al., 1989). Following the identification of the CF gene, the
Cystic Fibrosis Genetic Analysis Consortium consisting of 90 laboratories in 26
countries was formed to accumulate and collate information on the identification and
nature of CF mutations. To date, nearly 300 additional mutations have been
described and include mis-sense, non-sense, frame-shift and splice-site mutations
(Tsui, 1992). The predominance of a particular mutation is population dependant; for
example, the frequency of the AF508 mutation is 90% in Denmark (CF Genetic
Analysis Consortium, 1990) but only 46.2% in Southern Europe (Estivill et al., 1989).
Cloning of the CF gene represented a milestone in molecular genetics and presented
the possibility of new approaches to determine the nature of genetic diseases and
improve treatment. For CF patients the benefits of characterising the CF gene are
already apparent.
Diagnosis and Screening
At the diagnostic level, there is potential to confirm the diagnosis of CF in doubtful
cases by identification of the CF mutation within the patient's cells (Scambler, 1989).
Pilot population screening programmes, using polymerase chain reaction (PCR) for
both prenatal or neonatal diagnosis and heterozygote screening have proved
successful and welcome if accompanied by the appropriate counselling. Due to the
large number of mutations 100% detection is impossible at present, but it is possible
to look for the most common mutations in the local population and to identify up to
85% of theCF mutations (Shrimpton et al., 1991; Burn et al., 1992).
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Correlation of Genotype with Phenotvpe
Attempts to correlate the CF genotype with clinical phenotype are complicated by a
number of factors including the large number of mutations, environmental influences
and genetic factors outside the CF locus (Kerem et al., 1989; Kerem et al., 1990).
However, an association between CF patients homozygous for AF508 and earlier
diagnosis of CF, meconium ileus, pancreatic insufficiency and even chronic
Pseudomonas aeruginosa infection is reported (Johansen et al., 1991; Kubesch et al.,
1993; Rosenstein, 1994).
Animal Models
The simultaneous development of a transgenic CF mouse in North Carolina,
Cambridge, Edinburgh and Texas has facilitated both studies of the clinical pathology
associated with CF and the testing of novel therapies (Higgins & Trezise, 1992;
Wilson & Collins, 1992). The Edinburgh CF mice, developed by targeted insertional
mutagenesis (Porteous & Dorin, 1990; Dorin et al., 1992; Porteous, 1993), differ
from the other models in that the mutation is not a null mutation and some residual
low level function of native cystic fibrosis transmembrane conductance regulator
(CFTR) is present. As a result the Edinburgh mice survive longer and display several
key features of CF: male infertility, gut blockage and importantly lung disease.
Furthermore these mice have an intrinsic reduction in mucociliary clearance and a
decreased ability to clear pathogens (Davidson et al., 1994). In addition the model
mice have successfully been used to establish optimum conditions for gene therapy;
for example, the influence of liposome properties on the delivery of the gene construct
(McLachlan et al., 1994).
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Gene Therapy
The aim of gene therapy is to introduce the normal CF gene into the lungs of patients
by means of a vector which may be of viral or synthetic origin. At present,
researchers in the USA appear to favour the adenovirus approach, however, this may
be associated with adverse inflammatory responses. Trials using an adenovirus vector
have been performed on six CF patients over the last 12-13 months in the US
(Crystal, 1994). Gene transfer was evident in all patients, and no chronic adverse
effects have been noted although one patient experienced a mild inflammatory
reaction. In late 1993, the first of two separate UK trials using a liposome vector
began on CF patient volunteers in the Brompton Hospital in London. Preliminary
results of the Phase 1 trials are encouraging; liposome mediated gene transfer was
shown to be safe and some correction of chloride and sodium ion transport was
observed. It is likely, however, that the efficiency of delivery via liposome vectors
will need to be improved (Caplan et al., 1994).
1.1.4 Function of the CF Gene and the Cellular Defect in Cystic
Fibrosis
Cloning of the CF gene enabled the primary amino acid sequence to be predicted
together with a proposal for a potential structure and function of the gene product.
The protein, designated Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR), consists of 1480 amino acids with a predicted molecular weight of 168 kDa
(Riordan et al., 1989). Comparing amino acid sequences of CFTR with a protein
database showed sequence homology and a shared overall structural scheme with the
ABC super-family of transporters, which includes the multidrug resistance (MDR) P-
glycoprotein and several bacterial periplasmic permeases (Hyde et al., 1990). CFTR
is predicted to consist of five domains: two repeats of a membrane spanning domain
each composed of 6 transmembrane segments with external carbohydrate regions; and
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two nucleotide binding domains separated by a polar regulatory domain (R) which
contains multiple phosphorylation sites (Anderson et al., 1991).
Elucidation of the structure of CFTR led to speculation as to the normal function of
the protein and how mutations in the CF gene caused dysfunction. Early observations
of increased sodium and chloride ion concentrations in sweat (Di1 Sant Agnese, 1953),
had implied a defect in ion transport in epithelial cells affected by CF. Low
permeability of sweat glands to chloride ions resulting in poor sodium and chloride
ion reabsorption was reported to account for the saltiness of CF sweat (Quinton,
1990). Studies on chloride channels of the epithelial cells of airway, sweat glands and
pancreatic tissue showed that chloride secretion in response to cAMP was impaired in
CF (Welsh, 1990). Following cloning of the CF gene, transfection of cDNA into CF
airway and pancreatic epithelial cells was shown to correct the defect in cAMP
regulated chloride impermeability (Rich et al., 1990). At this time there was some
debate as to whether CFTR was a chloride channel or a regulator of chloride
channels. Evidence that CFTR was a chloride channel followed expression of CFTR
in heterologous cell types: in each case a unique chloride current was generated that
was activated by cAMP agonists (Anderson et al., 1991). Further studies in which
CFTR was purified and reconstituted into lipid bilayers confirmed that CFTR was the
chloride channel (Bear et al., 1992). How mutations in CFTR may alter protein
function has recently been addressed by Welsh and Smith (1993). Four mechanisms
have been proposed: Class 1 representing defective protein production; Class 2, e.g.
the common AF508 mutation, is associated with defective processing; Class 3
defective regulation, and Class 4, defective conduction. A relationship between the
genotype, biochemical dysfunction and clinical phenotype can be identified in some
CF patients (Welsh & Smith, 1993).
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Antibody studies and in situ hybridisation have indicated that expression of CFTR on
the apical surface of epithelial cells is consistent with clinical pathologies (Gregory et
al., 1990; Denning et al., 1992), although the level of expression in lung epithelial
cells, the site of most severe symptoms, was unexpectedly low. In spite of this
apparent paucity of expression recent reports suggest that the CFTR dysfunction in
pulmonary epithelial cells can be correlated with Pseud.omon.as aeruginosa infection
(Barasch et al., 1991). CF epithelial cells bind approximately twice as many P.
aeruginosa as do cells from normal subjects due to an increase in the proportion of
glycolipids lacking sialylation resulting from defective acidification in the trans-Golgi
caused by mutations in CFTR.
1.1.5 Pulmonary Infection in Patients with Cystic Fibrosis
Pulmonary dysfunction, primarily as a result of chronic airways infection, is
responsible for more than 90% of mortality in CF (Shale, 1991). At birth the lungs
are structurally normal but pathological changes occur within the first few months of
life (Bedrossian et al., 1976). The primary pathogenic event is dilation of the acinar
and duct lumens in submucosal glands followed by opportunistic infection and mucus
hypersecretion. Hypertrophy of bronchial glands, goblet cell hyperplasia and
squamous cell metaplasia further contribute to impaired mucociliary clearance. The
outcome is a destructive cycle of obstruction, infection and inflammatory-mediated
tissue damage, characterised by recurrent acute exacerbations with extensive
bronchiectasis. Pulmonary function progressively declines with each exacerbation and
with advancing lung disease, ventilation perfusion imbalance leads to hypoxia, cor
pulmonale and ultimately death (Hodson & Warner, 1992).
Microbial infection in CF typically remains localised in the lung, confined to the
conducting airways rather than the lung parenchyma. Systemic infection is rare,
suggesting that only local immune defences are defective, although the slow,
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inexorable progress of lung disease indicates that local defences are able to maintain a
quasi-stable homeostasis in the early stages of disease. The various aspects of local
respiratory defences, both non-specific defences such as the cough reflex and
mucociliary clearance and specific immunity are ineffective once pulmonary infection
is established, and eradication of infecting organisms is virtually impossible.
Pulmonary infection in CF patients is characterised by a limited spectrum of
pathogens. Chronic bacterial colonisation, notably by Staphylococcus aureus,
Haemophilus influenzae and P. aeruginosa, is most commonly associated with
episodes of acute pulmonary exacerbation and deterioration in lung function although
the role of common respiratory viruses, chlamydia, mycoplasma and fungi in
contributing to worsening pulmonary status should not be underestimated (Efthimiou
et al., 1984; Friend, 1986; Govan & Nelson, 1992a and b). A negative aspect of the
improved life expectancy for CF patients is the evolution of this spectrum to include
previously uncommon bacterial opportunists, in particular mycobacterial species and
Burkholderia (aka. Pseudomonas) cepacia. Susceptibility of CF patients to
colonisation by individual pathogens appears to be age-related. Generally S. aureus
colonisation occurs in early infancy, followed by H. influenzae which tends to be
replaced by P. aeruginosa (Iacocca et al., 1963; Mearns et al., 1972; Govan &
Nelson, 1992a and b).
The predominant role of S. aureus was first recognised in 1946 in a microbiological
study of post-mortem lung tissue from 14 CF infants aged 1-40 months. The fact that
in the pre-antibiotic era S. aureus was the major cause of mortality in CF infants was
emphasised by the culture of the organism from 12 of these lungs (Di' Sant Agnese &
Anderson, 1946). S. aureus produces a number of virulence factors, comprising
adhesins, immuno-evasive mechanisms and toxins although a precise role for any of
these putative virulence factors in lung damage has not been defined. There is little
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doubt, however, that the organism is an important cause of respiratory distress and
progressive lung damage during the life of a CF patient. Effective anti-staphylococcal
therapy has been available since the 1950's. The sequential nature of bacterial
colonisation in CF led to the hypothesis that S. aureus 'primed' the lung for
subsequent colonisation by H. influenzae and P. aeruginosa and in some CF centres,
prophylactic therapy was instituted upon diagnosis of CF with the hope of providing
prolonged protection. However, this stratagem has been the subject of some
controversy and retrospective studies have indicated an association between anti-
staphylococcal prophylaxis and increased incidence of H. influenzae, P. aeruginosa
and a poorer prognosis (Bauernfeind et ai, 1987; Kulczycki et ai, 1988).
The role of non-capsulate, non-typable H. influenzae in respiratory exacerbations is
probably underestimated, due to difficulties in laboratory culture of this fastidious
organism in the presence of other organisms and distinguishing colonisation from
infection with this respiratory commensal. In CF children, however, high
concentrations of the inflammatory marker C-reactive protein were associated with H.
influenzae exacerbations (Govan & Glass, 1990).
Both S. aureus and H. influenzae can be effectively treated by antibiotics. In contrast
P. aeruginosa, despite significant increases in the potency of anti-pseudomonal
antibiotics, is highly resistant to antibiotic therapy and once established is seldom, if
ever, eradicated (Govan et al., 1987). P. aeruginosa is the major bacterial pathogen
in lung disease in CF adolescents and adults and the most common cause of morbidity
and mortality. By the 1980's colonisation with P. aeruginosa and the subsequent
progression to the mucoid alginate-producing phenotype was associated with a poor
prognosis and regarded as a 'harbinger of death' (Pier, 1985). P. aeruginosa is widely
recognised as an opportunist pathogen par excellence, and an impressive array of
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virulence factors have been well described (Gilligan, 1991; Govan & Nelson, 1992a
and b).
The emergence of new opportunistic pathogens during the 1980's in CF centres both
in North America and the UK has been a major concern amongst the CF population
and their carers, and has prompted clinicians to take unprecedented actions. Current
concern is due to three major features associated with colonisation of patients with
CF by B. cepacia: (1) many clinical strains of B. cepacia are highly resistant to
currently available antimicrobials and even those showing in vitro susceptibility are
often clinically intractable; (2) recently some strains of B. cepacia have been shown to
be readily transmissible (Govan et al., 1993); and (3) approximately 20% of CF
patients unexpectedly succumb to an accelerated fatal decline in pulmonary function
with necrotising pneumonia and bacteraemia, known as "Cepacia Syndrome"(Isles et
al., 1984).
1.1.6 Immune Defence in Cystic Fibrosis Patients
There is little evidence to suggest that a generalised primary immune defect exists in
CF although certain consistent aberrations, likely to be secondary effects of chronic
infection, drug therapy and malnutrition are observed. Infection in CF rarely spreads
to extra-pulmonary sites indicating that systemic immunity is intact. In the CF lung a
combination of local host and bacterial factors enables opportunistic pathogens to
become established.
Anatomical and Mechanical Protection
The aerodynamic design of the upper airways deflects aerosolised particles to impact
with the mucosa where they may be removed by effective mucociliary clearance and
the cough reflex (Reynolds, 1989). The normal barrier function of the mucus blanket
prevents microbial penetration to the underlying epithelia and enhances shedding of
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offending particles via mucociliary clearance (Piedra & Ogra, 1986). Mucus
retention, however, is characteristic of CF airways and may exert a deleterious role by
protecting bacteria from other airway defence mechanisms (Lamblin & Roussel,
1993). Impaired retention and clearance is thought to be due to the inspissated and
copious nature of CF mucus as studies to date suggest that cilia morphology and beat
frequency are normal (Katz & Holsclaw, 1980; Rutland & Cole, 1981).
Non-Specific Defences
Potential pathogens which manage to bypass mucociliary clearance and reach the
lower airways encounter a second line of defence - non-specific phagocytosis by
pulmonary macrophages, the primary effector cell in the lung. Multiple roles of the
pulmonary macrophage include induction and regulation of cellular and humoral
immunity. Colonising microorganisms must also be able to establish themselves in the
presence of an array of non-specific protective factors including lysozyme, anti-
proteinases, iron chelating proteins (transferrin and lactoferrin) and the anti-bacterial
activity of lung surfactant.
Humoral Immunity
Once chronic pulmonary colonisation is established total circulating levels of
immunoglobulin G (IgG), IgA and IgM become significantly raised in CF individuals.
Paediatric studies have indicated that hypogammaglobulinaemia is associated with less
severe disease (Matthews et al., 1980; Wheeler et al., 1984); similarly in adult CF
patients high levels of IgG are associated with poor clinical condition and prognosis
(Warner, 1992). In the terminal phases of disease, IgG2 becomes the major IgG
subclass in serum and lungs. CF patients also mount a specific antibody response
against a range of bacterial pathogens; patients with the highest levels of serum
precipitins and/or individuals in which the antibody levels rise rapidly have the worst
prognosis (Hpiby et al., 1977; Baltimore et al., 1986). Phagocytosis in CF patients
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was thought to be defective following observations that CF serum inhibited
phagocytosis of P. aeruginosa by human and rabbit macrophages (Thomassen et al.,
1979). More recent observations of the nature of the IgG subclass response imply
that the defect is in fact opsonic rather than cellular. Defective opsonisation may be
attributed to a number of factors: (1) the predominance of IgG2 which may inhibit
opsonic mediated clearance as pulmonary macrophages only express receptors for
IgGl and IgG3 (Fick et al., 1986); (2) proteolytic cleavage of IgG by neutrophil and
bacterial elastases (Bainbridge & Fick, 1989); and (3) competitive inhibition for
macrophages and neutrophils by circulating immune complexes (CIC). CF sputa are
reported to contain a high proportion of free secretory component, suggesting
defective secretion or assembly of IgA (Wallwork & McFarlane, 1976), which may
explain why levels of IgG are often higher than levels of IgA in respiratory tract
secretions (Fick et al., 1984). However, organisms recovered from the lungs of CF
patients are often coated with IgA which may further inhibit clearance as IgA does not
activate complement and is a poor opsonin (Piedra & Ogra, 1986). A number of
studies have identified CIC in CF serum, sputum and also deposited in tissues of
patients chronically colonised by P. aeruginosa. Although high levels of CIC are
associated with an aggressive humoral response to P. aeruginosa and decreased
survival prospects a precise pathogenic role remains to be established (Lagace et al.,
1989; Warner, 1992).
Cellular Response and Inflammation
In CF patients the numbers of B and T lymphocytes and their ability to proliferate is
normal (Warner 1992), although lymphocyte hyporeactivity specifically to P.
aeruginosa as a result of antigen overload may be observed with increasing severity of
pulmonary disease (Sorensen et al., 1979). Polymorphonuclear leukocytes (PMN)
and alveolar macrophages are present in huge numbers in CF lungs and sputum. No
consistent abnormality in the levels of serum complement components are reported
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(Speert, 1985). CF bronchopulmonary secretions are rich in inflammatory exudate
and would be expected to contain complement. Several cytokine classes have been
measured in CF sputum and serum. Tumour necrosis factor-a (TNFa), produced by
macrophages and monocytes in response to lipopolysaccharide (LPS) is considerably
increased in CF (Norman et al., 1991), contributing to the inflammatory process by
activating neutrophils and causing lung damage and weight loss (Greally et al., 1993).
Interleukin 1 (IL-1) levels are raised in CF but there is no correlation with clinical
condition, whilst IL-2 levels are raised even prior to the isolation of organisms
(Warner, 1992). IL-8, a potent neutrophil chemoattractant produced in response to
LPS, TNFa and IL-1 is greatly increased in CF patients and correlates well with
disease severity (Assadullahi et al., 1992; Massion et al., 1994).
Continuous antigenic stimulation as a result of persistent microbial infection leads to a
chronically over-active immune response and considerable immune-mediated damage
to the CF lung as illustrated in Figure 1 (Sordelli et al., 1988; Auerbach, 1988; Elborn
& Shale, 1990; Winnie & Cowan, 1991; Warner, 1992;). It is proposed that activated
T-helper lymphocytes produce IL-2 and IL-2 receptor which causes T-lymphocyte
proliferation and cytokine production. IL-2,3,4,5 and 6 promote B lymphocyte
transformation to plasma cells resulting in generation of antibodies.
Chemoattractants, IL-3,4,5,6 and 8 in combination with C5a and leukotriene A4
cause massive influx of PMN which release oxygen radicals as well as lysosomal and
proteolytic enzymes. Lung damage occurs as PMN products are released by cells
ineffectively attempting to engulf P. aeruginosa microcolonies (frustrated
phagocytosis; Govan & Glass, 1990) and protease inhibitors such as a1-antitrypsin
are overwhelmed by sheer volume and are also broken down by bacterial proteases
(Suter et al., 1989).
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The host - pathogen interaction is a continually evolving process, in CF it would
appear that the pathogens have the upper hand; particularly P. aeruginosa which also
possesses an arsenal of immuno-evasive and modulatory mechanisms (Speert, 1985;
Buret & Cripps, 1993).
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1.2.1 Taxonomy and Nomenclature
The genus Pseudomonas includes a heterologous collection of organisms, some of
doubtful taxonomic status, which are widely distributed in nature as saprophytes or as
commensals and pathogens for man, animals and plants. In 1992 the transfer of the
seven species, P. cepacia, P. mallei, P. pseudomallei, P. caryophylli, P. gladioli, P.
pickettii, and P. solanacearum. of the Pseudomonas rRNA homology group II, to the
new genus Burkholderia was proposed with B. cepacia as the type species (Yabuuchi
etal., 1992; List No. 45, 1993).
B. cepacia (Latin fern. n. caepa, onion) was first described in 1950 as a
phytopathogen causing soft rot in onions (Burkholder, 1950). The organism was later
referred to as Eugonic Oxidiser 1, P. kingii, and P. multivorans (Stanier et al., 1966;
Gilardi, 1970; Jonsson, 1970) before the name P. cepacia was revived in 1981
(Palleroni & Holmes, 1981). The previous nomenclature and also the association with
CF may imply that B. cepacia is closely related to P. aeruginosa-, however, the two
organisms are very different and the renaming emphasises this fact. For the purpose
of this thesis the organism will be referred to as B. cepacia.
1.2.2 General Characteristics
B. cepacia is an aerobic, Gram-negative, non-fermentative bacillus (Palleroni, 1984).
The organism is typically catalase and oxidase positive, although the latter reaction
may take some minutes to develop (Mrs C. Doherty, personal communication).
Yellow or green pigments, and in some cases the brown pigment melanin, are
produced but not fluorescent pigments. Peritrichous fimbriae or pili may be present
and the organism is motile by means of multiple polar flagella. B. cepacia will grow
at 41°C but not at 4°C, and does not survive for sustained periods on agar slopes in
17
refrigerators (Ballard et al., 1970; Palleroni, 1984). Poly-f3-hydroxybutyrate is
accumulated as a reserve material (Morris & Roberts, 1959).
B. cepacia is remarkable in its exceptional nutritional versatility, hence the earlier
name P. multivorans or 'eater of everything'. Most strains are able to utilise a
substantially larger number of organic compounds, including penicillin G, as sole
carbon and energy sources than any of the fluorescent pseudomonads (Stanier et al.,
1966; Beckman & Lessie, 1979). The natural habitat of B. cepacia is reported to be
soil, water, sewage and vegetation (Ballard et al., 1970; Carson et al., 1973) but,
despite being frequently described as ubiquitous, B. cepacia is in fact relatively
difficult to isolate from the environment (Fisher et al., 1993; J. Govan, unpublished
observations). Given that it possesses such extraordinary nutritional capability it is
surprising that B. cepacia does not predominate in habitats such as soil, where it is
often outgrown by fluorescent pseudomonads (Palleroni, 1984). In common with P.
aeruginosa, B. cepacia has successfully adapted to survival within the hospital
environment. Reservoirs of B. cepacia are commonly moist surfaces or water-based
solutions; contamination of disinfectant solutions may occur intrinsically at time of
manufacture or extrinsically at the user site (Holmes, 1986; Martone et al., 1987).
1.2.3 Clinical Infections
B. cepacia is an opportunist pathogen and does not generally pose a threat to healthy
individuals with an intact immune system, requiring impaired host defences or an
unusually large inoculum to initiate infection (Sobel et al., 1982). B. cepacia is
increasingly recognised as an important cause of nosocomial infection and, given
appropriate conditions, can colonise and infect human soft tissue, respiratory tract,
urinary tract and cause nosocomial bacteraemia which may lead to endocarditis or
septic shock (Basset et al., 1970; Rapkin, 1976; Sobel et al., 1982; Pegues et al.,
1993). Generally epidemic infections of B. cepacia involve the bloodstream and
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urinary tract; in contrast, endemic infection primarily involves the lower respiratory
tract (Jarvis et al., 1987). In the majority of cases, this behaviour may be attributed to
the ability of B. cepacia to contaminate and grow in water supplies and commonly
used hospital antiseptics associated with the minimal growth requirements of B.
cepacia. Several reports indicate that antiseptics such as Povidone-Iodine and
Resiguard are bactericidal against B. cepacia if used at sufficiently high
concentrations or if the contaminating inoculum is small (Berklemman et al, 1981;
Craven et al., 1981; Levey & Guiness, 1981).
Children with chronic granulomatous disease (CGD) appear to be particularly
susceptible to B. cepacia pulmonary infection and to a lesser extent septicaemia
(Bottone et al., 1975, O'Neil et al., 1986; Lacy et al., 1993). Phagocytic cells of
patients with CGD do not produce peroxide and other reduced oxygen species
necessary for efficient intracellular killing and organisms able to resist non-oxidative
killing mechanisms, such as S. aureus and B. cepacia are a particular problem (Speert
et al., 1994). B. cepacia septicaemia has also been documented in patients with
acquired neutrophil dysfunction, a report of a fatal B. cepacia pneumonia in a young
girl with an acquired bacterial killing defect emphasises that defective neutrophils are
an important predisposing factor for infection with B. cepacia (McCracken et al.,
1972). Recently, there have been reports describing community acquired B. cepacia
causing pneumonia and septicaemia in apparently previously healthy individuals
(Wong et al., 1991; Pujol et al., 1992); however, Cohen et al. (1993) questioned the
immune status of the case described by Pujol et al..
In conclusion the presence of B. cepacia in clinical material may involve
contamination rather than infection and the numbers of cases remain relatively low.
There is no doubt however that B. cepacia poses a significant threat to patients with
CF.
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1.2.4 Beneficial role of Burkholderia cepacia: Biological Control
Agent
B. cepacia has attracted considerable attention due to its potential for biological
control of plant pathogens and may be considered to be a microbial "Jekyll and
Hyde". The ability of B. cepacia to antagonise and repress soil-borne pathogens
makes the organism an interesting proposition from an agricultural point of view
(Bevivino et al., 1994). Biological control by B. cepacia has already been
successfully demonstrated against the aetiologic agents of a number of crop diseases
such as southern maize leaf blight, tobacco leaf spot and damping-off of onion
seedlings (Sleesman & Leben, 1976; Spurr, 1978; Kawamota & Lorbeer, 1976).
More recently antibiotic activity of B. cepacia against Pseudomonas solanacearum
was reported to suppress the incidence of bacterial tobacco wilt disease (Aoki et al.,
1991).
Several mechanisms have been proposed for antagonism against fungi: (1)
competition for iron by siderophores; (2) production of antibiotics and, (3)
competition for nutrients (Homma et al., 1989; Meyer et al., 1989). Jayaswal et al.
(1993), have isolated a strain of B. cepacia with strong antagonistic properties against
several plant pathogens due to the production of volatile compounds and, importantly
for a biocontrol agent, this strain exhibits this activity over a range of temperatures
and pH.
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1.3 BURKHOLDERIA CEPACIA AND CYSTIC FIBROSIS
1.3.1 Epidemiology
An association between B. cepacia and CF was first noted in the 1970's but at that
time, was not considered to be of particular concern (Ederer & Matsen, 1972; Laraya-
Cuasay, 1977). However, several reports from large North American CF centres in
the early 1980's demonstrated a disturbing increase in the prevalence of B. cepacia
isolated from CF sputa, with prevalence rates doubling in this time (Isles et al., 1984;
Thomassen et al., 1985). An increase in patient deaths associated with B. cepacia
from 9% to 55% during the period 1978 to 1983 also gave rise for concern
(Thomassen et al., 1985). Several salient features of B. cepacia colonisation in CF
were described by Isles et al. (1984) following a 10 year study, notably the three
distinct clinical sequelae: (1) chronic asymptomatic carriage of B. cepacia, alone or in
combination with P. aeruginosa', (2) progressive deterioration over many months with
recurrent fever and frequent hospitalisation; and (3) in approximately 20% of CF
patients, a rapid decline in pulmonary function with necrotising pneumonia and
bacteraemia with a 67% fatality rate, known as "Cepacia Syndrome". Concern over
acquisition of B. cepacia led to the institution of precautionary infection control
measures including segregation of B. cepacia colonised CF patients from non-
colonised patients in some CF centres. Coincident with these measures the incidence
of B. cepacia declined from 8.2% in 1983 to 1.7% in 1984 (Thomassen et al., 1986).
This data strongly suggested that the increased incidence of B. cepacia amongst CF
patients resulted from nosocomial infection and person-to-person transmission. In
1984 a collaborative case controlled study by the Centres for Disease Control (CDC)
and the Rainbow Babies' and Children's Hospital, Cleveland, investigated the risk
factors for acquisition of B. cepacia, and evaluated the clinical outcome of
colonisation (Tablan et al., 1987). The risk factors associated with B. cepacia
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colonisation were reported to be:-
(a) increasing severity of underlying pulmonary disease;
(b) increasing age;
(c) having a sibling with cystic fibrosis colonised with B. cepacia;
(d) hospitalisation within the previous six months.
In patients with mild CF, no difference in clinical outcome was observed between
those colonised with B. cepacia and matched controls during the period of study. In
contrast, B. cepacia colonised CF patients with moderate or advanced disease were
hospitalised longer and died sooner after colonisation.
In many respects B. cepacia colonisation of patients with CF resembles that of P.
aeruginosa. Both are opportunist pathogens with a predilection for CF patients with
severe pulmonary impairment, causing episodes of acute exacerbation and chronic
respiratory tract colonisation that is difficult to eradicate (Tablan et al., 1985; Govan
& Glass 1990). Colonisation with either organism can be associated with a poor
prognosis due to deterioration in pulmonary function. However, several features of
B. cepacia infection differ from that of P. aeruginosa infection in CF. Firstly a subset
of patients with mild or moderate CF succumb to an acute rapid deterioration
involving bacteraemia (i.e. "Cepacia Syndrome"); a similar clinical course has not
been attributed to P. aeruginosa infection in CF (Isles et al., 1984; Rosenstein & Hall,
1980). Secondly, the majority of CF isolates of B. cepacia are innately resistant to
currently available anti-pseudomonal antimicrobials and pose a major therapeutic
challenge (Gold et al., 1983). Finally, P. aeruginosa is not readily transmitted
between patients with CF and epidemic scenarios similar to those currently observed
with B. cepacia in the CF community are not associated with P. aeruginosa.
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A number of studies suggest that close and prolonged exposure to B. cepacia
colonised patients increased the risk of acquisition in non-colonised patients
(Thomassen et al., 1986; LiPuma et al., 1990). In addition, early investigations had
indicated that hospitalisation was an important factor in acquisition of B. cepacia in
CF patients (Tablan et al., 1987). There are several routes via which B. cepacia may
colonise the CF respiratory tract: (1) person-to-person, either directly from a
colonised CF patient or indirectly via contact with a contaminated fomite; (2) from an
environmental reservoir, either the natural habitat or a contaminated hospital source;
and (3) by autoinfection from a site other than the respiratory tract, a route that has
not been investigated in CF (Tablan, 1993). The first good evidence for person-to-
person transmission of B. cepacia between CF patients was provided by the study of
LiPuma et al. (1991) who used ribotyping to show transfer of B. cepacia between
two patients attending a residential camp. Transfer of B. cepacia occurred within six
days of exposure to the initial single colonised patient; however fourteen other camp
attendees who remained in contact with the index case showed no evidence of B.
cepacia. Unfortunately no environmental data was available from this study and
therefore indirect transmission cannot be discounted. Recent epidemiological
investigations by the CDC and the North American CF Foundation in four CF summer
camps have reported a 9-11% sputum conversion from B. cepacia negative to
positive in CF patients after attending such camps (Pegues & Tablan, 1993).
Ribotyping studies indicated that the newly colonised patients had acquired B.
cepacia strains belonging to the same ribotype as those present in individuals who
were colonised prior to attending the camp; strains isolated from the camp
environment were found to belong to different ribotypes suggesting that person-to-
person transmission was the major mode of acquisition (Pegues & Tablan, 1993).
The risk for acquisition of B. cepacia by CF patients was found to be proportional to
the prevalence of B. cepacia colonised individuals attending the camps and to the
duration of exposure. Certain activities, such as sharing eating utensils or kissing,
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were considered to be 'high-risk' and agree with a contemporary report confirming the
importance of social contact in B. cepacia transmission (Govan et al„ 1993).
Evidence that B. cepacia may be transmitted by social contact, the unfavourable
clinical progression in some patients following acquisition of B. cepacia and the threat
of litigation has forced clinicians and scientists in North America to recommend that
B. cepacia colonised CF patients no longer attend summer camps or CF meetings
(Speert et al., 1993). As a result of the stigma and anxiety associated with B. cepacia
colonisation for the CF patient and the risk of transmission to other susceptible
patients it has become vital for diagnostic laboratories to correctly identify B. cepacia.
The study of CF camps suggests that there is little risk of acquisition of B. cepacia
from the natural environment (Pegues & Tablan, 1993). Recent studies present
strong circumstantial evidence that nosocomial acquisition from contaminated
healthcare equipment such as nebulisers and humidifiers does occur (Burdge et al.,
1993). Similarly, studies demonstrating that B. cepacia colonised patients may
contaminate their immediate environment both in the hospital and in the home
emphasises the need to maintain good standards of hygiene (Nelson et al., 1991;
Fisher et al., 1993).
1.3.2 Isolation andDetection
In the US, the apparent disparity in the prevalence of B. cepacia between different CF
centres prompted the CDC to investigate the proficiency of microbiology laboratories
in culturing and identifying B. cepacia. Although 105 out of 111 (95%) of
laboratories were able to identify B. cepacia, only 36 out of 115 (32%) could detect
B. cepacia in a simulated sputum specimen. Ability of individual laboratories to
detect B. cepacia correlated with the use of a selective medium for the organism and
when the laboratories were asked to repeat the investigation using selective media
97% were successful (Tablan et al., 1987). B. cepacia grows slowly on commonly
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used isolation media such as MacConkey agar and is often overgrown by P.
aeruginosa and other respiratory tract organisms (Gilligan et al., 1985; Welch et al.,
1987). The range in prevalence of B. cepacia may therefore represent real inter-
centre differences or may be an artefact due to lack of laboratory awareness. The
CDC has therefore recommended the routine use of B. cepacia selective medium in
laboratories processing sputa from patients with CF (Tablan et al., 1987). Two
selective media are superior for the recovery of B. cepacia from respiratory
secretions; B. cepacia agar (CEP) containing polymyxin B and ticarcillin and OFPBL
in which the ticarcillin is replaced by bacitracin (Gilligan et al., 1985; Welch et al.,
1987). Additional media for the isolation of B. cepacia from soil and environmental
samples have also been described, however on this media cultures of B. cepacia tend
to be overgrown by fungi (Wu & Thompson, 1984; personal observation).
In conclusion laboratory culture and identification of B. cepacia may present
difficulties; in our experience cultures of B. cepacia from sputum may require up to
72 hours incubation, even on CEP, and other species in particular Xanthomonas
maltophilia and Comamonas acidovorans, will grow readily on this medium. It is
therefore essential to confirm B. cepacia by an appropriate multi-test system such as
API 20NE. In the near future it is possible that molecular diagnostic techniques will
aid in early diagnosis of respiratory tract infections; recently O'Callaghan et al. (1994)
have used PCR and DNA hybridisation based on 16S rRNA sequences to detect small
numbers of P. aeruginosa and B. cepacia in respiratory tract secretions.
1.3.3 Typing Systems
Early epidemiological studies of B. cepacia were hampered by a lack of typing
systems to identify individual strains. Segregation, a policy which is stressful for
patients and logistically difficult for clinics, was based on fear and the observation of
clusters of cases in centres as there was little scientific evidence to demonstrate
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transmission. Initially typing systems for B. cepacia were based on phenotypic traits,
for example serotyping, biotyping and bacteriocin typing (Heidt et al., 1983; Goldman
& Klinger, 1986; Govan & Harris, 1985, McKevitt et al., 1987). Unfortunately
serotyping is of little value for CF isolates as 40% of CF B. cepacia isolates
agglutinate multiple sera or are nonagglutinable (Gilligan, 1991). Typing based on
bacteriocin production and sensitivity testing has proved useful in our laboratory;
however some strains of B. cepacia exhibit instability in bacteriocin type after storage
at -70°C (Mrs C. Doherty, personal communication).
Recently a number of molecular typing systems based on detecting genotypic
differences have been developed which are able to discriminate between epidemic and
non-epidemic strains (Rabkin et al., 1989). Ribotype analysis depends on rRNA
probing of restriction endonuclease digests of chromosomal DNA. This technique has
been successfully used to confirm patient to patient transmission in a summer camp
and has shown that single strains of B. cepacia persist in chronically colonised CF
patients. More recently acquisition of B. cepacia from the 'local' environment has
been demonstrated (LiPuma et al., 1990; LiPuma et al., 1991; Fisher et al., 1993).
An adaptation of ribotyping, PCR-ribotyping has also been used (Kostman et al.,
1992), and similarly Arbitrarily Primed PCR has been used successfully to investigate
cross infection in CF patients in a B. cepacia outbreak in a French CF clinic (Bingen
et al., 1993). Both these techniques are particularly attractive to diagnostic
laboratories as they are less time consuming than traditional ribotyping and do not
require radioactive probes. Both are, however, less discriminative than Pulsed Field
Gel Electrophoresis (PFGE), although this method is somewhat time consuming (Sun
et al., 1993).
The choice of typing system for any pathogen depends upon the laboratory facilities
available and also the level to which identification is required (Pitt, 1994).
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Epidemiological investigations of B. cepacia in our laboratory combine a number of
approaches. Routinely bacteriocin typing and the API 20NE multi-test system are
used, the latter detects a range of biochemical properties allowing diagnosis and
preliminary strain identification. PFGE is used in cases to confirm or differentiate
clonal relationships; for example, in our own laboratory PFGE has recently confirmed
that two new concurrent cases of B. cepacia in the Edinburgh paediatric CF clinic
were unrelated.
1.3.4 Antimicrobial Therapy
B. cepacia is innately resistant to a wide range of currently available antimicrobials,
including colistin, aminoglycosides and traditional anti-pseudomonal agents such as
penicillins, third generation cephalosporins and quinolones (Gilligan et al, 1985;
Prince, 1986). Undoubtedly, the resistance of B. cepacia plays an important role in
the persistence of this organism and antimicrobial therapy rarely, if ever, leads to
eradication of B. cepacia. Treatment of patients colonised by B. cepacia therefore
poses a significant challenge in the management of CF patients; there has been some
concern that the aminoglycosides and penicillins used to treat P. aeruginosa infection
might be selective for B. cepacia (Goldman & Klinger, 1986; Govan & Glass, 1990).
Historically, trimethoprim-sulfamethoxazole and chloramphenicol were the most
effective antibiotics but resistance soon develops during or after therapy (Nord et al.,
1974; Gilligan, 1991). More recently developed antimicrobials such as imipenem,
aztreonam and ceftazidime exhibit some in vitro activity against B. cepacia (Aronoff
& Klinger, 1984; Klinger & Thomassen, 1985; Tablan et al., 1987). Ceftazidime
appeared particularly promising initially as most CF isolates of B. cepacia were
susceptible in vitro, but clinical experience proved variable (Gold et al., 1985). In the
most recently reported study, Lewin et al. (1993), investigated the activity of three
newly developed antimicrobials meropenem and two quinolones, PD 127391 and PD
131628, against 130 isolates of B. cepacia from various sources. Although the results
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were promising two CF strains of B. cepacia, both particular 'problems' in the
Edinburgh CF clinic, were highly resistant even to these new agents. A novel
approach has been to combine tobramycin with amiloride in an aerosol. Cohn et al.
(1988) have shown that tobramycin and amiloride act synergistically against B.
cepacia. As it is unlikely that any current antimicrobial or those under development
will have a significant impact on B. cepacia infection in CF patients, clinicians and
scientists will be well advised to concentrate on preventing the acquisition of B.
cepacia.
1.3.5 Burkholderia cepacia in the UK: The Edinburgh Experience
Experience of B. cepacia colonisation in CF patients treated at UK regional centres
has provided important new data on B. cepacia and confirmed both the threat for
colonised patients and the efficacy of precautionary measures. In the UK, surveillance
in large CF centres indicated that B. cepacia presented little problem amongst CF
patients in the early 1980's. By the end of the decade, however, several regional CF
centres had reported a situation reflecting that previously described in North America
(Simmonds et al., 1990; Lancet Editorial, 1992; Millar-Jones et al., 1992; Govan et
al., 1993; Smith et al., 1993; Smyth et al., 1993). In the UK studies, regional
differences in the prevalence of B. cepacia could, in part, be attributed to the
emergence of a particularly transmissible strain of B. cepacia with well defined
characteristics (Table 1.) and originally known as the Epidemic Strain.
The studies by LiPuma et al. (1988; 1991) had previously shown that CF patients
within a clinic tended to harbour the same strain of B. cepacia and demonstrated
transfer of B. cepacia from a colonised CF patient to a previously non-colonised
patient. The most compelling evidence for person-to-person transmission of B.
cepacia has been provided by the recent studies on the epidemic strain of B. cepacia,
the first strain of B. cepacia to show transmission between patients attending different
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regional centres including Belfast, Birmingham, Cardiff, Edinburgh, Leeds, Liverpool
and Manchester. The clonal relationship of epidemic strain isolates from the different
centres within the UK and, interestingly strains from Ontario, Canada has recently
Table 1. Phenotypic and genotypic characteristics of the Epidemic Strain of B.
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Figure 2. Colony morphology of B. cepacia: (a) the epidemic strain with distinctive
small, dry colonies; (b) CI409, a CF isolate with 'typical' B. cepacia colony
morphology.
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been confirmed by multilocus enzyme typing (Johnson et al., 1994). Intense
epidemiological investigations revealed a considerable degree of inter-regional social
contact between adult CF groups, providing strong circumstantial evidence that social
contact outwith the hospital environment had been important in the spread of this
strain.
The spread of the epidemic strain of B. cepacia within and between CF centres is
typified by the experience in the Edinburgh Adult and Paediatric CF Clinics (Figure
3.) where surveillance for B. cepacia had began in 1982 (Govan et al., 1993). In
1986, Glass & Govan described an isolated case of "Cepacia Syndrome" in a nine
year old female CF patient, the first report of a CF death due to B. cepacia in the UK.
In 1989 the first isolate of the epidemic strain was cultured from the index case, a 20
year old CF male (patient 7), and in the subsequent four years a further 12 patients
attending the adult CF clinic became colonised with the epidemic strain; in 1992 the
prevalence of B. cepacia had reached 26.7%. Investigation, in view of the opinion
that colonisation with P. aeruginosa precedes colonisation with B. cepacia, revealed
that only eight of the 13 (62%) patients colonised by the epidemic strain in Edinburgh
were co-colonised by P. aeruginosa. The clinical significance of colonisation by the
epidemic strain varied between patients; however, between 1990 and 1992, seven
deaths (five female) occurred in B. cepacia colonised CF patients of whom six were
colonised by the epidemic strain. In the same period no deaths occurred in B. cepacia
negative patients. The impact of the epidemic strain in Edinburgh can clearly be seen
from Figure 3. Analysis of the social contacts of colonised patients revealed that a
number of patients attended a weekly CF fitness class, which was disbanded in 1991
following the deaths of two of the attending CF patients within the same week. The
relationship between male patient 19 who was colonised by the epidemic strain and an
additional unrelated strain of B. cepacia, and female patient 22 who was B. cepacia
negative at the start of the relationship, provides the most convincing evidence of the
31
transmissibility of this strain. During the course of a short and intimate relationship
patient 22, who had severe pulmonary dysfunction became B. cepacia positive and
died six weeks later. Interestingly, despite the fact that patient 19 was colonised by
two distinct strains of B. cepacia, patient 22 only acquired the epidemic strain.
Following the death of his girlfriend patient 19 experienced considerable emotional
trauma and despite having comparatively good lung function died one month later due
to pulmonary failure with overwhelming B. cepacia pulmonary infection and
bacteraemia. Following the segregation of B. cepacia colonised CF patients in the
Edinburgh clinic in August 1992 there has been no further acquisition of the epidemic
strain by Edinburgh CF patients.
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Figure 3. Consecutive cases of B. cepacia colonisation in CF patients attending the
Edinburgh adult and paediatric CF clinics.
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1.4 PATHOGENICITY AND VIRULENCE OF BURKHOLDERIA CEPACIA
1.4.1 Virulence Factors and Pathogenicity
Virulence factors may be defined as components and products of the bacterial cell
which bestow on the bacterium the potential to cause disease (pathogenicity).
Instances in which pathogenicity is the result of a single bacterial factor, for example
the neurotoxin of Clostridium tetani, are rare. More often, pathogenesis is a
multifactorial interaction involving both bacterial and host factors. Many potential
virulence factors have primary functions in the normal anatomy and physiology of the
bacterium - any association with disease may be purely coincidental. While some
pathogens regularly cause disease in individuals with intact host defences, other
potential pathogens, the microbial opportunists, are only able to take advantage of
immunocompromised hosts (Finlay & Falkow, 1989).
A sequence of potentially pathogenic interactions between a bacterium and a
susceptible host begins when the bacterium has reached a target or colonisation site
on or in the host (Finlay & Falkow, 1989; Poxton & Arbuthnott, 1990). Bacterial
adherence to host mucosal or epithelial surfaces via specific receptor-ligand
interactions is generally considered to be prerequisite for initial colonisation.
Subsequently, the bacterium multiplies and may need to adapt in order to persist
within the host; for example, by regulating the production of factors which enable it to
compete against commensal flora for nutrients and avoid non-specific and specific
host immune responses. Damage to the host tissues may occur directly via toxins or
invasion, or indirectly via the immune response. Finally, to complete the process the
pathogen may disseminate to other susceptible hosts.
Bacterial virulence factors are generally classified as being cell surface factors such as
fimbriae, or extracellular such as the toxins or exo-enzymes (Poxton & Arbuthnott,
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1990). Studies to improve our understanding of the pathogenicity and virulence of
individual pathogens are challenging for several reasons. Firstly, virulence may be
primarily manifested in vivo; in vitro grown bacteria may not express all their
virulence factors, thus relevant model systems are required which mimic the disease
situation. Another problem is that virulence factors relevant to one type of infection
may be of no importance in another. Thirdly, when the organism involved is an
opportunistic pathogen, such as P. aeruginosa or B. cepacia, it is difficult to decipher
which aspects of the disease are mediated by the bacterium and which are due to pre¬
existing host factors and the host immune response.
1.4.2 The BacterialCell Surface
The cell envelope of Gram-negative bacteria (Figure 4.) is a complex structure
conferring shape and rigidity on the bacterial cell and functioning as a barrier through
which the bacterium interacts with the environment. Three principal layers make up
the cell envelope; 1) the outer membrane; 2) the periplasmic space; and 3) the
cytoplasmic membrane. Additionally an extracellular polysaccharide material may
also be present, as a capsule or slime layer (Stanier et al., 1986). The outer
membrane is an asymmetric bilayer containing phospholipids, proteins and the unique
lipid, lipopolysaccharide (LPS). Three major classes of protein are found in the outer
membrane including lipoprotein, major outer membrane proteins and minor outer
membrane proteins, each being induced or repressed depending on the environment.
Many of the major outer membrane proteins are pore proteins or porins which form
relatively non-specific, water-filled pores spanning the outer membrane for the passive
entry of low molecular weight, hydrophilic solutes (Nakae, 1986). Other minor outer
membrane proteins act as specific transport systems for solutes which are too large or
present at low concentrations. The tubular protein polymers of the flagella and
fimbriae that are involved in motility and adherence are associated with both the











Figure 4. The cell surface of a Gram-negative bacterium.
LP=lipoprotein; LPS=lipopolysaccharide; P=protein; PL=phospholipid;
(From Hancock & Poxton, 1988).
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phospholipids in the outer leaflet; the hydrophobic terminal is inserted into the
hydrophobic core of the membrane whilst the hydrophilic terminal extends outward
from the cell surface. The varied normal physiological functions of the cell surface
components include acquisition and transport of nutrients, receptors for bacteriophage
and bacteriocins and bacterial adhesins; several of these cell surface components have
been shown to be potential virulence factors for B. cepacia.
1.4.3 Pathogenicity of b. cepacia
Our knowledge and understanding of the pathogenesis of B. cepacia infection in the
lungs of patients with cystic fibrosis and the bacterial factors responsible for
colonisation and virulence is minimal, particularly when compared to the wealth of
literature concerning the pathogenesis of P. aeruginosa in CF. There is also debate as
to whether B. cepacia is a true pathogen or merely a marker of severe lung disease;
despite the fact that a number of potential virulence factors have been described for B.
cepacia there is little evidence to demonstrate that primary pathology in the CF lung
results directly from any of these products. The aim of this chapter is to review the
literature describing potential virulence factors of B. cepacia', most of the available
information concerns the role of this organism in CF as it is in this area that interest
and concern are focused.
Several theories have been postulated in attempts to explain the spectrum of disease
associated with B. cepacia colonisation in CF: (1) different strains of B. cepacia may
vary significantly in virulence; (2) synergistic interaction with other CF pathogens
such as P. aeruginosa (Sokol, 1986; Saiman et al., 1990): and (3) the severity of B.
cepacia infection may be dependant on the degree of pre-existing tissue damage
(Gilligan, 1991). Postulates (2) and (3) may be questioned as not all patients
colonised by B. cepacia are co-colonised by P. aeruginosa (Govan et al., 1993) and a
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recent report describes CF patients with new lung transplants succumbing to
overwhelming pulmonary infection with B. cepacia (Snell et al., 1993).
Data pointing to a purely commensal role for B. cepacia comes from several studies
with animal models which show that B. cepacia is avirulent compared to P.
aeruginosa. For example, in a guinea pig model of pneumonia, B. cepacia caused
only mild disease whilst equivalent concentrations of P. aeruginosa caused fulminant
fatal pneumonia (Goldman & Klinger, 1986). Similarly, P. aeruginosa was highly
virulent in a burned mouse model but B. cepacia was avirulent although it did show
tenacious persistence in the wound (Stover et al., 1983). The apparent avirulence of
B. cepacia may largely be explained by the fact that B. cepacia does not appear to
express any of the virulence factors associated with P. aeruginosa such as exotoxin A
and alginate and, as implied by several studies, B. cepacia strains may vary in
virulence with certain isolates being highly virulent and others essentially avirulent
(McKevitt & Woods, 1984; Goldman & Klinger, 1986; Gilligan, 1991).
1.4.4 Colonisation and Adherence
A dogma of bacterial pathogenesis states that the first interaction between a potential
pathogenic organism and its host entails attachment to a eukaryotic cell surface and
that this is a prerequisite for local bacterial proliferation in the host and therefore for
tissue damage, bacterial invasion and dissemination (Finlay & Falkow, 1989; Krogfelt,
1991). Attachment to host cell surfaces occurs via receptor-ligand interactions; the
bacterial ligand or adhesin is located on the bacterial cell surface and recognises
specific binding sites on the host cell surface. Fimbriae are amongst the best described
of bacterial adhesins; for example the PAP fimbriae of uropathogenic Escherichia coli
(Pere et al., 1986). Correlation between the presence of fimbriae and pathogenicity of
B. cepacia in CF has been addressed by several groups investigating the adhesive
properties of B. cepacia fimbriae.
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B. cepacia has been reported to express polar and peritrichous fimbriae (Saiman et
al., 1990; Sajjan & Forstner, 1992; Kuehn et al., 1992). Kuehn and colleagues
(1992) showed that outer membrane protein preparations of B. cepacia were enriched
with 3 proteins at 16, 20 and 40 kDa which were not present in non fimbriated strains.
The fimbrial subunit (16 kDa) appeared similar to those observed with other bacteria
and showed homology with PAK fimbriae of P. aeruginosa. In contrast, Saiman et
al. (1990a & b) demonstrated minimal cross-reactivity of B. cepacia fimbriae with
monoclonal antibodies to P. aeruginosa fimbriae, and no homology between P.
aeruginosa fimbrial probes and B. cepacia genomic DNA. This apparent discrepancy
may be due to sequence variation of fimbrial genes between different strains of B.
cepacia (Kuehn et al., 1992).
Krivan and co-workers (1988) demonstrated in in vitro binding experiments that both
P. aeruginosa and B. cepacia adhere to GalNAc(3l-4Gal sequences in the glycolipids
Asialo GM1 and Asialo GM2. No competition for epithelial receptors between these
two organisms has been observed indicating that different receptors may be used
preferentially or that the bacteria may bind to each other (Saiman et al., 1990). In the
same report, the authors described an 8-fold increase in the binding of two strains of
B. cepacia in the presence of P. aeruginosa or P. aeruginosa products. The authors
postulated that enhanced binding occurred through a synergistic relationship between
P. aeruginosa and B. cepacia whereby P. aeruginosa exoproducts modified the
epithelial cell surface exposing receptors and facilitating B. cepacia adherence
(Saiman et al., 1990).
Several studies describe specific binding of B. cepacia isolates from CF patients to CF
and non-CF mucins (Sajjan et al., 1992; Sajjan & Forstner, 1992; Sajjan & Forstner,
1993). Isolates exhibiting the highest degrees of mucin binding tended to be
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associated with CF patients with the most severe illness leading to speculation that
variability in binding of different B. cepacia isolates to respiratory mucin may
contribute to morbidity and mortality or that tissue damage results in increased
adhesion. Variable strain-specific binding potentially may explain why some B.
cepacia strains colonise CF patients transiently and other strains, once acquired, are
never lost. Unfortunately in the study by Sajjan et al. (1992) typing data was not
provided; B. cepacia is known to be highly transmissible and the possibility of a clonal
relationship between B. cepacia strains could not be excluded. Deglycosylation
procedures indicated that mucin receptors for B. cepacia include N-acetylglucosamine
and N-acetylgalactosamine (Sajjan et al., 1992). B. cepacia isolates also bind to
buccal epithelial cells (BEC) via two different adhesin-receptor systems one of which
is independent of bacterial fimbriation. The other binding mechanism is mediated by a
22 kDa adhesin located on the fimbriae and a 55 kDa epithelial cell receptor. The 22
kDa adhesin is also involved in binding to mucin and may therefore be an important
virulence factor in the early stages of colonisation. The presence of fimbriae also
increased the binding of B. cepacia to pneumocytes in vitro (Kuehn et al., 1992).
1.4.5 Outer Membrane Proteins
B. cepacia expresses five major OMP's; A (56 kDa), B (38 kDa), C (36 kDa), D (27
kDa) and E (21 kDa). The C and D proteins have been identified as porins and are
antigenic in most patients chronically colonised by B. cepacia (Parr et al., 1987;
Aronoff & Stern, 1988). Synthesis of the outer membrane constituents is influenced
by the environment; for example Anwar et al. (1983) showed that the simplest OMP
profile of B. cepacia was obtained following growth in magnesium deficient
conditions and that a 66 kDa OMP was induced in iron deficient conditions. Similarly
the variable micro-environment of the CF lung, in particular ionic content and
concentrations of essential elements, may explain the intra-isolate variability observed
in the OMP profiles of single strains of B. cepacia from patients with CF (Larsen et
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al., 1993). Major roles for OMP's in B. cepacia colonisation in CF include enabling
the organism to persist by promoting nutrient uptake and by preventing antibiotic
agents from reaching their target sites.
Siderophores
One of the most important roles of OMP's in terms of virulence are to act as receptors
for iron-chelating siderophores, which are induced in iron deficient conditions.
Siderophore-mediated iron acquisition is an important prerequisite in establishing and
maintaining infection in many bacterial pathogens (Payne & Finklestein, 1978).
Production of siderophores enables the bacteria to compete against host iron binding
proteins such as transferrin and against other bacteria for the limited amount of free
iron. The fact that many bacteria express more than one iron transport mechanism
and may be able to utilise systems from other species, thus gaining a competitive
advantage, emphasises the importance of iron.
B. cepacia expresses at least three siderophore-mediated iron transport mechanisms
including pyochelin, cepabactin and azurechelin (Sokol, 1986; Sokol & Woods, 1988;
Meyer et al., 1989; Sokol et al., 1992). In the study by Sokol (1986), pyochelin
production was observed in only 49% of B. cepacia strains examined. The fact that
the majority of pyochelin producing strains (86%) were from patients with severe
infection suggested that pyochelin may contribute to virulence. Later studies using a
chronic pulmonary infection model in rats demonstrated that exogenously supplied
pyochelin increased the area of pathology observed in the rat lungs, suggesting a role
for pyochelin in dissemination of B. cepacia in the lung and also in the induction of a
greater inflammatory response (Sokol & Woods, 1988). Both pyochelin producing
strains of B. cepacia and those which do not produce pyochelin can take up
ferripyochelin. This may be important in CF infections where P. aeruginosa is also
involved as the pyochelin of P. aeruginosa and B. cepacia appear identical suggesting
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that, in some cases, a synergistic relationship may occur between these opportunistic
pathogens (Sokol & Woods, 1988).
Two additional iron transport systems have been described in B. cepacia; cepabactin
which strongly chelates Fe III and azurechelin which is a salicylic acid and has been
identified in 88% of B. cepacia strains isolated from the respiratory tract ( Meyer et
al., 1989; Sokol et al., 1992; Visca et al., 1993). No potential role in virulence has
yet been described for either of these siderophores; they may simply perform a
supplementary role as pyochelin is reported to be inefficient when competing for iron
against host serum proteins (Meyer et al., 1989).
1.4.6 Lipopolysaccharide
LPS is considered to be one of the main virulence factors of Gram-negative bacteria
and is a major surface antigen (Poxton & Arbuthnott, 1990). Numerous and varied
biological activities are associated with LPS including antigenic and endotoxic
properties, as a receptor for bacteriophage and bacteriocins and possibly a role in
recognition and adhesion via lectins (Wilkinson, 1983). Immunomodulatory functions
of LPS include influencing polymorphonuclear leukocyte function (Kharazmi et al.,
1991), and smooth-LPS (S-LPS) serves to protect the organism from opsonisation
and phagocytosis as well as the bactericidal activity of serum (Taylor, 1983; Crokaert
et al., 1992).
Structure
The architectural norm for LPS is an amphipathic tripartate macromolecule with an
O-specific polymer side chain attached to a hydrophobic lipid via a common core
(Wilkinson, 1983). The O-side chain is highly variable, consisting of repeating
oligosaccharide units and is the basis for O-serotyping. Lipid A, based on a l,6'-(3-
linked disaccharide of glucosamine with O and N fatty acid substituents and the
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proximal region of the core typically containing L-glycero-D-rarmno-heptose and 3-
deoxy-D-tfwnno-octulosonic acid (KDO) are relatively conserved. Both Lipid A and
the core are usually phosphorylated. The LPS of B. cepacia has a number of unusual
features. Initial chemical analysis indicated an absence of KDO (Manniello et al.,
1979; Anwar et al., 1983); however, Straus et al. (1989; 1990) reported the isolation
of KDO from the culture supernate of 2 out of 10 strains of B. cepacia examined and
from six clinical isolates of B. cepacia and more recently Cox & Wilkinson (1991)
detected low levels of KDO for one strain of B. cepacia. Compared to LPS of P.
aeruginosa that of B. cepacia has a low phosphorus content but more heptose
(Manniello et al., 1979). Extensive studies on the O-side chain of B. cepacia
serogroups 01, 03, 05 and 07 have indicated that in serogroups 01, 03 and 05 the
metabolic versatility of B. cepacia extends to the biosynthesis of unusual sugars
including D-rhamnose and D-fucose (Cox & Wilkinson, 1989; 1990a & b).
B. cepacia LPS and Cystic Fibrosis
An unusual feature of chronic P. aeruginosa colonisation in CF is the emergence of
mucoid, serum-sensitive, polyagglutinating phenotypes lacking the O-side chain of
LPS (Hancock et al., 1983; Govan & Harris, 1986). Although in one study the
majority of CF isolates of B. cepacia (54%) expressed R-LPS (McKevitt & Woods,
1984), there is no evidence to date to confirm that B. cepacia undergoes a similar
transition in chronically colonised CF patients.
The investigations of Straus et al. (1988; 1990) indicated that an extracellular toxic
complex (ETC) produced by various strains of B. cepacia may be responsible for the
lethality and lung tissue destruction associated with B. cepacia pneumonia. The ETC
consisted of a surface carbohydrate antigen, LPS and protein and enhanced the
virulence of B. cepacia when co-injected into mice (Straus et al., 1990). The most
toxic ETC preparation was that which contained the most LPS. Immunisation of
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rabbits with ETC resulted in the production of antibodies that were protective in 90%
of mice inoculated with the homologous strain.
1.4.7 Antimicrobial Resistance
The high intrinsic resistance to antibiotics in Gram-negative bacteria is often
associated with the barrier properties of the outer membrane. Various studies indicate
that in B. cepacia reduced permeability is a major contributing factor in resistance to
p-lactam antibiotics as well as to aminoglycosides and other hydrophobic compounds.
The small size of the hydrophobic channels formed by B. cepacia porins retards
diffusion of ^-lactams (Parr et al., 1987). In addition decreased expression of the
major C and D porin proteins is associated with high level P-lactam resistance in some
CF isolates of B. cepacia (Aronoff, 1988). Similarly resistance to aminoglycosides
and chloramphenicol is due to the inability of the antibiotic to disrupt and permeabilise
the outer membrane (Moore & Hancock, 1986, Burns et al., 1989).
Resistance to cationic antimicrobial agents is, in part, attributable to the unusual
structure of B. cepacia LPS with its relative dearth of anionic sites and the presence
of fixed counter-cationic sites (Moore & Hancock, 1986; Cox & Wilkinson, 1991).
In P. aeruginosa the loss of the O-side chains, independent of diminished porin
expression, has also been associated with P-lactam resistance (Godfrey et al., 1984).
Recent studies on B. cepacia have also demonstrated that a high level of p-lactam
resistance correlates with the expression of rough-LPS (R-LPS) (Simpson et al.,
1994).
In addition to an impermeable outer membrane, all pseudomonads produce an
inducible chromosomal ^-lactamase (Prince, 1986). At least three p-lactamases have
been described for B. cepacia; one with the unique ability to utilise P-lactam
compounds as a source of carbon (Beckman & Lessie, 1979; Aronoff & Labrazzi,
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1986). Activity of B. cepacia (^-lactamases has been shown to increase in a CO2
enriched atmosphere (Corkill et al., 1994), which may contribute to the clinical
intractability of B. cepacia in CF. Recently carbapenemase activity has been
described as widespread in B. cepacia (Simpson et al., 1993).
1.4.8 Exopolysaccharide
The role of exopolysaccharide is another key example of the differences between P.
aeruginosa and B. cepacia colonisation in CF. Many bacterial species synthesize
organic polymers which are deposited outside the cell wall as a capsule or as a slime
layer (Sutherland, 1985). The roles of these exopolymers are varied including
receptors for bacteriophage, mediating cell-to-cell interactions and also providing a
protective barrier as typified by bacterial microcolonies (Costerton et al., 1990). A
prime example of a bacterial exopolysaccharide is the alginate polymer produced by
mucoid strains of P. aeruginosa, which is considered to be the major virulence factor
in pulmonary colonisation and immune-mediated damage in CF lungs (Govan &
Harris, 1986). There is little evidence for alginate biosynthesis in B. cepacia with the
exception of an alginic acid-like compound, containing 72% guluronic acid with
1.75% acetylation, described in one strain of B. cepacia (Straus et al., 1990). Recent
PCR studies with primers of the P. aeruginosa alg D gene, which encodes the
essential enzyme GDP mannose dehydrogenase, indicate that it is unlikely that B.
cepacia could produce an alginate like compound as this gene was absent in 10 B.
cepacia strains studied (Nelson et al., 1994). Sage et al. (1990) demonstrated that B.
cepacia strains which were glucose dehydrogenase deficient (Gcd~) formed large
amounts of an exopolysaccharide comprising galactose, glucose, mannose, guluronic
acid and rhamnose. Surveys of clinical isolates from patients with CF indicated that
there was no correlation between the ability of B. cepacia to colonise the respiratory
tract and the capacity of Gcd" strains to produce exopolysaccharide.
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1.4.9 Extracellular Virulence Factors
P. aeruginosa colonisation in CF is associated with the production of several classic
extracellular virulence factors such as exotoxin A, an ADP-ribosyl transferase similar
to diphtheria and cholera toxin, and the potent proteolytic enzyme elastase in addition
to a multitude of other factors (Vasil, 1986; Bainbridge & Fick, 1989). B. cepacia
does not appear to produce the factors associated with P. aeruginosa virulence and
pathogenicity in CF lung infections, namely exotoxin A or elastase. B. cepacia does
however, produce a number of extracellular products including protease, gelatinase,
haemolysin and lipase although a role for any of these products in the pathogenesis of
CF lung infection has not been shown (McKevitt & Woods, 1984; Nakazawa et al.,
1987; Gessner & Mortensen, 1990). B. cepacia isolates from plants produce high
levels of pectolytic enzyme; however this enzyme has only been found in low levels in
strains of clinical origin (Gonzalez & Vidaver, 1979). In a study of potentially
pathogenic factors, Gessner & Mortensen (1990) demonstrated that a number of
characteristics are more frequently observed in isolates of B. cepacia from CF patients
than from other clinical sources or the environment. These factors include the
production of catalase, ornithine decarboxylase, valine aminopeptidase, C14 lipase,
alginase, trypsin, the reduction of nitrate to nitrite, hydrolysis of urea and xanthine and
complete haemolysis of bovine erythrocytes. The significance of these observations in
relation to pathogenesis in CF is not clear. Indeed, the epidemic strain of B. cepacia
which is associated with a fatal clinical outcome in CF does not produce C14 lipase
(Govan et al., 1993).
B. cepacia Protease
Bacterial proteases have been shown to damage host tissues directly (Marks, 1981).
Several studies describe protease production by CF and non-CF isolates of B. cepacia
suggesting that protease production is probably a characteristic feature of most strains
(Burkholder, 1950; McKevitt & Woods, 1984; Montie et al., 1985; Nakazawa et al.,
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1987; McKevitt et al., 1989). Further characterisation of the B. cepacia protease
showed that it was a 34 kDa metalloprotein capable of cleaving hide powder and
collagen but, unlike P. aeruginosa elastase, the B. cepacia protease did not degrade
IgG, IgM, IgA or secretory-IgA. Immunologic cross-reactivity of B. cepacia
protease with P. aeruginosa elastase was observed, although the amino acid
composition of the two proteases is dissimilar (McKevitt et al., 1989). Intratracheal
installation of B. cepacia purified protease into rat lungs produced bronchopulmonary
pneumonia characterised by polymorphonuclear cell infiltration and proteinaceous
exudation into large airways. Active immunisation of rats with B. cepacia protease
elicited an immunological response, although this was not protective against
subsequent lung infection with B. cepacia (McKevitt et al., 1989). Montie et al.
(1985) reported that a highly proteolytic isolate of B. cepacia from a patient with CF
was found in cultures of liver cells five days after inoculation into the wound in a
burned-mouse model, suggesting that bacteraemia had occurred. A clinical corollary
to this was observed when two gelatinolytic strains of B. cepacia were isolated from
two cases of B. cepacia bacteraemia subsequent to burn wound colonisation (Brauner
etal., 1985).
B. cepacia Lipases
There is some evidence that lipases, especially phospholipase C (PLC), play an
important role in virulence. PLC is a lecithinase which cleaves phosphatidylcholine, a
phospholipid found in mammalian cell membranes, into phosphorylcholine and
diacylglycerol (Esselmann & Liu, 1961). The normal physiological role of lipases is
probably nutritional - liberating fatty acids for use as an energy source, for example
PLC of P. aeruginosa has been implicated in the scavenging of phosphates (Lonon et
al., 1988). PLC is associated with the cytopathology of lung disease and by acting
directly on pulmonary tissue the enzyme may be responsible for the extensive
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destruction of lung parenchyma observed in post-mortem lungs from CF patients with
"Cepacia Syndrome" (Thomassen, et al., 1985).
B. cepacia has often been described as lipolytic (Starr & Burkholder, 1941; Morris &
Roberts, 1959; Carson et al., 1973; McKevitt & Woods, 1984; Nakazawa et al.,
1987; Lonon et al., 1988). Lipase activity has been detected on a number of different
substrates including egg-yolk agar, polyoxyethylene sorbitans (Tweens) and p-
nitrophenylphosphorylcholine (Lonon, et al., 1988). B. cepacia lipase activity has
been detected in culture supernatants of exponentially growing and stationary phase
cells in the absence of exogenously supplied substrate, suggesting that lipase is
produced constitutively. The purified enzyme was found to have a molecular weight
of approximately 24 kDa and was not cytotoxic for HeLa cells or for mice injected
intravenously with the purified lipase. A recent study by Straus et al. (1992)
demonstrated that B. cepacia lipase acts indirectly to exert an antiphagocytic effect on
rat pulmonary macrophages. Phagocytosis of B. cepacia by rat pulmonary
macrophages was significandy reduced when the cells were preincubated with lipase
or when phagocytosis occurred in the presence of lipase. Scanning electron
microscopy showed that macrophages exposed to B. cepacia lipase had fewer
pseudopodia and microvilli when compared to untreated macrophages (Straus, et al.,
1992). Thus B. cepacia lipase may be an important virulence factor allowing the
bacteria to evade the mammalian host defences.
B. cepacia produces more than one haemolysin, including a heat-labile haemolysin
that has both PLC and sphingomyelinase activities (Vasil et al., 1990). The frequency
of haemolysin expression amongst B. cepacia strains is inconsistent, ranging from 4-
40% dependent on the type of erythrocytes used (Nakazawa et al., 1987; Gessner &
Mortensen, 1990; Vasil et al., 1990). Unlike PLC activity in P. aeruginosa, the
activity of PLC in B. cepacia does not correlate with haemolytic activity, although all
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strains of B. cepacia do produce detectable amounts of extracellular PLC activity
(Nakazawa et ai, 1987; Vasil et al., 1990). The gene that encodes the PLC of B.
cepacia is largely homologous to the P. aeruginosa PLC gene, particularly at the
amino terminus with the exception that there is considerable hypervariability in the
genetic organisation of the B. cepacia gene (Vasil et al., 1990).
1.4.10 Regulation of Virulence Factors in Burkholderia cepacia
The ability of a bacterial pathogen to sense a changing or new environment and to
modify expression of surface related and extracellular features accordingly confers
survival advantage and may contribute to pathogenicity. Several possible mechanisms
for genetic control of the regulation and expression of the potential virulence factors
of B. cepacia exist. Plasmids which may contain antibiotic resistance or virulence
genes have been described in B. cepacia although their distribution among B. cepacia
strains appears to be erratic (Beckman & Lessie, 1979; Gonzalez & Vidaver, 1979;
Williams et al., 1979; McKevitt & Woods, 1984; Gaffney & Lessie, 1987; Larsen et
al., 1993). Interestingly, B. cepacia genomic DNA contains numerous insertion
sequences (IS) (Gaffney & Lessie, 1987). IS are transposable elements which have
the ability to insertionally regulate chromosomal or plasmid-encoded determinants and
to mediate incorporation of foreign genes. B. cepacia is unique in the large numbers
of IS identified and, in contrast, these elements have yet to be discovered in P.
aeruginosa (Scordilis et al., 1987). The ability to control gene expression by
transposable gene-activating elements may explain the phenotypic variability,
including the apparent difference in virulence and virulence factors, that is observed in
isolates of B. cepacia.
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1.4.11 The Host Response
B. cepacia has several potential virulence factors which may be involved in
colonisation and pathogenesis in CF. In this section I have attempted to summarise
the accumulating data available on the pathogenicity and virulence factors of B.
cepacia. A striking feature of this literature is the dearth of information on the host
immune response to this opportunist pathogen. Observations of patients attending the
Edinburgh adult CF clinic, particularly those patients colonised with the epidemic
strain, lead us to the speculation that undetermined host factors are a major influence
on the clinical course of B. cepacia colonisation.
Aronoff and colleagues have shown that colonisation with B. cepacia occurs in CF
patients already colonised by P. aeruginosa despite the presence of serum IgG
antibodies against shared outer membrane proteins (Aronoff & Stern, 1988; Aronoff
et al., 1991). Similarly McKevitt et al. (1989) observed immunogenic cross-reactivity
between B. cepacia protease and P. aeruginosa elastase in CF patients colonised with
P. aeruginosa who subsequently acquired B. cepacia. Failure to prevent subsequent
B. cepacia colonisation suggests that these antibodies are not protective. More
recently, Jensen et al. (1993) have shown considerable homology between the GroEl
stress proteins of P. aeruginosa and B. cepacia. The authors speculate that
colonisation of CF patients by either or both of these organisms may be associated
with the autoimmune diseases seen in CF as there is extensive homology between
bacterial stress proteins and the homologous host protein. Immunological studies on
B. cepacia colonisation of patients with CF indicate that the organism persists in the
presence of a considerable antibody response and suggest the possibility of immune
mediated damage.
In the single study describing killing by human polymorphonuclear leukocytes and
normal human serum of one strain of B. cepacia (Anwar et al., 1983) the degree of
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sensitivity observed varied according to the conditions in which B. cepacia was
cultured.
Our knowledge of the behaviour and the significance of B. cepacia as a pathogen in
non-CF patients is limited. In chronic granulomatous disease where oxidative killing
mechanisms are absent, patients are at particular risk as B. cepacia is resistant to non-
oxidative neutrophil-mediated killing. However such a deficiency has not been
described in patients with CF.
Recently a strain of B. cepacia associated with rapidly fatal illness in a CF patient has
been shown to invade respiratory epithelial cells in vitro (Burns et al., 1992). The
ability to invade respiratory epithelial cells might not only be important in the context
of virulence, but also has implications for antibiotic therapy as bacteria in an
intracellular location would be protected from the activity of antimicrobial agents such
as (^-lactams and aminoglycosides which are often used in the management of
infection in CF patients.
In summary, the few studies that have been carried out to date indicate that B.
cepacia is able to persist in the presence of a pronounced humoral immune response
and evade other immunological defences. B. cepacia may be able to evade
eradication by inactivating defence mechanisms; for example the B. cepacia lipase
activity which appears to affect phagocytosis (Straus et al, 1992). The possibility
that B. cepacia may be intracellular is a concept which is gaining increasing support,
particularly since B. cepacia is closely related to Burkholderia pseudomallei which
has recently been shown to be an intracellular pathogen (Pruksachartvuthi et al.,
1990).
51
AIMS OF THIS THESIS
Pulmonary colonisation of patients with cystic fibrosis by B. cepacia has become a
cause of considerable concern for CF patients, their relatives and their carers and
represents a significant medical and scientific challenge. Our knowledge and
understanding of the virulence and pathogenesis of B. cepacia, particularly with
respect to the interaction with the CF host, is inadequate to answer the multitude of
questions posed by those involved with CF patients. The objective of this thesis was
to evaluate the basic characteristics of B. cepacia, in particular those which may be
relevant to pulmonary infection in the CF lung, and to study the interaction of B.
cepacia with the CF host by investigating aspects of the humoral immune response.
The following four major topics of research were covered:-
1. A study of the general characteristics and biological properties of B. cepacia, with
particular emphasis on the properties of the highly transmissible epidemic strain.
2. Investigation of the adherent properties of B. cepacia to mucin and epithelial cells
and the possible contribution of adherence to the initial stages of pulmonary
colonisation.
3. In view of the association of B. cepacia with bacteraemia in cystic fibrosis, the
ability of B. cepacia to resist the bactericidal activity of normal human serum was
examined.
4. Detection and characterisation of anti-5. cepacia antibodies in serum and sputum
from patients with CF. The nature of the antibody response was investigated to
determine specificity, the potential use for diagnosis and as a prognostic indicator
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and finally the antibodies were examined for deficiencies which may explain why





2.1.1 Patients and Specimens
Patients
Sputum and serum were obtained from CF patients attending the adult CF clinic (age
range 19 - 29 years) at the Western General Hospital (WGH), Edinburgh. In addition
saliva, nasal and buccal scrapes were also obtained from selected patients as required.
Sputum from CF patients attending the Edinburgh paediatric unit and serum from
adult CF patients attending the Manchester CF clinic were also examined. For the
purpose of this thesis, CF patients were classified on the basis of colonisation with B.
cepacia: a) non-colonised patients, from whom B. cepacia had never been isolated; b)
transiently colonised patients from whom B. cepacia had been isolated on one or two
occasions only; c) chronically colonised patients who were persistently colonised by
B. cepacia; and d) those patients who were chronically colonised with the epidemic
strain of B. cepacia. The bacteriology of each patient, particularly co-colonisation
with P. aeruginosa, was taken into account. Controls were chronic bronchitics
attending the Respiratory Unit at the WGH matched for degree of bronchiectasis, and
normal human volunteers from the laboratory.
Specimen Processing
Sera to be used in antibody studies were aliquoted into micronic tubes (Alpha
Laboratories, Eastleigh, Hants.) and stored at -20°C until analysis. Serum required in
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serum sensitivity assays was prepared by placing fresh venous blood in a water bath at
37°C for 30 min to allow clotting and then separated by centrifuging at 3980 g for 20
min (Bactifuge, Heraeus-Christ GMBH, Osterodf. W, Germany). Normal human sera
were pooled (PNHS) and half was aliquoted in 2 ml volumes in cryotubes (Nunc,
Inter Med, Kamstrup, Roskilde, Denmark) and stored at -70°C whilst the remaining
sera was heat inactivated (HIS) for 30 min at 56°C prior to storage. CF sera were
treated in the same manner but not pooled.
Bacteriology of sputum specimens was routinely performed by Mrs C. Doherty
(Department of Medical Microbiology, University Medical School, Edinburgh).
Sputa were homogenised in sputalysin (Calbiochem, La Jolla, CA, USA) and
following dilution were cultured quantitatively on blood agar, Hardey broth agar
(incorporating bacitracin), Pseudomonas isolation agar (PIA) and Pseudomonas
cepacia Medium (CEP). Any remaining sputum was aliquoted into 1.5 ml Eppendorf
tubes (Elkay Products Inc., Shrewsbury, MA, USA) and centrifuged (Micro Centaur,
MSE, Crawley, Surrey) at 11,600 g for 15 min. The sol phase was aliquoted in 200 |il
volumes and stored at -70°C until analysed.
2.1.2 Bacteria
Bacterial cultures were identified as B. cepacia by growth on CEP, colonial
morphology and by biochemical profile using API 20NE multi-tests.
B. cepacia Typing
B. cepacia typing, performed by Mrs C. Doherty, included bacteriocin typing of B.
cepacia strains by the spotting method described by Govan & Harris (1985) and
genotypic typing by Pulsed Field Gel Electrophoresis (PFGE: CHEF Bio-Rad
Laboratories Inc., Hercules, CA, USA).
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Table 2. Bacterial Strains used in this Thesis.
Bacterial Strains Description Source
B. cepacia ATCC: 10856; ATCC Catalogue (1989)






B. gladioli ATCC 10248 ATCC Catalogue (1989) Dr I.N. Simpson
B. cepacia ATCC 17616
(and derivatives)




B. cepacia Pc 5, Pc 24. Sajjan et al. (1992) Dr J. Forstner
Hospital For Sick Children
University of Toronto
Toronto, Ontario.
B. cepacia: J2534; 2535; 2536; Environmental survey, Royal DrJ.R.WGovan

















Rowe & Meadow (1983)
Dr I.R. Poxton
Dept. of Medical Microbiology
University Medical School,
Edinburgh.
Neisseria meningitidis A14 clinical isolate Dr John Stewart




Strains used in this thesis
The bacterial strains used in this thesis are shown in Table 2. All other strains,
including environmental, clinical and CF isolates of B. cepacia and P. aeruginosa, are
indicated in the relevant section of the Results, prefixed with SBC, J , JN or C.
Maintenance of bacterial strains
Bacterial strains were maintained at -70°C in 10% w/v skim milk (Oxoid L31, Oxoid
Ltd., Basingstoke, Hants.). Bacterial suspensions were prepared by emulsifying
several single colonies in 1.0 ml volumes of skim milk in 2.0 ml cryotubes. Fresh
maintenance cultures were prepared at approximately four monthly intervals.
2.1.3 Chemicals and media
Chemicals
Unless otherwise stated all chemicals were Analar grade (BDH, Merck Ltd., Poole,
Dorset) and were prepared in distilled water.
Complex Media
a) Nutrient yeast broth (NYB) was Oxoid No.2 supplemented with 0.5% w/v yeast
extract (Oxoid).
b) Isosensitest broth (ISTB) was Oxoid.
c) Nutrient agar (NA) was Columbia agar base (Oxoid).
d) Pseudomonas cepacia selective Medium (CEP) (Mast Laboratories, Bootle,
Merseyside).
e) Pseudomonas Isolation agar (PIA) (Difco Laboratories, Detroit, Michigan, USA).
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f) Furunculosis agar (Ogunnariwo & Hamilton-Miller, 1975) for detection of melanin
pigment production consisted of 1.0% w/v tryptone, 0.5% w/v yeast extract, 0.1%
w/v L-tryptone, 0.25% w/v sodium chloride and 1.5% w/v Bacteriological agar
(Oxoid).
g) Elastin-TSA plates for determination of elastase production consisted of 4.5% w/v
tryptone soy agar (TSA, Oxoid) with 0.1% w/v UV sterilised elastin-orcein (Sigma
Chemical Co., Poole, Dorset).
h) Tryptose minimal broth (TMB) for PLC production consisted of 0.2% w/v
tryptose (Sigma), 120 mM Tris HC1 pH 7.2, 50 mM glucose, 16 mM CaCl2, 10 mM
KC1 and 20 mM (NH4)2S04 (Based on Berka et al., 1981).
i) Semi-solid agar for motility studies (Luzar et al., 1985) consisted of 0.1% w/v
tryptone (Difco), 0.3% w/v yeast extract (Oxoid), 0.5% w/v sodium chloride and
0.4% w/v Bacteriological agar (Oxoid).
j) EMB/Glucose Indicator Media (Sage et al., 1990) for detection of glucose
dehydrogenase deficient (Gcd") strains of B. cepacia consisted of 0.2% w/v yeast
extract, 1.0% w/v glucose, 1.5% w/v Bacteriological agar, 200 (ig/ml eosin Y
(Sigma) and 33 (ig/ml methylene blue (Sigma).
k) TBT media for recovery of B. cepacia from soil (Hagedorn et al., 1987) consisted
of 2% w/v Bacteriological agar (Oxoid), 0.1% w/v L-asparagine, 0.1% w/v
NaHC03, 0.05% w/v KH2PO4, 0.01% w/v MgS04_7H20, 0.005% w/v Trypan Blue
(Sigma) and 0.002% w/v tetracycline. The pH was adjusted to 5.5 with 10%
phosphoric acid and the filter sterilised tetracycline was added to the autoclaved
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medium. To reduce fungal contamination crystal violet (5 mg/litre) and 0.005% w/v
filter sterilised nystatin were added.
All commercial media were prepared by the departmental Media Kitchen according to
manufacturers' instructions. Media were made up in distilled water and sterilised by
autoclaving at 15 psi for 15 min.
1) Malka minimal media (MM) was prepared as follows
Solution A: Na2HPC>4 (73.4 mg/ml); KH2 PO4 (32.4 mg/ml)
Solution B: MgS04-7H20 (20.5 mg/ml)
Solution C: 1% w/v glucose
Solution D: FeSC^JF^O (1.83 mg/ml) in sterile distilled water to which one
drop of concentrated hydrochloric acid (HC1) was added.
Solution E: (NH4)2S04 (50.0 mg/ml)
Solutions were prepared with sterile distilled water and were filter sterilised. All
solutions except C were stored over chloroform. To prepare 1 litre of Malka, 20 ml
A, 20 ml B, 20 ml C, 1 ml D and 20 ml E were added to 919 ml sterile distilled water.
m) B. cepacia enrichment broth (BcEB) was Malka minimal media with 300 U filter
sterilised polymyxin B (Sigma).
2.1.4 Miscellaneous
Animal Blood and Serum
Citrated animal blood for use in haemagglutination assays was obtained from
Moredun Animal Diseases Research Institute, Gilmerton Road, Edinburgh; the
Transgenic Unit, University Medical School, Edinburgh and Becton Dickinson
Laboratories. For serum sensitivity assays heat inactivated sheep serum was also
obtained from Moredun and sheep erythrocytes for determination of complement
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activity were obtained from the Scottish Antibody Production Unit, Law Hospital,
Carluke, Lanarkshire.
Lipopolvsaccharide
Rough- and smooth-LPS from P. aeruginosa were prepared by Dr J. Nelson (Dept.
of Medical Microbiology, University Medical School, Edinburgh). Phenol water
extracts of B. gladioli ATCC 10248 were prepared by Mrs D. Shaw (Dept. Medical
ofMicrobiology, University Medical School, Edinburgh).
Mucins
Purified human mucins for adherence studies were obtained from Dr J.K. Sheehan and
Dr D.J. Thornton (Department of Biochemistry and Molecular Biology, University of
Manchester) from asthmatic and CF patients. Mucin was supplied and stored as a
solution in 4 M guanidinium chloride at 4°C. Prior to use in adherence assays mucins
were diluted in coating buffer (100 |ig/ml), added to pre-boiled dialysis tubing with a
2000 molecular weight cut-off (Spectrum Medical Industries Inc., Los Angeles, CA,
USA) and dialysed overnight with stirring against 1 litre of coating buffer at 4°C.
Buffv Coat
Monocytes for chemiluminescent opsonophagocytosis assays were prepared from
Buffy Coat obtained from the Blood Transfusion Service (BTS, RIE, Lauriston Place,
Edinburgh, Lothian).
Antisera
Polyclonal antisera to B. cepacia was prepared in Dutch rabbits provided by Dr I.R.
Poxton (Department of Medical Microbiology, University Medical School,
Edinburgh). B. cepacia (J2395, CI359 and CI409) were heat killed in a water bath
at 62°C for 15 min (C1359) or 30 min (J2395 and C1409). Rabbits were immunised
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with 1.0 ml doses into the marginal vein of the ear on days 1,2,3,8,9,10 and 22 by Mr
J. Verth (Transgenic unit, University Medical School, Edinburgh) and a test bleed
performed on day 29 according to the method of Hancock & Poxton (1988). The
rabbit anti-P. aeruginosa flagella type-a and -b antisera were provided by Dr G.H.
Shand (Statens Seruminstitut, Copenhagen, Denmark).
2.1.5 Equipment
Equipment and apparatus used in the experimental studies is indicated in the relevant
section of the text. Manufacturers' addresses are only cited once.
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2.2 EXPERIMENTAL METHODS
2.2.1 Culture of Bacteria
Unless stated otherwise bacteria were all cultured at 37°C. Bacteria were streaked
onto NA or CEP as appropriate from the maintenance culture and were subcultured
onto fresh plate media within seven days. A maximum of four subcultures were
performed after which time fresh cultures were prepared from maintenance cultures.
Bacteria were inoculated into 10 ml of liquid medium which when required could be
inoculated into larger volumes for bulk growth. Liquid cultures were incubated in an
orbital incubator (Gallenkamp, Loughborough, Leics.) at 100-120 rpm unless
otherwise indicated.
2.2.2 Measurement of Bacterial Concentration
Viable counts
Serial ten-fold dilutions of bacteria were prepared in sterile phosphate buffered saline
(PBS; 50 mM phosphate buffer, pH 7.4, containing 0.15 M NaCl) and volumes of 100
pi were spread onto NA plates. Plates were incubated at 37°C for 24-48 h,
depending on the B. cepacia strain, and colonies were counted using a colony counter
(Gallenkamp).
Measurement of Optical Density
Measurements of absorbance were made at 525 nm (spectrophotometer, Spectronic
20, Bausch & Lomb). The suspending medium was used as a blank and as a diluent
for optical density (OD) measurements. A standard curve of log bacterial numbers (as
determined by viable count) against OD 525 was drawn. An optical density of 0.15 at
525 nm is equivalent to a concentration of approximately 1x10^ colony forming units
(cfu) of B. cepacia /ml.
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2.2.3 Measurement of Bacterial Growth
Effect of Temperature
A 250 ml flask containing 150 ml NYB was inoculated with 150 |il of an overnight
precuiture grown in NYB. The flasks were incubated at 25°, 37° or 43°C in an
orbital incubator. At 2 h intervals (up to 10 h) and at 24 h, samples were removed for
measurement of optical density and viable counts.
Effect of Culture Conditions
An overnight precuiture of B. cepacia grown in NYB was harvested by centrifugation
(3250 g for 10 min) and washed twice in PBS. The bacteria were resuspended in PBS
and retained at room temperature for 2-3 h prior to adding 150 pi of this suspension
to a 250 ml flask containing 150 ml NYB or MM. Flasks were incubated statically or
with aeration at 37°C. Measurement of optical density and viable counts were
performed as above.
2.2.4 Survival of b. cepacia
Water
Several single colonies of B. cepacia were emulsified in 10 ml of tap or pyrogen-free
water which were retained at room temperature. At weekly intervals, for a period of
4 months, 100 pi was removed and spread onto CEP. After incubation at 37°C for
24-48 h the plates were examined for growth of B. cepacia.
Antiseptics
The triple challenge capacitance test of Kelsey & Sykes (1969) was used to determine
the efficacy of antiseptics against B. cepacia. The antiseptics were used neat (as
directed by manufacturer) or diluted in sterile distilled water to three concentrations:
(1) the manufacturer's recommended concentration; (2) 25% less concentrated; and
(3) 25% more concentrated than the recommended concentration. Bacteria (1.0 ml of
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an overnight culture) in NYB were added to 3 ml of the antiseptic, and the mixture
was shaken. After 8 min at room temperature, five 50 |il volumes were removed and
spotted onto NA. After 2 min the antiseptic was challenged with a further 1 ml of the
bacterial culture, and 8 min later five 50 (il volumes were removed as before. The
process was repeated once more. After allowing the spots to dry the plates were
incubated for 24-48 h. The antiseptics and recommended concentrations were
Povidone Iodine (neat; Betadine, Napp Laboratories Ltd., Cambridge, Norfolk),
Listerine (neat; Warner Lambert Healthcare, Hampshire), 70% ethanol, Cetavlon
(1:20; ICI Pharmaceuticals Division, Macclesfield, Cheshire), Hibitane (1:100; ICI)
and Roccal (1:10; Winthrop Pharmaceuticals, Surbiton-upon-Thames, Surrey)
2.2.5 Screening b. cepacia forMelanin Production
B. cepacia was subcultured from CEP to furunculosis agar and incubated for 48 h at
37°C. Plates were then examined for the production of melanin, a dark brown
diffusable pigment.
2.2.6 Determination of Elastase Production
An elastase assay, based on that of Baker (1982) was used to examine strains of B.
cepacia for elastase production. Elastase-TSA plates were inoculated with bacterial
suspensions (1 colony emulsified in 1 ml sterile saline) using a multi-point inoculator
(Denley Instruments Ltd., Billingshurst, Sussex). After incubation for 24-48 h plates
were examined and the diameter of any zone of clearing was measured.
2.2.7 Determination of Phospholipase C Activity
The assay to determine PLC activity was based on the method of Berka et al. (1981).
Single colonies from CEP and PIA were used to inoculate 2 ml TMB in capped test
tubes (16 x 150 mm). The tubes were shaken at 120 rpm for 48 h at 37°C, and the
optical density of each culture was measured at 540 nm. Cells were removed from 1
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ml of culture by centrifugation at 11,600 g for 5 min, and approximately 10 pg of
activated charcoal was added to the supernatant to remove pigment. After
centrifuging to remove the charcoal 10 pi of the clear supernatant was added to 90 pi
NPPC reagent in a 96 well flat-bottomed microtitre plate (Nunc). The NPPC reagent
contained 250 mM Tris HC1 pH 7.2; 60% w/w glycerol; 1.0 pM ZnCl2 and 10 mM p-
nitrophenylphosphorylcholine (NPPC; Sigma). The plates were incubated for 1 h in a
plate incubator (Dynatech Laboratories Ltd., Billingshurst, West Sussex) shaking at
37°C before the absorbance at 405 nm was measured in an automated plate reader
(Titertek Multiskan/MC, Flow Laboratories Ltd., Irvine, Strathclyde).
2.2.8 Screening of b. cepacia for Exopolymer Production
B. cepacia strains were patch inoculated on to the following plate media: CEP; NA;
PIA; EMB/glucose indicator medium; MM and MM with solution E replaced by 10
mM KNO3. The plates were incubated at 37°C for 72 h in a moist atmosphere and
then examined for mucoid colonial phenotype. Those strains which appeared to
produce an exopolymer were mixed with India ink and examined under phase contrast
microscopy for capsule production.
2.2.9Motility assays
Motility in Semi-solid Agar
Bacterial strains were cultured on CEP and five colonies for each strain were stab
inoculated into the centre of the motility medium. For each assay triplicate plates per
strain were incubated at 37°C and examined for colony spreading. Colony diameter
was measured after 24-48 h.
Motility in Liquid Culture
Bacterial strains were cultured in NYB for 16 h and examined for motility under
phase contrast microscopy.
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2.2.10 Electron Microscopy ofWhole Cells
Simple negative staining was performed using the method described by Hancock &
Poxton (1988). Overnight cultures of B. cepacia grown in NYB were harvested by
centrifugation, washed once in sterile PBS and the pellet was resuspended to milky
turbidity in 1.0% w/v ammonium acetate. Formvar-coated 400 mesh copper grids
were floated on a drop of this suspension for approximately 1 min then touched
against filter paper (Whatman No. 1) to remove excess moisture. The grid was then
placed on a drop of 2.0% w/v phosphotungstic acid (PTA) (neutralised to pH7.0 with
sodium hydroxide) for 1 min. Grids were dried in a desiccator prior to viewing in a
Hitachi 12A transmission electron microscope at 75 KV.
2.2.11 Measurement ofCell Surface Hydrophobicity
Cell surface hydrophobicity was determined by hydrophobic interaction
chromatography (HIC) based on the method of Smyth et al. (1978) using octyl
sepharose CL-4B (Pharmacia LKB, Uppsala, Sweden) as the non-polar ligand and
Sepharose CL-4B (Pharmacia) to correct for non-specific adsorption.
Disposable polystyrene chromatography columns (Pierce & Warriner (UK) Ltd.,
Chester) were prepared fresh according to the manufacturing instructions. Columns
were packed with pre-swollen gel slurries which had been washed to remove
preservative and then prepared with 50 mM phosphate binding buffer (pH 7.0)
containing 1.7M (NH^ SO4 (gel constitutes approximately 70% of the final
volume). The gel slurries were degassed prior to adding to columns to give a 2 ml
packed bed volume. Columns were then washed with binding buffer and capped until
required to prevent drying.
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Bacteria cultured overnight in 10 ml NYB were harvested and washed twice in sterile
binding buffer. The bacteria were resuspended in binding buffer to give 1()4 cfu/ml
before application to the columns. Bacterial suspensions (2 ml) were added to the
column followed by 2 ml 4M NaCl to ensure adequate wash-through of cells.
Retention of cells by the columns was assessed by viable counts of the initial
suspension and of the column eluates.
2.2.12 Proteinase K digestion of Bacteria for the Preparation of
Lipopolysaccharides
The Proteinase K digestion of bacteria (Hitchcock & Brown, 1983), suitable for both
R- and S-LPS types, was used to prepare LPS for analysis by polyacrylamide gel
electrophoresis (PAGE) and immunoblotting. Bacteria cultured overnight in 10 ml
NYB were harvested by centrifugation and washed twice in PBS. The bacteria were
resuspended in PBS to give an absorbance between 0.5 and 0.6 at 525 nm as
measured on the spectrophotometer. Bacterial suspension (1.5 ml) was transferred to
an Eppendorf tube and the bacteria sedimented by centrifugation at 11,600 g for 3
min. The pellet was resuspended in 50 fil single strength PAGE sample buffer (see
page 7 V) and boiled (100°C) for 10 min. Once cooled 10 |il sample buffer containing
25 fig Proteinase K (protease Type XI, Sigma) was added and samples were
incubated at 60 °C for 60 min in a water bath. Samples were stored at -20°C.
2.2.13 Preparation of Rough Lipopolysaccharide
The aqueous phenol, chloroform, petroleum ether (PCP) method of Galanos et al.
(1969) incorporating the diethyl ether precipitation of LPS described by Qureshi et al.
(1982), was used to prepare LPS from the epidemic strain of B. cepacia which
expresses the R-LPS phenotype.
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Two litre flasks (ten) containing 1 litre of NYB were inoculated with 2.0 ml of an
overnight preculture grown in NYB. After incubation in an orbital incubator (120
rpm) at 37°C for 48 h bacterial cells were harvested by centrifugation at 15,000 g
using a KSB continuous flow system (Dupont UK Ltd., Stevenage, Herts.). Cells
were then washed twice in PBS with centrifugation (Sorval RC-5B refrigerated
superspeed centrifuge, Dupont) at 10,000 g for 10 min. The bacterial pellet was
frozen at -20°C, freeze dried (Edwards Modylo freeze dryer, Edwards High Vacuum
Ltd., Crawley, Surrey) and weighed.
The extraction solvent (PCP) consisted of 90% w/v aqueous phenol (90 g phenol
were dissolved in 10 ml water at 45°C and then made up to a total of 100 ml with
distilled water), chloroform and petroleum spirit (boiling point 40°-60°C) in the
proportions 2:5:8 by volume. Dried bacteria were solubilised in PCP at 25% w/v,
stirred for 2 min at room temperature and centrifuged at 10,000 g for 15 min. The
supernatant was filtered through Whatman No. 1 filter paper into a round bottomed
flask. The centrifuged pellet was re-extracted by the same procedure and the filtered
supernatants were pooled and then rotary evaporated (Buchi Rotavapor-REl 11,
Switzerland) to remove petroleum spirit and chloroform.
In order to precipitate the LPS six volumes of diethyl ether/acetone in the ratio of 1:5
by volume were added to one volume of the phenol solution (Qureshi et al., 1982).
After standing at room temperature for at least one hour the LPS was sedimented by
centrifugation at 5000 g for 10 min. The centrifuge tubes were drained and the pellet
washed three times with diethyl ether/acetone, the pellet being recovered by
centrifugation each time. The final pellet was dried under vacuum until the smell of
ether/acetone was no longer detectable. The dried pellet of LPS was resuspended in 5
ml pyrogen-free water with the aid of a syringe and a 23-gauge needle and recovered
by ultracentrifugation (Sorval ultracentrifuge - OTD65B, Dupont) at 100,000 g for 4
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h. The LPS was then taken up in a minimal amount pyrogen-free water, lyophilised
and stored at -20°C.
2.2.14 Preparation of Smooth Lipopolysaccharide
Extraction of S-LPS from B. cepacia strains was based on the aqueous phenol
method of Westphal & Luderitz (1954). Bacteria were cultured and lyophilised as
described for R-LPS preparations.
The lyophilised pellet was finely divided, resuspended to a concentration of 5% w/v in
pyrogen-free water and heated to 67°C in a water bath. An equal volume of 90% w/v
aqueous phenol was added to the bacterial suspension in the water bath and the
mixture stirred at 67°C for 15 min. The mixture was transferred to 50 ml centrifuge
tubes, cooled in an ice bath to allow initial separation of the aqueous and phenol
phases and centrifuged at 10,000 g for 15 min to complete the separation. The upper
(aqueous) phase containing the LPS was removed and the extraction procedure
repeated on the lower phase. The aqueous phases were pooled, transferred to pre-
boiled dialysis tubing and dialysed against running tap water overnight until the smell
of phenol was no longer detectable. Any insoluble deposit was removed by
centrifuging twice for 15 min at 10,000 g. The dialysed extract was then concentrated
by rotary evaporation to approximately one-fifth of the original volume and then
ultracentrifuged at 100,000 g for 3 h. The gelatinous pellet obtained was resuspended
in pyrogen-free water with the aid of a syringe and a 23-gauge needle and
recentrifuged. The final LPS pellet was suspended in approximately 0.5 ml pyrogen-
free water, freeze dried, weighed and stored at -20°C.
2.2.15 Crude Preparation ofOuterMembrane Proteins
Overnight cultures of B. cepacia strains grown in one litre flasks containing 500 ml
ISTB at 37°C with aeration were harvested and washed twice in PBS at 6000 g for
69
10 min at 4°C. The pellet was resuspended in 20 ml pyrogen-free water and
sonicated at an amplitude of 8 |im (Microson, Ultrasonic Cell Disruptor, Heat
Systems-Ultrasonics Inc., NY, USA) to break cells. Unbroken cells were removed by
centrifugation at 7000 g for 10 min. Outer membranes were derived by solubilisation
in 2% w/v Sarkosyl (N-lauroyl sarcosinate; Sigma) for 45 min at room temperature.
Outer membranes were collected and washed by centrifugation at 38,000 g for 1 h at
4°C. The pellet was resuspended in 0.5 ml pyrogen-free water and frozen at -20°C.
Protein concentration in the samples was approximated by comparing density of bands
on a polyacrylamide gel to known standards.
2.2.16 Preparation of Flagella
For preparation of B. cepacia flagella, 2 litre flasks containing 1 litre NYB (two flasks
per strain) were inoculated with 2.0 ml of an overnight preculture of B. cepacia
grown in NYB. The flasks were incubated for 48 h at 37°C in an orbital incubator
(120 rpm). Bacterial cultures were then harvested by centrifugation at 10,000 g for
15 min at 4°C and washed twice in PBS. Each bacterial pellet was suspended in 2 ml
PBS and homogenised (T1500, Ystral GmbH, W. Germany) for approximately 2 min.
Bacterial cells were removed by up to ten cycles of centrifugation (10,000 g for 10
min at 4°C). Removal of cells was monitored at intervals by microscopy and culture
of supernatant. The cell free supernatant was ultracentrifuged at 100,000 g for 2 h at
4°C, and the resultant pellet washed twice in pyrogen-free water. The pellet was then
resuspended in 0.5 ml pyrogen-free water, dialysed overnight with stirring at 4°C
against pyrogen-free water containing 0.05% w/v sodium azide (Sigma) and stored at
-20°C. The amount of protein in each sample was determined using a protein assay
(Bradford reagent, Bio-Rad).
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Negative Staining of Flagella with PTA
The flagella preparations were viewed by electron microscopy to confirm absence of
whole cells. Formvar-coated 400 mesh copper grids were floated onto a 10 pi drop
of flagella sample diluted 1:10 in pyrogen-free water. Grids were then processed and
viewed as previously described.
2.2.17 Preparation of Samples for Polyacrylamide Gel
Electrophoresis
Sample buffer (pH 6.8) contained 0.0625 M Tris with 2.0% w/v sodium dodecyl
sulphate (SDS) (BDH Specially Pure), 10% v/v glycerol, 1% v/v 2-mercaptoethanol
and 0.001% bromophenol blue. Double strength sample buffer (pH 6.8) was prepared
in the same manner except that concentrations of constituents were doubled.
Protein Samples
The protein concentration of flagella preparations, as determined by the Bradford
reagent, was adjusted to 1.0 mg/ml. The outer membrane preparations were used
directly. Samples were mixed with an equal volume double strength sample buffer
and denatured by boiling at 100°C for 10 min prior to adding to a gel.
Lipopolvsaccharide
Proteinase K samples prepared as described, were added to gels at 15 |il per track.
Samples of extracted LPS (1.0 mg/ml), were mixed with an equal volume of single
strength sample buffer and boiled at 100°C for 10 min. Samples were added at 10 pg
per track.
2.2.18 PolyacrylamideGel Electrophoresis (PAGE)
PAGE was performed with the buffer system of Laemmli (1970). The following
buffers and solutions were used in PAGE:
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a) Electrode buffer (pH 8.3) consisted of 0.025 M Tris, 0.192 M glycine (BDH
Chromatographically Homogeneous) and 0.1% w/v SDS. For the Mini-Gel system
lOx Tris/glycine/SDS buffer (Bio-Rad, Electrophoresis Purity Reagent) was used,
made up in pyrogen-free water.
b) Separating gel buffer (double strength, pH 8.8) consisted of 0.75 M Tris-HCl to
which 0.2% w/v SDS was added, (SDS was omitted in buffer intended for use in
preparing immunoblots).
c) Stacking gel buffer (double strength, pH 6.8) consisted of 0.25 M Tris-HCl to
which 0.2% w/v SDS was added, (SDS omitted as in (b) above).
d) Acrylamide stock solution (40% w/v) contained 100 g acrylamide (BDH
Electrophoresis Grade) and 2.7 g methylene bis acrylamide (BDH Electrophoresis
Grade) and was made up to 250 ml with distilled water.
The separating gel was prepared as described in Table 3 and poured between cleaned
(with methanol) glass plates (160 mm x 125 mm x 1.5 mm) with the aid of a 50 ml
syringe and a 19-gauge needle. The gel was overlaid with water-saturated butan-2-ol
and allowed to set. After removal of the butan-2-ol, the stacking gel (see Table 3)
was poured onto the separating gel and a 20 well comb was inserted before the gel
began to set. On removing the comb the gel was fitted into an electrophoresis tank
(Jencons Scientific Ltd., Leighton Buzzard, Beds.) and the electrode buffer added.
Samples, prepared as described, were loaded into the wells of the stacking gel.
Samples were electrophoresed through the stacking gel at a constant 60 V and
through the separating gel at a constant 150 V until the dye front had run 80-100 mm.
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After electrophoresis, samples were analysed by staining or by immunoblotting after
transfer to nitrocellulose.
Table 3. Preparation of Polyacrylamide Gels
Volume (ml) to give acrylamide
concentration of:
Reagent Separating gel Stacking gel
12% 14% 4%
Distilled water 5.2 3.45 3.5
Separating buffer 17.5 17.5 -
Stacking buffer - - 5.0
Acrylamide solution (40% w/v) 10.5 12.25 1.0
TEMED (NNN'N'-tetramethyl-1,2-
0.05 0.05 0.02diaminoethane)
Ammonium persulphate (15 mg/ml) 1.75 1.75 0.5
2.2.19 Silver Staining of Polyacrylamide Gels for Lipopolysaccharide
The methods of Tsai & Frasch (1982) and Hitchcock & Brown (1983) were adapted
to visualise LPS in polyacrylamide gels. The following reagents and solutions were
used in the silver staining procedure:
a) Fixative consisted of 7% v/v acetic acid and 25% v/v propan-2-ol.
b) Oxidising solution contained 1.05 g periodic acid in 150 ml distilled water to
which 4.0 ml of fixative was added.
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c) Ammoniacal silver nitrate solution was made up by mixing 1.4 ml ammonia
solution with 21.0 ml of 0.36% w/v sodium hydroxide and the slow addition of 4.0 ml
19.4% w/v silver nitrate accompanied by vigorous agitation. The volume was made
up to 100 ml with distilled water.
d) Developing solution consisted of 0.019% v/v formaldehyde solution containing
0.005% w/v citric acid.
Following electrophoresis the gel was placed in fixative and left overnight at room
temperature. Fixative was poured off and freshly prepared oxidising solution added
to the gel for 5 min. The gel was washed in at least four changes of 200 ml distilled
water over a period of 4 h. Silver staining was carried out by addition of fresh
ammoniacal silver nitrate solution. After staining for 15 min the gel was washed in
four changes of distilled water (200 ml) over 40 min. LPS was visualised by the
addition of 200 ml of fresh developing solution. Once the desired staining intensity
was attained (approximately 15 min) the gel was washed in large volumes of distilled
water. All the above reaction steps were carried out on a shaking platform.
2.2.20 Silver Staining of PolyacrylamideGels for Protein
The method of Oakley et al. (1980) was adapted for the staining of polyacrylamide
gels to visualise protein. The following solutions and reagents were used in addition
to those described for silver staining LPS:
a) Prefix 1 consisted of 50% v/v methanol and 10% v/v acetic acid made up to 200
ml in distilled water. Prefix 2 consisted of 5% v/v methanol and 7% v/v acetic acid
also made up to 200 ml with distilled water.
b) 200 ml of 10% v/v glutaraldehyde (unbuffered) in distilled water.
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c) Dithiothreitol, 5|ig/ml in distilled water.
The gel was placed in prefix 1 for 30 min, followed by prefix 2 also for 30 min. Prefix
2 was poured off and 10% glutaraldehyde solution added for a further 30 min. The
gel was then washed twice in 250 ml distilled water and then soaked overnight in
fresh distilled water. Freshly prepared dithiothreitol solution was added for 30 min,
poured off and replaced by fresh ammoniacal silver nitrate. The remaining steps were
as described for silver staining of LPS.
2.2.21 Coomassie Blue Staining of Polyacrylamide Gels for Protein
The Coomassie blue stain described by Hancock & Poxton (1988) was used. The
solutions were made up in distilled water and were:
a) Solution 1 - 25% v/v propan-2-ol, 10% v/v acetic acid and 0.05% w/v Coomassie
brilliant blue R-250 (Bio-Rad).
b) Solution 2 - 10% v/v propan-2-ol, 10% v/v acetic acid and 0.005% w/v
Coomassie blue.
c) Solution 3 - 10% v/v acetic acid and 0.0025% w/v Coomassie blue.
d) Solution 4 - 40% v/v methanol and 10% v/v acetic acid.
e) Solution 5 - 10% v/v acetic acid.
The gel was placed in solution 1 overnight and then sequentially through solutions 2-
5, each for 45-60 min at room temperature with gentle shaking throughout.
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2.2.22 IMMUNOBLOTTING
A modification of the method of Towbin et al. (1979) was used in the
immunochemical analysis of bacterial cell components separated by PAGE and
transferred to nitrocellulose (NIC) paper (pore size 0.3 |im) (Schleicher & Schuell,
Dassel, Germany). The following reagents and solutions were used:
a) Electrode transfer buffer (pH 8.3) contained 12 g Tris (Bio-Rad, Electrophoresis
Grade), 57.68 g glycine (BDH Chromatographically Homogeneous) in 4 litres
distilled water and 1 litre methanol.
b) Tris buffered saline (pH 7.5) (TBS) contained 4.84 g Tris and 58.48 g sodium
chloride in 2 litres distilled water.
c) Tween-Tris buffered saline (pH 7.5) (TTBS) was as for TBS with 0.025% v/v
Tween-20 (Sigma).
d) Blocking solution was as for TBS with 3% w/v gelatin (Bio-Rad, EIA Purity
Grade)
e) Antibody diluent was as for TBS with 1% w/v gelatin.
f) Horseradish peroxidase (HRP) colour development solution was made up directly
before use and contained 30 mg HRP colour reagent (Bio-Rad EIA Purity Grade)
dissolved in 10 ml methanol and added to 50 ml TBS containing 70 (il hydrogen
peroxide.
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Electrophoretic Transfer of Antigens from Polyacrvlamide Gels to Nitrocellulose
The gel was removed from the PAGE apparatus and placed in a ScotchbriteTM pad
cassette of the blotting apparatus (made by Mr J. Duffus, Dept. of Medical
Microbiology, University Medical School, Edinburgh). The gel was then covered
with a sheet of NIC pre-soaked for 10 min in transfer buffer. The cassette was then
closed sandwiching the gel and NIC between the Scotchbrite pads and placed into the
immunoblotting tank containing transfer buffer, ensuring that the gel was placed
towards the cathode and the NIC towards the anode. A constant current of 40 mA
was applied overnight at 4°C.
Visualisation of the Antibodv-antigen Reactions
After transfer the NIC was removed and washed in TBS for 10 min before placing in
blocking solution for 30-45 min. The blocking solution was poured off and the
antibody diluent, containing an appropriate dilution of sample (serum or sputum),
added and incubated for 3 h at room temperature. The NIC was rinsed briefly in
distilled water and then washed twice (each for 10 min) in TTBS, following which it
was incubated for 60 min with HRP-conjugated secondary antibody diluted 1:500 (for
anti-human conjugates) or 1:1000 (for anti-rabbit conjugate) in antibody diluent. The
type of conjugate used depended upon the particular investigation (see Results) and
included: anti-human IgG; anti-human-IgA and anti-rabbit IgG (ICN Biomedicals Ltd,
high Wycombe, Bucks.). After rinsing in distilled water and washing in TTBS (as
above), the binding of antibody to separated antigenic determinants was visualised by
addition of the HRP colour solution until colour development was sufficient. The
reaction was stopped by rinsing with copious quantities of distilled water, the NIC




For analysis of multiple sera against a single antigen Mini-Gel and Multi-Screen
apparatus (Bio-Rad) were used. The procedures for running mini PAGE,
electrophoretic transfer and visualisation of the antibody-antigen reaction were
essentially the same as for the larger system, with the following exceptions.
Following electrophoretic transfer and blocking the NIC was placed in the multi¬
screen apparatus which was then firmly secured. Samples (sera or sputa) were diluted
1:200 in TIBS containing 1.0% v/v Bovine serum albumin (BSA; Boseral, Organon
Teknika B.V., Boxtel, Holland) and added to each lane carefully to avoid formation of
air bubbles. Following overnight incubation in the multi-screen apparatus, the
apparatus was shaken vigorously over a sink to empty-out the TTBS-BSA/sample,
the NIC was removed and placed in a staining tank, rinsed twice in distilled water and
then washed twice in TTBS. The remaining stages, from the addition of HRP-
conjugated secondary antibody were as described above.
2.2.24 Enzyme-Linked Immunosorbent Assay (ELISA)
Polystyrene microwell strips (Greiner Labotechnik, Dursley, Glos.) fixed in to a frame
to form 'plates' were used in ELISA experiments. Mini-sorb tubes (Nunc) were used
for making antigen dilutions. The following diluents and buffers were used in the
various ELISA procedures:
a) Coating buffer (pH 9.6) consisted of 0.05 M carbonate/bicarbonate buffer (6.2
g/litre Na2CC>3 H2O and 4.2 g/litre NaHC03) with 0.05% w/v sodium azide.
b) Post-coat buffer consisted of PBS (pH 7.2) containing 5% v/v BSA and 0.05%
w/v sodium azide.
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c) Wash buffer consisted of PBS (pH 7.2) containing 0.05% v/v Tween-20 and
0.05% w/v sodium azide.
d) Dilution buffer consisted of PBS (pH 7.2) containing 0.05% v/v Tween-20, 4.0%
w/v polyethylene glycol 6000 (Sigma) and 0.05% w/v sodium azide.
e) Alkaline phosphatase substrate buffer consisted of 0.05 M carbonate buffer (pH
9.8) (21.2 g/litre Na2CC>3 and 16.8 g/litre NaHC03) and 1.0 mM MgCl2-6H20.
Immediately prior to use, one alkaline phosphatase 5 mg tablet (Sigma 104
phosphatase substrate tablets) per 5 ml buffer was added. The alkaline phosphatase
substrate buffer was also used as a blank to calibrate the plate reader.
ELISA Coating Procedure
Coating with LPS-polvmyxin complex (Scott & Barclay, 1987)
Stock solutions of LPS and polymyxin were made up in distilled water and sonicated
for 8x30 s prior to mixing. Complexes were formed by adding polymyxin B sulphate
(Sigma) at a concentration of 0.2 mM to LPS at a concentration of 0.1 mM and then
sonicating for another 8x30 s. The mixture was then dialysed (in 2000 molecular
weight cut-off dialysis membrane) overnight at 4°C against pyrogen-free water
containing 0.05% w/v sodium azide to remove unbound polymyxin. Complexes were
stored in mini-sorb tubes at -20°C. To coat microwell strips, the complex was diluted
1:50 in coating buffer and added at 100 (il per well. After coating overnight at room
temperature plates were washed four times with wash buffer (Microwash 2, Skatron,
Traby, Lier, Norway). Wells were post-coated with post-coat buffer at 100 (il per
well overnight at room temperature. (Wells coated with post-coat only were
background controls). After washing four times plates were rinsed with distilled
water and stored at -20°C. Plates were also coated with P. aeruginosa LPS in the
same manner.
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Coating with Whole Bacteria
Bacteria were grown overnight in NYB, harvested and washed twice with PBS. Cells
were resuspended to a density of 10^ cfu/ml (determined spectrophotometryally) in
coating buffer and added at 100 p.1 per well. Plates were then centrifuged at 1365 g
for 5 min to sediment bacteria to the wells. Following overnight coating at room
temperature the procedures were as described for LPS-polymyxin coating.
Coating with Mucin
Mucins were diluted in coating buffer and added at 100 pi per well. A coating
concentration of 1C |ig/ml gave optimal sensitivity, showing the maximal difference
in OD between background controls and mucin-coated wells. Wells were coated
overnight at room temperature, washed and post-coated as described above.
ELISA Experimental Procedures
The coated microwell strips were used in the following ELISA studies:
Detection of serum IgA. IgG and IgM. anti-^. cepacia LPS antibodies
Serially diluted sera (1:100 - 1:12800 for IgA and IgM and 1:400 - 1:52000 for IgG)
in dilution buffer were added to the R-LPS/polymyxin B microwell strips at 100 pi
per well in triplicate. After incubation at 37°C for 90 min in a plate incubator, plates
were washed four times with wash buffer. Conjugates, alkaline phosphatase
conjugated to anti-human IgA, IgG or IgM (Sigma) were diluted 1:1000 in dilution
buffer and added at 100 |il per well. Plates were incubated for a further 90 min at
37°C, washed as above and then rinsed five times in distilled water before addition of
alkaline phosphatase substrate at 100 pi per well. After incubation at room
temperature for 30 min, the OD of wells was read at 405 nm in an automated plate
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reader. Final results were expressed as the titre giving an OD >0.1 after subtraction
of the OD of negative control wells.
Detection of Serum IgG Subclass Anti-B. cepacia Antibodies
Serially diluted serum was added to R-LPS/polymyxin coated plates as above. After
washing, mouse anti-human IgG (clone HP-6017, Sigma), IgGl (clone HP-6069,
ICN), IgG2 (clone HP-6002, ICN), IgG3 (clone HP-6047, ICN) and IgG4 (clone HP-
6025, Sigma) monoclonal antibodies conjugated to biotin, diluted 1:1000 in dilution
buffer were added and incubated at 37°C for 90 min. Plates were washed and
streptavidin alkaline phosphatase (Sera-Lab Ltd., Crawley Down, Sussex) diluted
1:500 in dilution buffer was added and plates re-incubated. After washing, substrate
was added the plates treated as described above.
Detection of Sputum IgA and IgG
The assay was as for detection of antibodies in serum with the exception that sputum
was diluted 1:25 - 1:3200.
Anti-ff. cepacia LPS Antibody Specificity
To investigate the specificity of the anti-5. cepacia LPS antibodies serum was serially
absorbed with preparations of purified R-LPS of the epidemic strain of B. cepacia
(CI359) and P. aeruginosa PAC608. Sera were mixed with an equal volume of R-
LPS at 1 mg/ml and incubated for 60 min at 37°C followed by overnight incubation at
4°C. Samples were suitably diluted prior to use in ELISA studies.
2.2.25 Measurement of Serum IgG
The concentration of serum IgG subclasses was determined by Radial
Immunodiffusion Assay (BindArid, the Binding Site, Birmingham). The assay was
performed as described in the manufacturing instructions; for determination of IgGl
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and IgG2 concentration, test and control serum (the latter provided by manufacturers)
were diluted 1:10 in BSA, whilst serum was used neat for determination of IgG3 and
IgG4 concentration. Volumes of serum (5 (il) and calibrators (also provided) were
added to the radial immunodiffusion plates, which were then incubated at 22°C in a
moist box for 72 h. Diffusion was read, to the nearest point-one of a millimetre, with
the aid of an eye-piece. Concentration of each IgG subclass was calculated from a
calibration curve drawn using the diffusion results of the calibrators and control sera.
2.2.26 Chemiluminescent Opsonophagocytosis Assay
The potential of the antibodies in CF sera to inhibit opsonophagocytosis was
investigated by chemiluminescent opsonophagocytosis assay.
Preparation of Mononuclear Cells from Buffv Coat
Buffy coat was diluted 1:1 with RPMI-1640 (Gibco BRL, Paisley, Strathclyde) and
carefully layered onto 25 ml lymphocyte separation medium (ICN Flow) in 50 ml
centrifuge tubes. The diluted buffy coat was centrifuged at 1000 g for 30 min without
the brake. The white layer (mononuclear cells) at the interface of the plasma and
lymphocyte separation medium was carefully removed. After centrifuging at 180 g
for 15 min the cell pellet was resuspended in RPMI-1640 and centrifuged again. The
final pellet was then resuspended in 8-10 ml HBSS (Sigma with Ca^+, Mg^+, 1
mg/ml filter sterilised glucose but no phenol red). The cells were counted using a
haemocytometer (Thoma, Hawksley, England), adjusted to approximately 4x10^
cells/ml and placed on a continuous roller until used.
Preparation of Bacteria
Overnight cultures of bacteria grown in NYB were harvested and washed twice in
HBSS and then resuspended in HBSS to a concentration of 1x10^ cells/ml
(determined spectrophotometrically). Bacterial suspension (0.5 ml) was added to 0.5
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ml heat inactivated serum (HIS) in a sterile Eppendorf tube and incubated at room
temperature for 90 min. The mixture was centrifuged at 5800 g for 5 min and the
supernatant carefully pipetted off. After washing twice in HBSS the pellet was
resuspended in 0.5 ml HBSS. Controls were bacteria treated in the same way without
addition of serum.
Chemiluminescence Assay
The order and timing of sample addition to the wells of luminostrips (Labsystems,
Basingstoke, Hants) is important and where possible a multi-channel pipette was used.
After addition of HBSS (100 |il per well) the bacteria/antibody suspension or bacteria
alone were added in duplicate at 50 |il per well and 50 |il of 6 mg/ml Zymosan A
(Sigma) in HBSS was also added in two control wells (as a control stimulant of
phagocytosis to indicate the activity of the mononuclear cells). Luminol (5-amino-
2,3-dihydro-l,4-phthalazinedione, Sigma: 10~3 M) diluted in HBSS was added at 100
|il per well and finally 50 |_tl per well of mononuclear cell suspension. The plate was
shaken and immediately placed in a Luminoskan (Labsystems) pre-warmed to 37°C
where readings of chemiluminescence were taken every 5 min for 90 min.
2.2.27 Examination of Upper Respiratory Tract Specimens for B.
cepacia
Mouth and peri-nasal swabs, buccal scrapings and saliva from CF patients on two
separate occasions were examined for B. cepacia. All samples were taken prior to
sputum collection. Swabs and scrapings were transported from the WGH in BcEB.
The BcEB containing peri-nasal and mouth swabs were incubated at 37°C for up to 3
weeks prior to subculturing onto CEP. The BcEB containing buccal scrapings was
filtered through a 2.2 |j,m pore filter, which allows passage of B. cepacia but not
buccal epithelial cells (BEC). The filter paper was then placed onto CEP, and the
filtrate cultured as above. Saliva was cultured quantitatively onto CEP.
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2.2.28 Haemagglutination assay
The capacity of B. cepacia to agglutinate a variety of defibrinated or citrated
erythrocytes was investigated by a haemagglutination assay based on that of Duguid
et al. (1979). Overnight cultures of B. cepacia grown in NYB at 37°C were
centrifuged and the pellet resuspended in 0.5 ml fresh NYB. Erythrocytes were
separated by centrifuging at 2545 g for 10 min and washed in sterile PBS four times
prior to resuspending in PBS to give a cell concentration of 3% v/v. One drop of
sterile PBS or 2.0% w/v a methyl mannoside was added to a porcelain tile, followed
by one drop of the erythrocyte suspension and finally by one drop of bacterial
suspension. The tile was rocked gently at room temperature for up to 30 min and the
wells examined for haemagglutination. Variations on the assay were culture of
bacteria in MM broth or growth at 30°C.
2.2.29 Bacterial Adhesion toBuccal Epithelial Cells
The binding of B. cepacia to BEC was investigated using fluorescent staining and
flow cytometry.
Preparation of Bacteria
Bacteria grown overnight in NYB, (the N. meningitidis control was grown on New
York City Agar (Oxoid) in 5% CO2), were washed three times in PBS at 1341 g for
25 min. The supernatant was poured off and the pellet 'loosened' with a 1 ml pastette
prior to addition of 1.0 ml FITC (fluorescein isothiocyanate, Sigma) in FITC buffer
(0.05 M NaC03, 5.84 g/litre; 0.1 M NaCl, 5.3 g/litre; pH 9.2). After washing twice




BEC from normal volunteers and CF patients were scraped, (six cotton wool swabs
per individual), suspended in PBS and then washed twice at 200 g for 10 min. After
washing, BEC were resuspended in 5 ml PBS, counted using a haemocytometer and
the cell number adjusted to 3x10^ BEC/ml. The BEC were then mixed with the
bacterial suspension (ratio 1:100) and incubated at 37°C for 30-45 min. The mixture
was washed three times at 200 g for 10 min, the supernatant poured off with care
each time so as not to lose cells. Cells were fixed in 3.0 ml buffered
paraformaldehyde and then placed at 4°C overnight prior to reading fluorescence on
an EPICS 'C' flow cytometer (Coulter Electronics, operated by Dr J. Stewart, Dept.
of Medical Microbiology, University Medical School, Edinburgh).
2.2.30 Bacterial Adhesion toMucin
Bacteria, cultured overnight in NYB were washed twice in PBS and resuspended to a
concentration of 1x10^ cells/ml (determined spectrophotometrically) in freshly made
PBS containing 0.05% v/v Tween-20 and 1.0% v/v BSA. The bacterial suspensions
were added in triplicate to microtitre wells coated with mucin at 100 (il per well and
incubated at 37°C for 60 min. After washing, hyperimmune CF sera (as determined
in LPS-ELISA) diluted 1:1000 in dilution buffer was added at 100 |il per well. The
remaining steps in the adherence assay ELISA were as described for detection of
serum IgG anti-B. cepacia LPS antibodies. Binding to mucin was determined by
calculating the mean of the triplicates and dividing the mean binding to mucin by the
mean binding to the control wells. The assay conditions were varied by changing the
growth environment, using MM or static incubation, and varying the incubation time
of the first step of the assay (bacteria binding to mucin).
85
2.2.31 Serum Sensitivity Assay
The method for the serum sensitivity assay was based on a method obtained from
Miss Elizabeth Allen (Dept. of Medical Microbiology, University Medical School,
Edinburgh).
Determination of Complement Activity
Complement activity (CH50) was determined by sheep erythrocyte lysis assay based
on that of Hudson & Hays (1980). Sheep erythrocytes (1.0 ml) were washed twice in
PBS at 200 g for 10 min and resuspended in 5.0 ml PBS. Erythrocyte suspension (0.2
ml) was added to 2.8 ml distilled water to determine the required proportion of PBS
to erythrocytes to give a concentration of 1 xlO^ rbc/ml (an OD 540 nm of 0.35 is
equivalent to 1 xlO^ rbc/ml). Equal volumes of the erythrocyte suspension and rabbit
anti-sheep antibody diluted 1:1000 in PBS were mixed and incubated at 37°C for 30
min prior to use. Test serum, stored at -70°C for a maximum of four weeks was
maintained on ice during this assay. Serum was diluted 1:2 in PBS and increasing
volumes (0.1 ml to 0.4 ml) were added to 0.3 ml of sensitised sheep erythrocytes in
individual tubes and incubated at 37°C for 45 min. Ice-cold PBS (3.0 ml) was then
added to each tube and tubes were centrifuged at 200 g for 5 min. The OD at 540 nm
for the supernatant in each tube was then measured and complement activity
determined.
Serum Bactericidal Assay
Overnight cultures of B. cepacia grown in ISTB were harvested and washed twice in
complement fixation test buffer (CFTB, pH 7.4, Oxoid). Bacterial pellets were
resuspended in CFTB to a density of 1x10^ cfu/ml (determined
spectrophotometrically) and further diluted 100-fold to give a final cell density of
1x10^ cfu/ml. The assay tube consisted of 1.0 or 1.6 ml CFTB with 0.8 or 0.2 ml test
serum respectively. Controls were 1.0 ml CFTB plus 0.8 ml HIS and 1.8 ml CFTB
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alone. To each tube 0.2 ml bacterial suspension was added. Assay tubes were
incubated in a shaking incubator at 37°C for 180 min. Samples (100 (il) were
removed at Tq, T30, T90 and TjgQ min' diluted 1:50 in CFTB and 100 (il was either
added directly to NA and spread or diluted 10-fold in CFTB before adding to NA.
NA plates were incubated at 37°C for 24-48 h before scoring.
Investigation of Serum Components
The roles of the classical complement pathway (CCP) and the alternative complement
pathway (ACP) were investigated by treating serum with 10 mM MgCl-EGTA (200
mM ethyleneglycol-bis (beta-amino-ethyl- ether) N,N'-tetraacetic acid, Sigma) which
specifically inactivates the CCP by chelating Ca^+ ions and not Mg^+ ions as
described by Fine et al. (1979). EGTA was dissolved in sterile normal saline by
heating at 60°C in a water bath and adding 5.0 M NaOH until EGTA went into
solution. The pH was titrated back to 7.45 with 1.0 M HC1 and the volume made up
to 200 ml with saline. The EGTA stock was added to PNHS to give a final
concentration of 10 mM.
PNFIS was replaced by hyperimmune CF serum in order to investigate the role of
specific anti-5. cepacia antibodies in serum killing. The CF sera were subjected to a
series of absorptions with B. cepacia whole cells to remove the specific antibody.
Overnight cultures of bacteria grown in NYB were harvested by centrifugation,
washed twice in PBS and resuspended to a cell density of 10^ cfu/ml. Bacterial
suspension (1.0 ml) was added to a 1.5 ml Eppendorf tube and bacteria were pelleted
by centrifugation at 1365 g for 5 min. After removal of supernatant, bacteria were
resuspended in serum diluted 1:200 in CFTB, incubated for 15 min at room
temperature and recentrifuged. The supernatant was then added to another pellet of
cells and the process repeated. This step was repeated at least three times.
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Influence of Culture Medium on Serum-sensitivitv
To determine the influence of the culture medium on serum sensitivity, B. cepacia
strains were cultured in MM and 50% heat inactivated sheep serum.
2.2.32 Environmental Isolation of b. cepacia
As part of a study to determine the environmental habitat of B. cepacia in the
environment, a laboratory 'field trip' to the Royal Botanic Gardens, Edinburgh, was
undertaken. The Botanic Gardens were thought to be appropriate as they provided a
variety of environmental sites and microclimates. Several different 'micro-
environments' were investigated including pools and vegetation of tropical and
temperate greenhouses, the local Edinburgh soil, plants and ponds. Specimens
including 100 ml volumes of pond water; 10 g soil samples collected in sterile
universals; leaf debris which was transported in BcEB; and finally swabs taken of
moist surfaces (for example rock pools) and transported in BcEB. B. cepacia
enrichment broth was added to any dry specimens. In the laboratory, specimens were
incubated at 30°C for seven days after which time the broths were subcultured onto
CEP and TBT media and re-incubated. Water specimens were filtered, and the filter
paper incubated on CEP as previously described. Any bacterial colonies were
subcultured onto fresh CEP and TBT. Individual colonies were then subcultured onto
MacConkey agar to enable elimination of lactose producers. Non-lactose fermenting
colonies were transferred to King's B medium (King et al., 1954) and fluorescent
colonies discarded whilst non-fluorescing colonies were inoculated onto Stewarts AG
medium (Stewart, 1972) (performed by Mrs C. Doherty). The colonies which were
identified as B. cepacia on AG medium were then screened by API 20NE. The clonal
relationships of colonies positively identified as B. cepacia were investigated by
bacteriocin typing and PFGE by Mrs Doherty. Individual isolates were then further
investigated to determine the nature of the LPS (R or S).
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CHAPTER 3
BIOLOGICAL PROPERTIES AND CHARACTERISTICS OF
BURKHOLDERIA CEPACIA
Biological properties and characteristics of B. cepacia strains, in particular the epidemic
strain, which may be of importance in contributing to the ability of B. cepacia strains to
colonise and infect the CF host were investigated.
3.1 Isolation of b. cepacia from the Environment
The aim of this study was to estimate the prevalence of B. cepacia in the environment
and determine the risk of environmental acquisition of B. cepacia by CF patients. To
investigate the general view that B. cepacia is ubiquitous in the environment, 55 samples
from the different micro-environments; e.g. soil, water and plant debris from the tropical,
temperate and external areas within the Botanic Gardens were screened for B. cepacia.
Environmental samples were processed as illustrated in Figure 5. Bacterial colonies
obtained on B. cepacia selection media were subcultured onto MacConkey agar and
King's B media in order to eliminate those colonies which were lactose fermenters or
fluorescent. The remaining colonies were confirmed as B. cepacia by use of the API
20NE multi-test system. Table 4 identifies the sites from which 12 B. cepacia were
isolated.
Further characterisation of the 12 B. cepacia strains was performed by phenotypic typing
(Bacteriocin typing) and genotypic typing (PFGE). Although several isolates were shown
to share the same bacteriocin type and five isolates were untypable (Table 4), PFGE
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SAMPLE 1 SAMPLE 2 SAMPLE 3
(soil, vegetation) (swabs from moist surfaces) (pond water)
0 0 £
Of!
10 ml BcEB directly onto CEP filter onto CEP






repeat subculture onto CEP+TBT
(30°C, 7 days)
subculture different bacterial colony types
onto MacConkey agar (48 h, 30°C)
t? <b
-0- discard lactose positive colonies,
subculture lactose negative colonies onto King's B media (48 h, 30°C)
■0 discard fluorescent colonies.
d
subculture non-fluorescent colonies onto Stewarts AG slopes (48 h, 30°C)
(B. cepacia colonies = yellow slope/green butt)
confirm B. cepacia by API 20 NE multi-test
£
further characterisation
a) phenotypic (bacteriocin) typing
b) genotypic typing (PFGE)
c) SDS-PAGE and silver stain for LPS
d) antibiotic profiles (data not shown).
Figure 5. Processing of environmental samples obtained from the Royal Botanic
Gardens, Edinburgh
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Table 4. Environmental sites in the Royal Botanic Gardens, Edinburgh from which B.
cepacia strains were cultured.
Isolate Site Area Bacteriocin type
J2534 rotting bark orchid and cycad house S16/P3
J2535 rotting bark orchid and cycad house S16/P3
J2536 soil gardens S1/P0
J2537 soil rhododendron house S1/P0
J2538 soil rhododendron house S1/P0
J2539 soil (near Hohenbergia
stalata)
temperate aquatic house S3/P0
J2540 soil (near banana plant) tropical aquatic house UT
J2541 soil (near Epidendrum
o'brieniamum)
orchid and cycad house UT
J2542 soil (near Nautilocalyx
lynchii)
orchid and cycad house S1/P0
J2543 pond water tropical aquatic house UT
J2552 soil (near Carludoucas
palmata)
tropical palm house UT
J2553 sanseveira leaf tropical palm house UT
UT - untypable by bacteriocin typing
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confirmed that the B. cepacia strains isolated were clonally distinct with the exception of
isolates J2541 and J2543 which shared a PFGE profile. The study suggests that a
preferred habitat for B. cepacia includes warm moist soil environments.
3.2 Growth of b. cepacia
The aim of this study was to determine the optimal growth conditions for B. cepacia in
terms of temperature, aeration, incubation time and nutrient availability. Three
representative strains of B. cepacia were used in this study; the epidemic strain (CI359);
a CF isolate (C1409) and an environmental isolate (J2395). Optimal growth of each B.
cepacia strain was observed following aerated culture for 24 h at 37°C in NYB as shown
in Table 5.
Table 5. Growth of B. cepacia in NYB and MM following static or aerated culture.
Strain Growth of B. cepacia (mean cfu/ml)
NYB MM
static aerated static aerated
C1359 l.OxlO8 l.OxlO9 3.4xl07 7.5xl07
CI409 5.0xl07 2.1xl09 1.6xl07 3.5xl08
J2395 4.5xl07 1.7xl09 5.1xl07 1.6xl09
The growth of each B. cepacia strain in NYB at 25°, 37° and 43°C over 24 h was
measured by optical density and by viable count (Figure 6). Under all conditions higher
growth rate and a greater final cell density was observed for J2395. The epidemic strain
(CI359) had the slowest growth at each temperature, with the longest initial lag phase
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Figure 6. Growth curves of B. cepacia strains J2395, CI409 and CI359 in NYB for 24
h at: a) 37°C; b) 43°C; and c) 25°C.
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J2395 were similar in NYB and MM; in contrast both C1359 and C1409 showed lower
final counts in MM.
3.3 Survival of B. cepacia
Water
Single colonies (approximately 10^ cfu/ml) of B. cepacia strains C1359, C1409 and
J2395 were inoculated into 10 ml volumes of tap and pyrogen-free water and examined at
weekly intervals by visual observation of turbidity and by subculture onto CEP for
survival and growth. In no instance did the water become turbid, suggesting that cell
numbers were no greater than approximately 10^ cfu/ml. All three B. cepacia strains
survived in both tap and pyrogen-free water up to 1 month, thereafter B. cepacia was
recovered only from pyrogen-free water. No difference was observed in the survival of
the individual B. cepacia strains, with the exception that when subcultured onto CEP
colonies of C1409 and J2395 were visible at 24 h, but 48-72 h incubation were required
before any colonies were visible for the epidemic strain and even at that time the colonies
remained very small.
Antiseptics
The antimicrobial efficacy of six antiseptics was examined according to the Kelsey-Sykes
Capacitance test procedure against the three B. cepacia strains (C1359, C1409 and
J2395), and also against a non-mucoid clinical isolate of P. aeruginosa (SBC 88) and S.
aureus for comparison. An antiseptic was considered to be effective when not more than
five colonies were observed after the second incremental addition of bacterial suspension.
The efficacy of the antiseptics at the manufacturers recommended concentration against
bacteria grown in NYB is shown in Table 6. The data indicate that the strains of B.
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cepacia investigated do not show particular resistance to the antiseptics in the test
conditions used in the assay. To investigate whether resistance might be increased
following growth in a nutrient depleted environment and also to try to replicate more
accurately what may be occurring in situ, the experiment was repeated following culture
of B. cepacia C1359 and J2395 and P. aeruginosa SBC 88 in MM instead of NYB. No
difference in the effect of the antiseptics on P. aeruginosa or B. cepacia J2395 was
observed following culture in MM. In contrast, against the epidemic strain of B. cepacia
CI359, Cetavlon was not effective at recommended concentration and Roccal was not
effective at the lowest concentration, suggesting that culture of the epidemic strain in a
MM promoted resistance to some antiseptics.
3.4 Extracellular Products of b. cepacia
Melanin
One hundred isolates of B. cepacia were screened for melanin production by culture on
furunculosis agar. The only strain of B. cepacia associated with melanin production was
the epidemic strain (Figure 7). Figure 7 illustrates melanin production by the epidemic
strain of B. cepacia (CI359) grown on furunculosis agar and growth of a non-melanin
producing CF strain of B. cepacia (C1409).
Elastase
Fifty three isolates of B. cepacia, including the epidemic strain, and three strains of P.
aeruginosa PAOl, J1385 and SBC 88 were screened for elastase production (the former
two P. aeruginosa strains were known elastase producers). Elastase production was
determined by a zone of clearing of the elastin-TSA medium around bacterial growth.
Elastase production was observed for each of the P. aeruginosa controls. In contrast, no
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Figure 7. Melanin production by the epidemic strain of B. cepacia grown on
Furunculosis agar (Ogonariwo & Hamilton-Miller, 1975) at 37°C for 48 h. a) The
epidemic strain, represented by C1359; b) CF isolate of B. cepacia (C1409).
97
evidence for elastase production was found for any of the B. cepacia isolates
investigated.
Phospholipase C
Phospholipase (PLC) production by B. cepacia has been described previously (Nakazawa
et al., 1987; Vasil et al., 1990). The aim of this study was to compare production of
PLC in B. cepacia strains from different sources and in particular to determine whether
there was any difference in production of PLC between the epidemic strain and other
strains of B. cepacia. Table 7 shows PLC production by 32 isolates of B. cepacia and a
P. aeruginosa PAOl control. PLC production was evaluated in a microtitre assay by
measuring the release of the yellow chromogen p-nitrophenol after hydrolysis of the
substrate NPPC by PLC. Activity was calculated as the absorbance at 405 nm with
NPPC divided by the optical density of the culture at 540 nm.








CF: epidemic strainc 6 0.20-0.88 0.42+/-0.034
CF: other strains 10 0.03-0.94 0.34+/-0.019
Environmental 7 0.07-0.40 0.23+/-0.008
Clinical (non-CF) 4 0.06-0.62 0.30+/-0.031
a ' Relative activity was defined as the ratio of activity of the B. cepacia
to the activity of PAOl.
^ - SEM, Standard error of the mean.
c - Epidemic strain isolates from six individual CF patients attending the
Edinburgh adult CF clinic.
98
PLC production by all the B. cepacia isolates investigated was less than that for PAOl.
The difference in PLC activity between the epidemic strain and other strains of B.
cepacia was not significant (p<0.1 Students I-test).
Exopolvmer Production
Following culture on nitrogen-deficient MM or glucose/EMB medium exopolymer
production was observed in a minority of the 53 B. cepacia strains investigated.
Exopolymer production following culture on the glucose/EMB media was observed for
two B. cepacia strains, CDC 8 and a glucose dehydrogenase-negative (gcd~) derivative of
B. cepacia ATCC 17616 (obtained from Dr T. Lessie). An alternative exopolymer was
produced by five gcd+ strains: two CF strains (J415 and CI409), two clinical strains
(J761 and J762) and one environmental strain (J2395) cultured on nitrogen-deficient
MM. Mucoid colonial morphology was observed for the environmental strains of B.
cepacia isolated from the Botanic Gardens when cultured on TBT media and also on
PLA, but not on either of the previously described media. Examination of India ink
stained preparations under phase contrast microscopy confirmed that the exopolymer was
not of a capsular nature.
3.5 Motility of B. cepacia
Motility was investigated in 39 B. cepacia isolates by measuring migration in semi-solid
motility agar (Table 8) and also by observing the motility of B. cepacia in liquid culture
under phase contrast microscopy . The 17 isolates of the epidemic strain showed a mean
diameter of spreading colony of 9.5 mm (range 5.0 - 14.0 mm), approximately half the
mean spreading diameter observed for the non-epidemic strains of B. cepacia investigated
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(mean spreading diameter 18.0 mm; range 4.0 - 46.0 mm). Statistical analysis showed
that this difference was significant (p<0.005, Students /-test).
A number of selected strains from each group of B. cepacia strains were additionally
examined for motility in liquid culture. Observations of motility under phase contrast
microscopy were consistent with those on semi-solid agar.
Table 8. Motility of B. cepacia strains in semi-solid agar as determined by diameter
(mm) of the spreading colony, 48 h.
Source No. of isolates Mean spreading Range of spreading
tested diameter (mm)+/-sd diameter (mm)
Environmental 5 (lnm) 30+/-13.8 18-46
Clinical/CF 17 (2nm) 16+/-8.7 4-41
Epidemic straina 17 (lnm) 9.5+/-2.8 5-14
P. aeruginosa b 2 37 35 - 39
a - Epidemic strain isolates from 9 individual CF patients from the Edinburgh and
Manchester CF clinics, plus paired strains from four CF patients.
^ - P. aeruginosa spreading motility measured at 24 h.
nm - non-motile
3.6 Cell Surface Features of B. cepacia
Cell surface features of B. cepacia which could be involved in colonisation and virulence
were investigated by comparing surface features of the epidemic strain to other CF and
non-CF strains of B. cepacia.
100
Electron Microscopy ofWhole Cells
The aim of this study was to investigate the general cell morphology of B. cepacia
including expression of fimbriae and flagella. Twenty of the 21 strains of B. cepacia
examined were coccobacilli in shape, one strain (NCTC 10744) was bacilli; all fimbriate
strains possessed peritrichous fimbriae and multitrichous polar flagella. Fimbrial
expression differed between strains of B. cepacia and even between individual cells of a
single culture. Sixteen (70%) of the B. cepacia strains examined expressed fimbriae,
however expression was rare; for example on a typical specimen grid approximately 10%
of cells were observed to express fimbriae. The range of fimbriae observed is shown in
Figures 8, 9 and 10. Two distinct fimbrial types were observed as shown in the electron
micrograph of a CF isolate of B. cepacia CI394 (Figure 8). The larger fimbriae were
regular and thick with no visible channels and typical of enterobacterial Type 1 fimbriae,
the smaller fimbriae were 'crinkly' in appearance. Long flagella can also be clearly
observed. Figure 9 is an electron micrograph of B. cepacia J415, a CF isolate associated
with a fatal case of 'Cepacia syndrome' (Glass & Govan, 1986). In this dividing cell only
one fimbrial type (Type 1) was visible. Figure 10 is an electron micrograph of the
epidemic strain, showing the extremes of fimbriation of cells from a single culture.
Characterisation of Isolated Flagella
Flagellar antigens were prepared from three B. cepacia strains; the epidemic strain
(CI359); CF isolate CI524 and environmental isolate J2395. In addition, flagellar
samples of P. aeruginosa JN62 (P. aeruginosa flagella type 'a') and PAOl (P. aeruginosa
flagella type 'b'), prepared by Dr J. Nelson, were included in SDS-PAGE as standards and
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Figure 8. Electron micrograph of B. cepacia CI394 stained with 2% w/v PTA, showing
both fimbriae and flagella. a) large, Type 1 fimbriae, b) small 'crinkly' fimbriae.
Magnification x 40,000.
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Figure 9. Electron micrograph of B. cepacia J415 stained with 2% w/v PTA, expressing
peritrichous fimbriae. Magnification x 25,000.
103
Figure 10. Electron micrograph of the epidemic strain of B. cepacia (SBC 9) stained
with 2% w/v PTA, showing a highly fimbriated and a less fimbriated cell. Magnification
x 23,000.
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Figure 11. Electron micrograph of flagellar antigen preparation from the epidemic strain
of B. cepacia stained with 2% w/v PTA. Magnification x 15,000.
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Flagella of the epidemic strain (CI359) and J2395 were characterised by molecular mass
determination in SDS-PAGE. Molecular mass of flagella separated by SDS-PAGE
(Figure 12) were estimated from a calibration curve of log molecular mass of protein
standards against Rf, where Rf is the distance moved by a standard protein through the
separating gel divided by the distance moved by the bromophenol blue marker. Flagella
from strain J2395 (Track3) appeared to have mobility in SDS-PAGE intermediate
between JN62 (Track 1) and PAOl (Track 2.) and had a calculated Mr of 51,000.
Flagella from the epidemic strain CI359 migrated further than either PAOl or JN62
flagella, and had a calculatedMr of 44,000.
Immunoblot analysis of flagella with P. aeruginosa flagellar type-a and -b antisera
showed that there was no cross-reactivity between either antisera and flagellar antigens of
B. cepacia CI359 and J2395 (Figure 13a & b).
Lipopolvsaccharide Analysis
Lipopolysaccharide prepared from 72 isolates of B. cepacia (including 16 isolates of the
epidemic strain) was examined after separation by SDS-PAGE and visualisation by silver
staining and immunoblotting (Table 9).
The majority of B. cepacia isolates examined (68%) expressed S-LPS. All isolates of the
epidemic strain express R-LPS, which may suggest that the majority of CF isolates
express R-LPS as the epidemic strain is the most prevalent strain of B. cepacia in several
UK CF centres. Figure 14a shows the S-LPS profiles for the ten genotypically distinct
environmental isolates of B. cepacia (isolated from the Royal Botanic Gardens,
Edinburgh) confirming the observation that a S-LPS profile is the more common form for
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Figure 12. SDS-PAGE of flagella preparations from P. aeruginosa strains JN 62 (Track
1), PAOl (Track 2) and B. cepacia strains J2395 (Track 3) and the epidemic strain
(Track 4). Flagella were separated using 12% w/v acrylamide gels and stained with
Coomassie blue. Molecular weights of protein standards are indicated.
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Figure 13. Immunoblots of flagellar antigens separated by SDS-PAGE followed by
electrophoretic transfer to NIC paper and probed with anti-P. aeruginosa flagellar type-a
antisera (a) and anti-P. aeruginosa flagellar type-b antisera (b): flagellar antigens from
J2395 (Track 1); C 1524 (Track 2); the epidemic strain (Track 3); JN 62 (Track 4) and
PAOl (Track 5).
108
B. cepacia. Figure 14b shows the range of S-LPS profiles observed in clinical,
environmental and CF isolates of B. cepacia and also the typical R-LPS profile for the
epidemic strain.
Table 9. Lipopolysaccharide Analysis of B. cepacia
No. of isolates LPS
Source tested R-LPS S-LPS
CF: epidemic strain ^ 16 16 0
other strains 17 5 12
Environmental 23 1 22
Clinical 16 1 15
Outer Membrane Protein Profile
Outer membrane preparations were prepared from five B. cepacia strains, the epidemic
strain (C1359), two other CF strains (C1409 & C1559) and the environmental strains
(ATCC 17616 & J2395). The outer membranes were separated by SDS-PAGE and
visualised by silver or Coomassie staining or by immunoblotting. Coomassie staining for
proteins was superior to the protein silver stain which was too sensitive and stained LPS
present in the crude outer membrane preparations.
Molecular masses of the major protein bands were determined as described above in
SDS-PAGE. Coomassie staining of the SDS-PAGE showed that the five B. cepacia
strains had dissimilar OMP profiles, with the exception of a major band with an Mr of
approximately 29,000 (Figure 15), possibly equivalent to the D porin described by
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Figure 14a. Silver stained LPS profiles of proteinase K whole cell digests of 10
environmental isolates of B. cepacia separated by SDS-PAGE (14% w/v acrylamide).
Track 1 to Track 10 are J2534 through J2543 sequentially.
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Figure 14b. Silver stained LPS profiles of proteinase K whole cell digests of five B.
cepacia strains separated by SDS-PAGE (14% w/v acrylamide). Track 1, J716 (UTI);
Track 2, J2395 (environment); Track 3, J1745 (environment); Track 4, C1409 (CF) and
Track 5, the epidemic strain (CF).
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Figure 15. SDS-PAGE of outer membrane preparations from B. cepacia strains J2395
(Track 1), C1409 (Track ?~), the epidemic strain (Track 3), C1559 (Track Q and ATCC
17616 (Track5)- Outer membranes were separated using a 12% w/v acrylamide gel and
stained with Coomassie blue. Molecular weights of protein standards are indicated.
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Aronoff (1988). The OMP profile of the environmental isolates, J2395 and ATCC 17616
(Tracks \ and 5 respectively) showed greatest similarity, with the exception of a broad
high Mr band expressed by J2395. The CF isolates C1359 and C1559 (Tracks3 and Q
express major high Mr bands of approximately 79,000 and 80,000 respectively, but other
bands are very faint suggesting a low level of expression. The remaining CF isolate,
C1409 (Track 7) expresses only the one major band.
Immunoblot analysis of the outer membrane preparations, probing with antisera raised in
rabbits against heat-killed whole cells of J2395, C1409 and the epidemic strain, C1359
showed that there is variable cross-reactivity between the OMP antigens (Figure 16a, b &
c). The sera from the rabbit inoculated with J2395 reacted strongly with the outer
membrane preparation from the autologous strain, particularly the O-side chain moiety of
the LPS (Figure 16a, Track 5), and also with two bands of ATCC 17616, CI559 and
C1409 (Track 1, 3 and 4) and less strongly with the same bands of C1359 (Track 2). A
weak reaction was also observed with various high molecular bands of each B. cepacia.
Similarly, the response observed in the immunoblots probed with sera from the rabbit
inoculated with CI409 (Figure 16b) showed a strong response against the autologous B.
cepacia, particularly the O-side chain of the LPS (Track 4). The rabbit antisera reacted
with the same two bands on each of the other strains of B. cepacia, and also faintly with
some high Mr bands. The reaction of the antisera from the rabbit inoculated with the
epidemic strain CI359 was slightly different (Figure 16c). There was no response to any
O-side chain LPS and additional bands were observed for CI409 (Track 4) and J2395
(Track 5). The antisera reacted strongly with the same pair of bands as the previous
antisera and with additional bands. The presence of the very high Mr band of J2395 was
confirmed. This antisera also reacted strongly with a low molecular weight band,
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Figure16.Imm noblotsofuterm mbraneantigenssep ratedySDS-PAGEf llowedylectrophoretictransf rNICaperandprobedwithanti-B.cepaciaantiserar isedi rabbitsoh t-killedwholecel sf.cepacia( )J2395,(b)C1409nd( )theepidemicstrain:outerme branentigensf omATCC17616( ack);theepid micstra n(Track2);C1559(Track3);1409(Track)andJ2395(Track5 .
possibly core-LPS, of the epidemic strain. The immunoblot results emphasised that
OMPs were heterogeneous in this group of B. cepacia isolates; however the immunoblots
also verify the existence of common antigens, demonstrated by the paired bands apparent
in each blot. The three CF isolates, C1359, C1559 and C1409 (Track 2, 3 and 4) appear
to express fewer OMP than the two environmental isolates ATCC 17616 and J2395
(Track 1 and 5), which may be consistent with increased antibiotic resistance.
The immunoblot analysis (Figure 16c) confirms the earlier observation that the epidemic
strain of B. cepacia expresses R-LPS.
Cell Surface Hydrophobicitv
Surface hydrophobicity of eight B. cepacia isolates, B. gladioli ATCC 10248 and P.
aeruginosa PAOl was determined by HIC (Figure 17). Bacterial suspensions were
chromatographed on octyl sepharose in the presence of binding buffer and relative
hydrophobicity was expressed as the percentage of cells retained on octyl sepharose
relative to the percentage retention by sepharose. A greater degree of retention was
considered to be due to higher cell surface hydrophobicity.
In general the cell surface hydrophobicity for the bacterial strains investigated was low,
less than 15% relative hydrophobicity, with the exception of one of the epidemic strain
isolates (CI359). The per cent relative hydrophobicity tended to be slightly greater for B.
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Figure 17. Cell surface hydrophobicity of eight B. cepacia strains, P. aeruginosa PAOl
and B. gladioli ATCC 10248.
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CHAPTER 4
ADHERENCE AND COLONISATION OF BURKHOLDERIA
CEPACIA IN CYSTIC FIBROSIS
In order to assess the possible role of the upper respiratory tract (URT) as a human
reservoir for B. cepacia and in particular for the epidemic strain, the URTs of CF patients
were examined for carriage of B. cepacia. The potential colonising ability of B. cepacia
isolates was then assessed by investigating haemagglutination and adherence to buccal
epithelial cells (BEC) or purified respiratory mucin
4.1 Determination of an Upper Respiratory Tract Reservoir for B.
cepacia
In order to determine whether the URT acts as a reservoir for B. cepacia in colonised CF
patients, samples from three URT sites (nasal swab, mouth swab and buccal scrape) were
investigated on two separate occasions in CF patients colonised or not colonised by B.
cepacia as determined by sputum culture of the organism. Quantitative counts for B.
cepacia and P. aeruginosa were also performed with saliva samples (Table 10). The
corresponding strain of B. cepacia was isolated from the mouth swab only in CF patients
I, II and IV, colonised with two different non-epidemic strains of B. cepacia and the
epidemic strain respectively. CF patients III to IX were colonised by the epidemic strain,
which was isolated from all sites in patient III and from two sites in patients V - IX. With
the exception of patient III, all the B. cepacia colonised patients studied were co-
colonised by P. aeruginosa. B. cepacia was not isolated from the URT sites in 17
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control CF patients who were sputum culture negative for B. cepacia (11 of these were
colonised by P. aeruginosa). Mean counts for P. aeruginosa in saliva of CF patients
colonised by P. aeruginosa alone and in those co-colonised by the epidemic strain of B.
cepacia were 10-100 fold less than counts for B. cepacia, although sputum counts of
both organisms were similar. On the basis of these results it would appear that the URT
may be a reservoir for the epidemic strain of B. cepacia in CF patients colonised by this
strain.
4.2 HAEMAGGLUTINATION BY B. CEPACIA
Fimbriation in some Gram-negative bacteria may be associated with the ability to
agglutinate various red blood cell types, and may therefore be detected by
haemagglutination assay (Tweedy et al., 1968). Furthermore, fimbrial haemaggluination
by Type 1 fimbriae is typically mannose sensitive, whereas non-fimbrial
haemagglutination is not inhibited by mannose. The capacity of 37 B. cepacia isolates
from environmental, CF and other clinical sources to agglutinate erythrocytes from seven
different species was investigated. Haemagglutination by B. cepacia was compared to
that of a control strain of E. coli expressing mannose-sensitive Type 1 fimbriae. Table
11 shows the number of B. cepacia isolates agglutinating each red blood cell type and
the effect of a methyl-mannoside.
Mannose sensitive haemagglutination was observed with the E. coli control strain and
each of the haemagglutinating B. cepacia isolates. Addition of a methyl-mannoside
inhibited haemagglutination regardless of erythrocyte type although the degree of
inhibition was dependent on the B. cepacia isolate. Four patterns of haemagglutination
were observed: (1) no agglutination with any cell type; (2) very weak agglutination,
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observed with guinea pig and horse red blood cells only; (3) weak agglutination with all
cell types; and (4) strong agglutination with guinea pig and horse erythrocytes but weak
agglutination with the remaining cell types. The epidemic strain isolate examined in this
study (CI359) was not observed to cause any of the red blood cell types to agglutinate.
In order to pursue this observation a further 23 isolates of the epidemic strain from
individual CF patients were investigated. None of the epidemic strain isolates were
capable of haemagglutination.
Table 11. Number of B. cepacia isolates haemagglutinating each of seven erythrocyte
types with and without addition of a methyl-mannoside.
Red blood cell type
No. of agglutinating
isolates out of 37 tested
No. of mannose sensitive









- determined by addition of 2.0 w/v % a methyl-mannoside
The haemagglutination patterns of B. cepacia with guinea pig and horse erythrocytes and
the effect of a methyl-mannoside on agglutination of each cell type was analysed with
respect to the origin of the B. cepacia isolate. The data presented in Table 12 indicate
that there is no association between the source of B. cepacia and capacity to agglutinate
red blood cells, as agglutination patterns are similar for isolates of B. cepacia from
different sources.
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Table 12. Haemagglutination of guinea-pig and horse red blood cells by B. cepacia
isolates and effect of a methyl-mannoside on haemagglutination of both cell types.
Haemagglutination
B. cepacia Guinea pig erythrocytes Horse erythrocytes a methyl-mannoside
J365a +++ +++ -
J759« ++ + -
J760« +++ ++ -
J761^ +++ +++ ++
J162b ++ ++ -
J1743^ + + -
J1744a ++ ++ -
J2395a ++ ++ -
C133c +++ ++ +
C1394c +++ +++ ++
C1402c ++ ++ -/+
C1406c ++ + -
J1745a +++ +++ ++
J1749^ +++ +++ ++
J415c +++ +++ ++
C1409c +++ +++ -
J1875c +++ +++ ++
J752c +++ +++ ++
J772c +++ +++ ++
J163b +++ +++ ++
CDC lb + - -
CDC 26b + - -
CDC 96* + - -
CDC 94* ++ ++ +
CDC \\a +++ +++ ++
CDC 8« ++ ++ +
CDC 80^ +++ ++ +




a - environmental isolate of B. cepacia
b - clinical isolate of B. cepacia
c - CF isolate of B. cepacia
no agglutination * - source not known
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To investigate whether haemagglutination was associated with fimbriation, transmission
electron microscopy was performed on representative isolates of B. cepacia from Table
12. The electron microscopy showed that both haemagglutinating and non-
haemagglutinating isolates of B. cepacia expressed fimbriae; for example the CF isolate
J415 (Chapter 3, Figure 9) has previously been shown to express peritrichous fimbriae
and strongly agglutinated all the red blood cell types whereas the epidemic strain of B.
cepacia also expressed peritrichous fimbriae (Chapter 3, Figure 10) yet did not
agglutinate any of the erythrocytes types. The B. cepacia isolates which were not
observed to express fimbriae by electron microscopy did not haemagglutinate. The
inability of B. cepacia isolates to haemagglutinate may be explained by the absence or
low frequency of fimbria! expression observed or alternatively the different fimbrial types
expressed by B. cepacia may not have equal capacity to haemagglutinate.
Overnight culture of B. cepacia isolates in NYB at 30°C instead of 37°C, did not affect
the degree of haemagglutination observed, however the capacity of ten of the
agglutinating strains of B. cepacia to agglutinate guinea pig and horse erythrocytes was
eliminated following culture in MM.
4.3 Adherence of B. cepacia to Buccal Epithelial Cells
Adhesion of three representative isolates of B. cepacia (the epidemic strain CI359, CF
isolate C1409 and environmental isolate NCTC 10744), P. aeruginosa SBC88 and N.
meningitidis A14 to BEC obtained from three CF patients and five normal controls was
analysed by flow cytometry (Table 13). The binding index is a guide as to the degree of
binding of the bacteria to the BECs. Table 13 shows clearly that there is considerable
variation in the degree of binding for each of the bacterial strains to the different BEC.
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a -CFpatientcolonisedbythepidemics rainlyb -CFpatientscolonisedbyP.eruginosaly c -normalcontrols.
With the exception of the BEC from subject VII, the greatest binding of B. cepacia to
BEC was observed with the epidemic strain. Maximum binding was demonstrated to the
BEC from subject I (a CF patient colonised by the epidemic strain) by the epidemic strain,
C1409, P. aeruginosa and N. meningitidis. Interestingly the binding index for the
epidemic strain and BEC I was almost twice the binding index for P. aeruginosa and
more than five times that for the control strain of N. meningitidis, which is considered to
demonstrate relatively high levels of binding to BEC (Dr J. Stewart, personal
communication). The second highest binding index was also observed with the epidemic
strain and BEC II from a CF patient not colonised by B. cepacia. The binding of B.
cepacia strains C1409 and NCTC 10744 to all the BEC samples is significantly less
(p<0.01, Students r-test) than the binding of the epidemic strain to the BEC. The binding
indices of the control organisms, P. aeruginosa and N. meningitidis, and all of the BEC
samples were greater than those for the B. cepacia strains C1409 and NCTC 10744 but
less than those for the epidemic strain. There is no significant difference (p<0.1) between
the binding of the CF isolate of B. cepacia and the environmental isolate of B. cepacia.
4.4 Adherence of B. cepacia to Purified Respiratory Mucin
Several methods were investigated to examine the adherence of B. cepacia to purified
respiratory mucin. The most successful method was a microtitre ELISA incorporating
hyperimmune sera obtained from CF patients colonised by the epidemic strain of B.
cepacia to measure adhesion of thirty B. cepacia strains to purified respiratory mucin
bound to the wells of polystyrene microtitre plates. In all mucin adherence experiments
adherence was considered to be significant when R value > 2.0 (Dr J Forstner, personal
communication).
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In preliminary experiments, hyperimmune sera from B. cepacia colonised CF patients
were screened against whole cells of several strains of B. cepacia bound to polystyrene
microtitre plates in a chequerboard ELISA to determine the optimum serum
concentration required for detecting multiple strains of B. cepacia. Sera from several CF
patients colonised by the epidemic strain or other strains of B. cepacia were screened
individually and also as a pool. Serum from CF patients colonised by the epidemic strain
diluted 1:1000 was observed to be superior in detecting B. cepacia bound to the
microtitre plates. In addition the concentration of mucin required to coat wells optimally
and the optimal concentration of bacteria added to wells were determined. A mucin
coating concentration of 10 |ig/ml was shown to give optimal sensitivity, yielding a
maximal difference in OD between coated wells and background controls. A bacterial
concentration of 10^ cfu/ml gave maximal measurable binding to mucin coated wells with
minimal non-specific to background coated wells. In control experiments performed with
strains of P. aeruginosa previously shown to exhibit high binding to mucin (Nelson,
1990) the optimal bacterial concentration was 10^ cfu/ml, as at concentrations higher
than this significant binding to uncoated wells was evident for P. aeruginosa.
Significant adherence to mucin, following overnight static culture in NYB at 37°C, was
observed in seven of the 30 B. cepacia isolates investigated (Table 14); all of these seven
isolates were obtained from CF patients. Of these adherent strains of B. cepacia, the
greatest adherence to the respiratory mucin was observed with the epidemic strain (R
value 20.0). To further investigate whether the enhanced capacity to adhere to
respiratory mucin was typical in isolates of the epidemic strain of B. cepacia, the
adherence of a further sixteen isolates of the epidemic strain from different CF patients
was examined. Significant adherence (R value 3.3 - 55.0) to respiratory mucin was
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observed in ten (62.5%) of the epidemic strain isolates. In control assays, adherent
strains of P. aeruginosa had mean adherence to mucin at least ten times greater than that
observed for B. cepacia. However, the background binding to non-coated wells was also
significantly higher than that for B. cepacia suggesting that adherence in P. aeruginosa is
non-specific.
Table 14. Adherence of B. cepacia strains to purified respiratory mucin following
overnight static culture in NYB at 37°C. Significance of adherence to mucin determined



















a R value - mean binding to mucin / mean background (BSA)
An R value >2 is considered to show significant binding to mucin
^ epidemic strain
c CF isolates from Toronto
The effect of altering the culture conditions; (1) growing bacteria in aerated culture, and
(2) culture in nutrient rich or nutrient poor media on the ability of the bacteria to adhere
to mucin was examined and found to be strain dependant. The epidemic strain and
SBC67 demonstrated greater adherence following static culture whereas J762, J2395 and
C1409 demonstrated significant binding only after aerated culture (Table 15). Following
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culture in nutrient deficient media the binding of two non-epidemic strain CF isolates
(C1406 and C1409) and two epidemic strain isolates (C1359 and SBC28), to mucin
appeared to increase. Non-specific binding to the control wells had also increased
proportionally however, suggesting that culture in nutrient-deficient conditions induced a
general increase in adhesion in some B. cepacia strains (data not shown).
Table 15. Adherence of B. cepacia strains to purified respiratory mucin following static
or aerated culture in NYB at 37°C.
Mucin Binding (R value a)
B. cepacia







a R value - mean binding to mucin / mean background (BSA)
An R value >2 is considered to show significant binding to mucin
^ - epidemic strain
c - CF isolate
^ - clinical non-CF isolate
e
- environmental isolate
To determine whether binding of B. cepacia to the mucin coated wells reached a
saturation point the binding of B. cepacia isolates was measured at 30 min intervals over
a period of 2 h (Figure 18). Figure 18 confirms the variable nature of mucin adherence in
B. cepacia strains for example; for the two epidemic strain isolates SBC58 and SBC75
maximum adherence is achieved by 60 min and 90 min respectively. The maximum
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Figure 18. Binding of four B. cepacia isolates to purified respiratory mucin measured at
30 min intervals over 2 h. Degree of binding determined by R value.
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adherence for C1409 and SBC67 is also achieved at 60 min and 90 min but the R value is
much lower. Two additional strains of B. cepacia were examined: for one strain (Pc 5)
the R value was still increasing at 2 h and the remaining isolate (J415) did not show
significant binding at any time (data not shown).
The purified respiratory mucin used in the above experiments was obtained from a
chronic asthmatic patient. Purified CF mucin from several patients became avilable at a
later date and the assay was repeated to compare the binding of B. cepacia to the
different purified respiratory mucins. In the first instance it appeared that the B. cepacia
strains bound with greater affinity to some of the CF mucins. However, when the assay
was repeated without bacteria, it was observed that the OD obtained depended on the CF
serum used to detect binding and that the reaction between CF serum and CF mucin was
variable. The OD obtained with asthmatic mucin was constant with different CF sera,
therefore this was used in all assays.
In this study, the epidemic strain of B. cepacia, which is associated with poor pulmonary
status and marked transmissibility exhibited the greatest binding to BEC and purified
respiratory mucin yet did not agglutinate any red blood cell type. In contrast, B. cepacia
J415, also associated with fatality in CF but not transmissibility (Glass & Govan, 1986),
strongly agglutinated red blood cells yet did not adhere significantly to mucin. On the
basis of the results obtained, there appears to be no correlation between the capacity of B.
cepacia strains to agglutinate erythrocytes and that to adhere to BEC or mucin,
indicating that different B. cepacia isolates may express different adhesins. Furthermore
any relation of the above with colonisation of the CF patient and clinical outcome would
be extremely difficult to determine from these results.
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CHAPTER 5
INVESTIGATION OF THE ANTIBODY RESPONSE TO
BURKHOLDERIA CEPACIA IN COLONISED CYSTIC FIBROSIS
PATIENTS
The aim of this study was to investigate the anti-fi. cepacia antibody response in CF
patients using an ELISA system based on defined antigenic preparations and
immunoblotting. The potential role of such assays in the early diagnosis of B. cepacia
colonisation in CF patients and also as an indication of prognosis was evaluated. Finally,
explanations were sought to account for the failure of the anti-B. cepacia antibodies to
eliminate B. cepacia from colonised CF patients. In this chapter, CF patients colonised
by B. cepacia will be referred to as Bc+, those colonised by the epidemic strain as ESBc+
and CF patients not colonised by B. cepacia as Be".
5.1 Serum Anti-LPS Antibodies Detected by ELISA
LPS prepared from the epidemic strain of B. cepacia, shown in Chapter 3 to express
rough-form LPS, was used in the ELISA system at a coating concentration of 20 |ig/ml.
Results for all the ELISAs are expressed as final serum titres, i.e. the reciprocal of the
serum dilution which gives an OD >0.1 after subtraction of background controls.
Analytical variation of the ELISA, including intra-plate and day-to-day (inter-plate)
variation, was determined using six serum samples (two each with low, medium and high
ELISA titres) to calculate the coefficient of variation. The intra-plate and inter-plate
variations of the ELISA were 5.5% and 13.9% respectively.
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Serum anti-5. cepacia LPS IgG titres were investigated in 74 Bc+CF patients who
represented a cross section of the CF patient population from UK CF centres in Cardiff;
Edinburgh, Leeds, Manchester and Newcastle. Controls comprised CF patients not
colonised by B. cepacia matched for age, sex and clinical status and chronic bronchitic
patients not colonised by either B. cepacia or P. aeruginosa but matched for clinical
status and normal healthy individuals (Figure 19). The duration of B. cepacia
colonisation in individual patients at the time of sampling ranged from six weeks to 4.5
years; the IgG titres shown in Figure 19 were obtained using the most recent serum
available for each CF patient. Elevated titres of anti-5. cepacia LPS IgG were observed
in Bc+CF patients (Bc+ CF IgG titre range 200 - 51200; titre median 800) and in
particular in ESBc+ CF patients (ESBc+ CF patients: IgG titre range 200 - 102400; titre
median 51200). Low serum IgG titres (<1600) were measured in patients recently
colonised by the epidemic strain, whilst titres in chronically colonised patients were
>6400. The serum IgG titres for Be" CF patients (IgG titre range 200 - 1600; titre
median 200), and the two non-CF control groups (titre range 200 - 800; titre median
200) were lower than in the B. cepacia colonised patients. Statistical analysis of
transformed data (converted to logarithms) revealed a highly significant difference
between IgG anti-fi. cepacia antibody titres in CF patients colonised by the epidemic
strain and patients colonised by other strains of B. cepacia, Be" patients and non CF
controls (p<0.0001 in each case). The anti-5. cepacia antibody titres in CF patients
colonised by other strains was significantly higher than titres in Be" CF patients (p<0.01).
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Serum IgA and IgM antibodies to B. cepacia LPS were also investigated in CF patients
and controls (Figure 20 and 21). The results for serum IgA (Figure 20) agreed with
those for serum IgG in that the IgA titres in patients colonised by B. cepacia, in particular
by the epidemic strain, are greater than the titres in Be" patients and controls. Similarly,
serum IgM anti-B. cepacia LPS antibodies were raised in CF patients colonised by the
epidemic strain (p<0.0001); interestingly, however there was no significant difference
between the titres in patients colonised by other strains of B. cepacia and Be" CF patients
or the non-CF patients (Figure 21).
To confirm that the increased antibody titre observed in CF patients colonised by the
epidemic strain of B. cepacia was a result of colonisation, paired sera from eight CF
patients was investigated by ELISA. Figure 22 shows the serum IgG, IgA and IgM anti-
B. cepacia antibody titres in patients prior to colonisation and after the establishment of
chronic colonisation with the epidemic strain. A rise in antibody titre, for each class of
immunoglobulin was observed for each CF patient. Serum from 10 Be" CF was
investigated for anti-B. cepacia LPS antibodies at similar time intervals. No increase in
antibody titre was noted for any of these control patients.
5.2 Absorption of Sera with b. cepacia and P. aeruginosa LPS
The possibility that there may be cross reactivity between the anti-B. cepacia IgG, anti-P.
aeruginosa IgG and antigens from either organism was investigated. Serum anti-P.
aeruginosa LPS IgG antibody titres were measured in 20 Bc+ and Be" CF patients, the
majority of which were colonised by P. aeruginosa. Regardless of B. cepacia
colonisation status, a specific anti-P. aeruginosa response was observed in those patients
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(titre range 200 - 800) observed in non-B. aeruginosa colonised CF patients equivalent in
magnitude to the anti-B. cepacia titre in Be" CF patients.
Sera from CF patients colonised with B. cepacia and/or P. aeruginosa or neither were
absorbed with purified R-LPS of the epidemic strain and the P. aeruginosa strain PAC
608 (expressing R-LPS) and analysed by ELISA (Figure 23a & b) and multiblotting. The
anti-B. cepacia IgG antibody titre in CF patients colonised by the epidemic strain
(patients I-VII), was considerably reduced following absorption of serum from with the
autologous strain but not after absorption with the P. aeruginosa LPS. Similarly, in
those CF patients colonised by P. aeruginosa (patients II, VI, VII and VIII) the IgG
antibody titre measured against the P. aeruginosa core LPS coating antigen was reduced
following absorption with P. aeruginosa but not after absorption with B. cepacia LPS.
These immunoblotting results confirmed the observation that specific serum antibodies
were only removed by B. cepacia or P. aeruginosa LPS as appropriate (data not shown)
and indicate that the anti-B. cepacia R-LPS antibody response was specific for B.
cepacia and not cross-reactive with P. aeruginosa R-LPS.
5.3 Longitudinal Studies of Serum IgG and IgM Anti-LPS Antibodies
The next experimental approach was to follow the serum IgG anti-B. cepacia LPS
antibody response at approximately six monthly intervals in 10 ESBc+ CF patients
attending the Edinburgh adult CF clinic (Figure 24a & b). Prior to colonisation with the
epidemic strain each patient had low anti-B. cepacia antibody titres in the range observed
for titres measured in Be" CF patients. Following colonisation by B. cepacia the profile
of the serum IgG response was patient dependent with a variable rate of increase in titre.
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strain
Figure 23. Serum IgG anti-fi. cepacia and anti-P. aeruginosa core LPS antibodies in CF
patients measured by ELISA with (a) core R-LPS from the epidemic strain of B. cepacia
and (b) core R-LPS from P. aeruginosa PAC608 as coating antigens. Patients I, III, IV,
and V were ESBc+; patients II, VI, and VII were ESBc+/Pa+; patient VIII was colonised
by P. aeruginosa only and patient IX was not colonised by either organism.
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Figure 24. Longitudinal study of serum IgG anti-5. cepacia LPS antibodies in 10 CF
patients colonised by the epidemic strain measured by ELISA with R-LPS from the
epidemic strain as coating antigen. Arrows indicate when the epidemic strain (t) or other
strains of B. cepacia (♦) were first isolated from sputum.
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cepacia in all patients with the exception of patient IV who was initially transiently
colonised by the epidemic strain and patient VII who was initially colonised by a different
strain of B. cepacia. Following the onset of chronic colonisation by the epidemic strain,
the serum IgG antibody titre in both patients IV and VII increased. The serum IgG titre
in each patient increased following chronic colonisation until a maximum level was
attained. None of the CF patients in this study lost B. cepacia once chronic colonisation
was established.
Longitudinal measurement of IgM anti-5. cepacia LPS antibody titres in serum obtained
from clinic visits immediately prior to the first isolation of B. cepacia and also from
subsequent visits were performed (data not shown). The aim was to investigate any
increase in specific IgM antibodies to B. cepacia LPS around the time of colonisation, in
order to relate laboratory isolation with colonisation. Clinic visits were not sufficiently
frequent (time in between visits varied from two weeks to two months) to enable any
correlation to be made. In three out of 10 ESBc+ CF patients investigated, a peak anti-5.
cepacia LPS IgM titre coincided with laboratory isolation of B. cepacia.
5.4 Sputum Anti-LPS Antibodies Detected by ELISA
Anti-fi. cepacia LPS IgA and IgG antibodies in sputum were also measured by ELISA
with epidemic strain core-LPS as coating antigen in nine ESBc+ CF patients, nine Be" CF
patients and nine chronic bronchitic patients. Longitudinal measurements of sputum IgA
antibody indicated that there was considerable variation in titre between samples, as
shown in 3 CF patients (Figure 25). Similar variation was not observed in either Be" CF
patients or in the chronic bronchitic control patients. Figure 26 shows anti-fi. cepacia
sputum IgA antibody titres in three patient populations. The sputum IgA titres in ESBc+
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Figure 25. Longitudinal study of sputum IgA anti-B. cepacia LPS antibodies in 3 CF
patients colonised by the epidemic strain of B. cepacia measured by ELISA with R-LPS






Figure 26. Sputum IgA anti-fi. cepacia LPS antibody titre measured by ELISA with R-
LPS from the epidemic strain of B. cepacia as coating antigen in three patient
populations: (A) ESBc+ CF patients, n=9; (B) Bc+ CF patients, n=9; and (C) chronic
bronchitic patients, n=9. Bar represents median values.
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CF patients (sputum IgA titre range 200 - 6400; titre median 1600) were significantly
higher (p<0.001) than for non-fi. cepacia colonised CF patients (titre range 25 -1(X); titre
median 50) and chronic bronchitics (titre range 25 - 400; titre median 50).
In contrast to the sputum IgA antibodies, IgG antibodies in sputum were difficult to
detect; in 10 BC" CF patients titre were <25, whilst 10 Bc+ CF patients showed titres of
<200 with the exception of one CF patient colonised by the epidemic strain who had a
sputum IgG titre of 3200.
5.5 IMMUNOBLOT ANALYSIS OF SERUM AGAINST B. CEPACIA ANTIGENS
The serum IgG response in Bc+ CF patients was further investigated by immunoblotting
and multiblotting. Antigens were separated by SDS-PAGE and electrophoretically
transferred to NIC paper for subsequent probing with sera from CF patients or controls.
The antibody response to the following B. cepacia preparations was investigated: (1)
purified R-LPS from the epidemic strain; (2) purified S-LPS from the environmental
isolate J2395; (3) Proteinase K digests of whole cells of six different B. cepacia isolates;
(4) outer membrane preparations of five B. cepacia isolates; and (5) flagellar preparations
from three B. cepacia isolates. Sera from CF patients colonised by the epidemic and
other strains of B. cepacia and also Be" CF patients were analysed.
Serum IgG Response to Purified LPS
Multiblots of purified R- and S-LPS from the epidemic strain and J2395 respectively,
probed with serum from CF patients pre- and post-colonisation with B. cepacia are
shown in Figure 27a & b (serum as for Figure 22). Patients I - IX (Tracks 1-18) were
colonised by the epidemic strain. Prior to colonisation serum from patient V only showed
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Figure 27. Multiblots of purified R- and S-LPS from (a) the epidemic strain and (b)
J2395 separated by SDS-PAGE (12% w/v acrylamide, for the mini-gel) followed by
transfer to NIC paper and probed with paired serum (1:200) from 9 ESBc+ CF patients
(Tracks 1-18: 'odd' numbers are serum pre-colonisation, 'even' numbers are serum post-
colonisation). No pre-colonisation was available for patient IV (Track 7). Patient X
(Tracks 19 and 20) was colonised by a non-epidemic strain of B. cepacia, C1524.
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low level reactivity with the O-side chain portion of the J2395 S-LPS. No reaction was
observed with pre-colonisation sera from the other CF patients with either of the LPS
preparations indicating that no detectable level of specific IgG anti-5. cepacia antibodies
were present. An anti-LPS antibody response to the core-LPS of the epidemic strain and
to the ladder of the O-side chain of J2395 following onset of chronic colonisation was
detected by immunoblot for patients I - IX. Patient X was colonised by a non-epidemic
strain of B. cepacia CI524; a positive reaction between serum antibodies from this
patient and LPS preparations from the epidemic strain and J2395 was not detected.
Interestingly, sera from all the ESBc+ CF reacted with LPS from B. cepacia J2395, an
isolate from a flower vase in a hospital ward near to patient VIII (Tracks 15 and 16;
Nelson et al., 1991). Based on phenotypic and genomic fingerprinting, this strain has
never been isolated from the sputum of any of the CF patients.
Figure 28 shows the LPS preparations from the epidemic strain and J2395 and also a
preparation of S-LPS from a representative strain of the closely related species B.
gladioli probed with antisera raised in rabbits and with CF sera. Rabbits inoculated with
the epidemic strain or J2395 only reacted with LPS antigens of the autologous B. cepacia
strain. In contrast, serum from CF patient I, colonised only by the epidemic strain,
reacted with the core-LPS of the epidemic strain, the O-side chain of J2395 and also with
a single band of the B. gladioli preparation. All of the ESBc+ CF patients attending the
Edinburgh adult CF clinic, and some of those attending the Manchester CF clinic react to
the O-side chain of J2395. The reactivity of CF patients' sera with J2395, and the lack of
reactivity of the rabbit antisera from the rabbit inoculated with the epidemic strain
suggests that 'silent' colonisation rather than the possession of shared antigens is
responsible for cross-reactivity. It is possible that these CF patients may have been
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Figure 28. Immunblots of phenol water extracts of B. gladioli ATCC 10248
(Track 1); purified R-LPS from the epidemic strain (Track 2) and purified S-LPS
from J2395 (Track 3) and separated by SDS-PAGE (14% w/v acrylamide) followed
by transfer to NIC paper and probed with rabbit antisera or CF sera (1:200) from:
(a) rabbit inoculated with epidemic strain (CI359); (b) rabbit inoculated with J2395;
and (c) ESBc+ CF patient I.
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transiently colonised by additional strains of B. cepacia or that in vitro the epidemic
strain may not express the same antigens that are expressed in vivo.
Serum IgG Response to Proteinase K Digests ofWhole Cells
Proteinase K digests of six non-epidemic strains of B. cepacia strains were probed with
sera from 20 CF patients attending the Edinburgh and Manchester CF clinics, (nine
ESBc+,10 Bc+ and one Bc'CF patient). Multiblots of the reaction of the CF sera with
each B. cepacia strain are shown in Figure 29 (a-f). Patients 1-7, 9 and 10 were also
analysed in the previous LPS study. Serum from ESBc+ CF patients contained IgG
directed against some bands of each Proteinase K digest (Figure 29 a-f; Tracks 1-7, 11
and 18). Sera from CF patients colonised with the non-epidemic B. cepacia strains
CI495 (Track 12), C1548 (Track 13), and C1454+C1499 (Track 14) reacted similarly.
No reaction was observed with sera from CF patients colonised by B. cepacia SiEC 74
(Track 8), C1524 (Tracks 10), C1559 (Track 15), C1454 (Track 16) and C1449 (Track
19) or from the Be" CF patient (Track 20), even when the digest was of the autologous
colonising strain. The absence of any reactive bands suggests a lack of serum IgG
directed against B. cepacia antigens in these patients.
Serum IgG Response to Outer Membrane Preparations
The serum IgG anti-B. cepacia antibody response in 13 B. cepacia colonised CF patients,
five non-colonised CF patients and two non-CF patients to the outer membrane
preparations (see Figure 15 for Coomassie stained OMP profile) of five B. cepacia strains
was analysed by multiblotting (Figure 30a-e). The observations agree with those in the
previous Proteinase K study in that sera from CF patients colonised by the epidemic
strain (Tracks 1-3, 5-8 and 20) generally reacted more strongly with the outer membrane
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Figure 29 (a-f). Multiblots of proteinase K digests of cepacia strains: (a) C1409; (b)
C1524; (c) C1449; (d) C1499; (e) SBC74; (f) C1454, separated by SDS-PAGE (12%
w/v acrylamide) followed by transfer to NIC paper and probed with CF sera (1:200). CF
patients were colonised by the following B. cepacia strains: Tracks 1-7, 11 and 18 the
epidemic strain; Tracks 10,12, 13, 15 and 17 B. cepacia strains not used in this study;
Track 8, SBC74; Track 9, ESBc++C1409; Track 14, C1454+C1499; Track 16, C1454;





Figure 30 (a-e). Multiblots of outer membrane preparations of B. cepacia strains: (a) the
epidemic strain; (b) J2395; (c) ATCC 17616; (d) C1409 and (e) C1559, separated by
SDS-PAGE (12% w/v acrylamide) followed by tranfer to NIC paper and probed with CF
sera (1:200). CF patients were colonised by the following strains of B. cepacia: epidemic
strain, Tracks 1,2,3,5-8,20; other strains of B. cepacia, Tracks 4,9,17,18; C1559, Track
19; Be" CF patients, Tracks 1, 10-14 ;and non-CF patients, Tracks 15 &16. Serum from




antigens from each strain than sera from CF patients colonised by other strains of B.
cepacia (Tracks 4, 9, 17-19). The serum from Be" CF patients colonised by P.
aeruginosa (Tracks 10-14) contained antibodies directed against some OMPs of J2395
and C1409 which was in agreement with the earlier studies of Aronoff et al. (1991). CF
patients colonised by C1559 and C1454 do not react with OMP bands of any of the B.
cepacia strains studied, even the homologous strain.
Serum IgG Response to B. cepacia Flagella Preparations
Serum IgG responses to flagella preparations of three B. cepacia strains were analysed by
multiblotting (Figure 31a & b) in 17 ESBc+ CF patients, including two patients colonised
by additional B. cepacia strains, and three Bc+ CF patients. Although the multiblots
demonstrated that the flagella preparations were crude, the heterogeneity of the serum
IgG response between B. cepacia colonised CF patients was striking, even in those
patients colonised by the 'identical' strain, may also be observed. Figures 31a & b show
the serum IgG response to flagella preparations of J2395 and CI524. Serum from
patients colonised by the epidemic strain (Tracks 1-9,11,13,15-20) with the exception of
patients 13 and 19, reacted with both flagellar preparations, although the strength of the
reaction and the bands against which the serum reacted varied. Serum from patient 10
(Track 10), colonised by C1524, responded to antigens of the autologous colonising
strain but to different bands than sera from the other CF patients. Serum from patient 12
(Track 12) responded strongly to low molecular weight bands of J2395 and weakly to
two bands of CI524. In the previous investigations, serum from patients 10 and 12 failed
to react with antigenic preparations from the epidemic strain. No antibody response was
detected by immunoblotting against any of the flagellar antigens in this study for Patient
14 (Track 14). Multiblots against flagella preparations of the epidemic strain showed an
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Figure 31. Multiblots of flagellar preparation of B. cepacia strains: (a) J2395 and (b)
CI524, separated by SDS-PAGE (12% w/v acrylamide) followed by transfer to NIC
paper and probed with CF sera (1:200). CF patients were colonised with the following
strains of B. cepacia: the epidemic strain, Tracks 1-8, 11, 15-20; the epidemic
strain+C1409, Track 9; C1524 (TracklO); C1449 (Track 12); the epidemic strain+C1506;
Track 13; and C1454 (Track 14).
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antibody response only in sera from patients colonised by the epidemic strain (data not
shown), suggesting that the epidemic strain flagella may be antigenically distinct from
other B. cepacia flagella.
5.6 Serum IgG Subclasses in b. cepacia Colonised CF Patients
The serum IgG subclass response to B. cepacia core R-LPS was investigated in CF
patients to clarify the nature of the immunoglobulin response in B. cepacia colonised CF
patients.
Total Serum IgG Subclass Concentration
Preliminary analysis was performed by RID with selected sera to confirm that the total
serum IgG subclass concentrations in ESBc+ and Bc+ CF patients were 'normal' and that
there were no previously undetected subclass deficiencies which might predispose this
group of CF patients to B. cepacia colonisation. Sera from 19 CF patients (nine ESBc+,
seven Bc+, three BcVPa+) and one BcVPa" chronic bronchitic patient were analysed.
The serum concentrations for the IgG subclasses and normal ranges are shown in Figure
32. No subclass deficiency was observed for any of the patients investigated, however a
wide range of concentration was obtained for each of the IgG subclasses. The serum IgG
subclass concentrations from the majority of the patients were in excess of the normal
ranges indicated. Serum concentrations of IgGl and IgG3 were significantly higher in
ESBc+ CF patients than in those Bc+ CF patients (p<0.1 and p<0.05 respectively,
Students Mest).
Increased concentrations of total serum IgG appeared, in some patients to correlate with
















































Figure 32. Distribution of serum IgG concentrations in 20 patients: (a) IgGl; (b) IgG2;
(c) IgG3; (d) IgG4. Vertical bar represents mean +/- 1SD. Normal values are indicated.
Patient populations are as follows: ESBc+, CF patients colonised by the epidemic strain
of B. cepacia; BC+, CF patients colonised by other strains of B. cepacia; Be", CF
patients colonised by P. aeruginosa only; the non-CF patient was not colonised by either
B. cepacia or P. aeruginosa.
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32) had increased concentrations of all (patient 1) or some (patient 2) of the subclasses.
Patient I is chronically unwell and is awaiting heart-lung transplantation; patient II died as
a result of overwhelming B. cepacia infection shortly after this serum was obtained. In
contrast, patients 3 and 4, also ESBc+, have serum concentrations of all the IgG
subclasses near or within normal ranges and are relatively well. Patient 5 had increased
concentrations of serum IgG 1, 2 and 4, however in previous antibody studies no antibody
response against any of the B. cepacia antigens was observed and in the following study
no specific anti-B. cepacia LPS IgG subclass antibodies were detected.
Detection of Serum IgG Subclass Anti-B. cepacia R-LPS Antibodies
A modified ELISA, incorporating a streptavidin-biotin conjugate system, was used to
measure the serum IgG and IgG subclass anti-B. cepacia R-LPS antibodies in 13 ESBc+
CF patients (including two patients colonised by additional strains of B. cepacia), eight
Bc+ CF patient and 20 Be" CF patients.
Figure 33 shows the total anti-B. cepacia core LPS IgG antibody titres and the titres for
IgG 1-3 in ESBc+ and Bc+ CF patients. The patients numbered 1-5 correspond to the
patients numbered 1-5 in Figure 32. The range in antibody titres for the ESBc+ CF
patients was: total IgG, 200-25600, median 6400; IgGl, 25-6400, median 400; IgG2, 50-
12800, median 3200 and IgG3, 50-6400, median 1600. The range in antibody titres for
Bc+ CF patients was: total IgG, 200-6400, median 400; IgGl, 50-800, median 50; IgG2,
50-800, median 50 and IgG3, 25-800, median 50. No anti-B. cepacia core-LPS specific
IgG4 was detected in any of the patients; although serum concentrations of IgG4 were
elevated in many of these patients. In ESBc+ CF patients and two of the Bc+ CF patients
















































Figure 33. Anti-B. cepacia LPS IgG subclass antibody titres in ESBc+ and Bc+ CF
patients detected by ELISA with R-LPS of the epidemic strain as coating antigen,
(a) anti-B. cepacia IgG; (b) anti-B. cepacia IgGl; (c) anti-B. cepacia IgG2; (d) anti-
B. cepacia IgG3. Data for IgG4 not shown as all anti-B. cepacia LPS IgG4 antibody
titres were <25. Bar represents median value. * indicates CF patients colonised by
two strains of B. cepacia.
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for IgG2 and IgG3 (median titres for ESBc+ patients 3200 and 1600 respectively). For
most of the CF patients colonised by non-epidemic strains of B. cepacia and non-
colonised controls (data not shown) there was no detectable levels of the IgG subclasses.
These studies are not conclusive but provide an interesting insight into pathogenicity of
B. cepacia and CF for example; a high level of specific IgG2 directed against B. cepacia
antigens may be important in preventing clearance of B. cepacia by pulmonary
macrophages as this subclass of IgG is a poor opsonin.
5.7 Opsonic Potential of Serum from CF Patients Colonised by B. cepacia
Following the observation of the pronounced immunoglobulin response to B. cepacia
colonisation the next step was to investigate the ability of serum from CF patients
colonised by B. cepacia to promote or inhibit opsonic phagocytosis of B. cepacia. A
chemiluminescent opsonophagocytosis assay was performed in 96 well microtitre plate
which enabled large numbers of samples to be investigated simultaneously whilst
requiring minimal numbers of phagocytic cells. Phagocytic activity was analysed by
measuring the luminol (which is linked to the myeloperoxidase-f^Q? system) enhanced
chemiluminescence which results from the oxidative burst induced by the phagocytosis of
bacteria.
In the first instance, preliminary experiments were performed to determine the optimum
concentrations of phagocytic cells, bacteria and serum. Phagocytic cells were obtained
from human buffy coat and were predominately monocytes. A monocytic cell
concentration of 2.0x10^ cells/ml (l.OxlO^ cells/weU) was found to give optimal
chemiluminescence without giving a double peak or interfering with chemiluminescence.
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The optimal bacterial concentration was 1.0xl()9 cfu/ml (5.0x10^ cfu/well), resulting in a
ratio of phagocytic cells to bacteria in each well of 1:50. Undiluted serum was found to
give the most reproducible results.
The characteristics and magnitude of the oxidative burst were strain and serum
dependent. Figure 34 shows the chemiluminescent output of phagocytes incubated with
Zymosan A or with the five bacterial strains (nonopsonic phagocytosis) measured at 5
min intervals over a period of 90 min. Results are the mean of four experiments. The
greatest peak was observed with P. aeruginosa PAOl (mean peak CL=117.2; sd+/-20.8),
which was larger than the peak chemiluminescence observed for the Zymosan positive
control (mean peak CL=78.0; sd+/-22.8). The magnitude of the oxidative burst induced
by the three B. cepacia strains and S. aureus was much lower than that for PAOl or
Zymosan: C1359 mean peak CL= 30.6 sd+/-10.4; C1559 mean peak CL=7.0 sd+/-3.5;
J2395 mean peak CL=18.4 sd+/-5.9; S. aureus mean peak CL=13.0 sd+/-7.0. The time
at which peak chemiluminescence occurred ranged from 15 min to 35 min,
chemiluminescent output was then observed to diminish at a varying rate until baseline
levels were reached.
The assay was repeated following preincubation of bacteria for 90 min at room
temperature with sera from 10 CF patients; four colonised by the epidemic strain; four
colonised by other strains of B. cepacia and two colonised by P. aeruginosa only.
Figures 35a - e show the chemiluminescence measured in phagocytic cells incubated with
bacteria and serum as a percentage of the chemiluminescence resulting from nonopsonic
phagocytosis of bacteria. The oxidative burst was clearly reduced in the presence of any
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Figure 35 (a-e). Effect of preincubation of bacteria with serum on oxidative burst in
monocytes. Results are peak CL expressed as a percentage of bacterial strain alone: (a)
PAOl; (b) epidemic strain; (c) J2395; (d) C1559 and (e) S. aureus. CF patients
colonised by the following: Patients I - IV, the epidemic strain; patients V-VII and X
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chemiluminescence was increased for the remaining B. cepacia strains (CI559 and J2395)
and also for S. aureus (Figures 35c-e). The degree of inhibition or promotion of the
oxidative burst was highly variable. There did not appear to be any correlation between
the bacterial status of the CF patient (with respect to colonisation by B. cepacia) and the
effect of the serum on the opsonophagocytosis. However the fact that
opsonophagocytosis of the epidemic strain was reduced in the presence of CF sera may
be of importance when considering the persistence of this organism.
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CHAPTER 6
BACTERICIDAL ACTIVITY OF NORMAL HUMAN SERUM
AGAINST BURKHOLDERIA CEPACIA
Traditionally, bacteria expressing R-LPS are considered to be serum-sensitive and are not
associated with bacteraemia. Approximately 20% of CF patients colonised by B. cepacia
succumb to 'Cepacia Syndrome', the rapid fatal decline in pulmonary function which may
be accompanied by B. cepacia bacteraemia. The aim of this study was to investigate the
bactericidal activity of normal human serum against strains of B. cepacia, particularly the
epidemic strain which has been shown to express R-LPS yet has been associated with
bacteraemia in CF patients.
6.1 Determination of Complement Activity
Serum obtained from two normal healthy volunteers and three CF patients colonised by
the epidemic strain of B. cepacia was examined by sheep erythrocyte lysis assay to
determine the activity of serum complement. Each of the sera tested had levels of
haemolytic complement within the acceptable range (20 - 50 CH50 units).
6.2 Serum Killing of b. cepacia
The sensitivity of 19 B. cepacia isolates from different sources, expressing both R- and S-
LPS phenotypes, to the bactericidal activity of normal human serum was investigated.
PFGE and bacteriocin typing demonstrated that there was no clonal relationship amongst
the B. cepacia isolates used in this study with the exception of CI359 and CI602 which
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are representative isolates of the epidemic strain. For each experiment the percent killing
was calculated from the number of organisms, as determined by viable count, at Tq min
and those still viable at the end of the experiment. Results were compared with those for
the controls (CFTB only and heat inactivated serum: HIS) and expressed as: serum-
resistant (SR) = <10% killing of bacteria; intermediate (I) = 10-90% killing; and serum-
sensitive (SS) = >90% killing.
Serum killing of B. cepacia by pooled normal human serum (PNHS: pooled from two
healthy adults) was measured at 90 min and also at 180 min to detect delayed killing
(Table 16). After 90 min exposure to serum, 7 (58.3%) of the 12 isolates expressing S-
LPS were resistant to serum bactericidal activity, 3 (25%) showed intermediate sensitivity
and 2 (16.7%) were serum-sensitive. In contrast, none of the seven B. cepacia isolates
expressing R-LPS were serum-resistant at 90 min, 4 (57.2%) showed intermediate
sensitivity and 3 (42.8%) were serum-sensitive. Following 180 min exposure to PNHS
there was a marked increase in the number of serum-sensitive isolates. All of the B.
cepacia isolates expressing R-LPS were serum-sensitive at 180 min. Of the B. cepacia
isolates expressing S-LPS seven (58.3%) were serum-sensitive at 180 min, one showed
intermediate sensitivity and four (33.3%) remained serum resistant. The two control E.
coli strains, R3 and 018, included in this study expressed R- and S-LPS respectively. The
rough strain was serum-sensitive at 90 min whilst the smooth strain of E. coli remained
serum-resistant at 180 min.
After 180 min exposure to PNHS, 18 of the B. cepacia strains examined fell within the
boundaries of the sensitivity classifications described above. Although serum sensitivity
was classified as a >90% reduction in the number of colony forming units when
168
Table 16. Serum killing of B. cepacia by 40% PNHS at 90 min and 180 min.
LPS
B. cepacia Source (R or S) 90 min 180 min
C1518 CF (sputum) S SR SR
CI 394 ti R SS SS
C1524
ti S I SS
CI 548 it R SS SS
C1559
ii S I SS
CI454
ii R I SS
CI409
ii S I SS
CI 704 ii S SR SR
C1359* ii R I SS
CI602* CF (blood) R I I
ATCC25609 Bronchial wash S SS SS
ATCC25608 Wound S SR SS
ATCC27515 Infected tissue s SR I
ATCC17762 Urine R SS SS
J162 Wound S SR SS
J2395 Flower vase s SR SR
SBC100 Potato s SS SS
ATCC 17616 Soil R I SS
J159 Onion s SR SR
E. coli R3 - R SS SS
E. coli 018 - S SR SR
*epidemic strain
SR - serum resistant
SS - serum sensitive
I - intermediate
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compared to the viable counts at 0 min, greater than 96% killing or reduction was
measured for the majority of serum-sensitive B. cepacia isolates with the exception of the
epidemic strain isolate CI602 (90% killing). At the other extreme 0-3% killing was
measured for the four serum-resistant B. cepacia isolates. Finally, a 58% reduction in the
viable count was observed for the intermediately sensitive isolate ATCC 27515.
The observation that all the isolates which remained serum-resistant after 180 min
exposure to PNHS expressed S-LPS, suggests that S-LPS may contribute to the ability of
B. cepacia isolates to resist the bactericidal activity of PNHS. Interestingly, the two
representative isolates of the epidemic strain expressimg R-LPS, CI359 and CI602 from
sputum and blood culture respectively, were serum-sensitive.
The killing curves for three B. cepacia isolates J2395 (serum-resistant), CI409 (delayed
killing) and the epidemic strain (C1359; serum-sensitive) over 180 min are shown in
Figure 36. The figure clearly illustrates the contrast in killing profiles: no decrease in cell
numbers was observed with J2395; for C1409 an initial gradual decline in cell numbers up
to 90 min was then followed by a steeper decline until 180 min; the epidemic strain was
rapidly serum-sensitive by 90 min.
B. cepacia strains expressing S-LPS exhibit a range of responses to the bactericidal
activity of PNHS; for example, the distinct killing curves for J2395 and C1409 (Figure
36). The O-side chain portion of the LPS of J2395 showed a greater degree of
polysaccharide substitution than the LPS of C1409 (Chapter 3, Figure 14b) and this may
contribute to increased the serum resistance observed for J2395.
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Figure 36. Serum killing of B. cepacia strains J2395 (serum-resistant, S-LPS), C1409
(intermediate, S-LPS) and CI359 (epidemic strain; serum-sensitive, R-LPS) by 40%
PNHS over 180 min. Each point is the mean of triplicates.
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Investigations with other bacteria, for example Aeromonas species, indicate that LPS is
not the sole determinant of serum resistance in Gram negative bacteria and that other cell
surface components such as OMPs and capsules may also be involved (Taylor, 1983). A
possible role of OMP in contributing to serum resistance in B. cepacia was investigated
by examining crude Sarkosyl preparations of serum-resistant, intermediate and serum-
sensitive B. cepacia strains by PAGE and Coomassie staining (Chapter 3, Figure 15).
The three CF isolates, C1359, C1559 and C1409, expressed fewer OMP than the
environmental isolates J2395 and ATCC 17616, however as the latter strain was not
serum resistant the bands observed presumably have no role in resistance. J2395
expressed a broad band of high molecular weight (150 - 200 kDa) not observed in any of
the other B. cepacia strains which may contribute to serum resistance in this strain.
6.3 Serum Requirement forBacterial Killing
The aim of this next series of experiments was to investigate several of the major serum
components; for example the two complement pathways and specific serum antibodies, to
determine their role in the serum killing of B. cepacia.
The majority of experiments were performed with 40% serum, although killing was
observed with 10% serum. Serum killing by 10% or 40 % PNHS was proportional to the
serum concentration; killing of serum-sensitive and intermediate strains of B. cepacia was
slower in the presence of 10% serum and complete killing was not always achieved. Two
controls were included in each serum sensitivity assay; PNHS was replaced by CFTB or
HIS. No bactericidal activity was associated with either of these controls indicating that
a serum factor was involved in serum killing and that the factor was heat labile.
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Role of Antibody in Serum Killing
To investigate the role of specific anti-/?. cepacia antibodies in serum killing, sera were
obtained from three CF patients of variable clinical status chronically colonised by the
epidemic strain of B. cepacia. In contrast to PNHS which contained negligible amounts
of anti-5. cepacia antibodies (mean antibody titre, 400), the hyperimmune CF sera
contained significant amounts of specific and-/?, cepacia antibodies. At the time serum
was obtained the general clinical status and antibody titre of each CF patient was: (a)
Patient I was chronically unwell with an anti-/?. cepacia LPS IgG antibody titre of
102400; (b) Patient II was 'well' with an anti-/?. cepacia LPS IgG antibody titre 51200;
and (c) Patient III was experiencing acute pulmonary exacerbation also with an anti-/?.
cepacia LPS IgG antibody titre 51200.
The bactericidal activity of PNHS and the CF serum against four strains of B. cepacia
(J2395, C1548, the epidemic strain (C1359) and ATCC 17616) is shown in Figure 37.
The serum from two of the CF patients (Patients I and II) were comparable in their killing
activity against the three heterologous strains of B. cepacia (CI548, J2395 and ATCC
17616) and also the epidemic strain. Serum from the third CF patient, however, whilst
equally active against heterologous strains of B. cepacia, was much less active against the
epidemic strain of B. cepacia.
Each CF sera was then subjected to a series of four absorptions against whole cells of
each of the B. cepacia strains in order to specifically remove anti-B. cepacia antibodies
and the serum sensitivity assay was repeated with the absorbed serum. No difference was
observed in the bactericidal potential of any of the CF sera. A belated ELISA with the
absorbed sera and whole cells as coating antigen showed unexpectedly that the
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Figure 37. Serum killing of 4 B. cepacia isolates the epidemic strain, CI548, J2395 and
ATCC 17616 by 40% PNHS and 40% CF serum. CF Patients I-III were chronically
colonised by the epidemic strain of B. cepacia, represented by CI359. Serum from
patient HI was obtained during an acute pulmonary exacerbation.
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absorption process had not resulted in a significant decrease in the anti-fi. cepacia
antibody titre. It was not possible to repeat the absorptions as the serum sensitivity
assays had used all the CF sera available from patients I - III. Attempts to obtain more
serum from the same patients or others in similar clinical condition were unsuccessful.
Role of the Complement Pathways
To determine whether the classical complement pathway (CCP) or the alternative
complement pathway (ACP), was more important in the complement mediated killing of
serum-sensitive B. cepacia, serum killing was investigated in eight isolates which were
incubated with 40% PNHS containing magnesium EGTA (in which only the ACP is
functional). Table 17 shows serum killing of these strains in the presence of 40% HIS,
40% PNHS and 40% PNHS+lOmM MgCl2 EGTA.
Decreased cell numbers in the presence of HIS was observed to a minor extent with
C1548 and more so for ATCC 17616 but not at all for the remaining six B. cepacia
isolates. With the exception of the serum-resistant B. cepacia isolate J2395, serum
killing of all of the B. cepacia strains was reduced in the presence of MgCl2 EGTA,
although the extent of this was strain dependent. The most marked reductions in serum
killing were observed with the two representative isolates of the epidemic strain, CI602
and CI359, and for environmental isolate ATCC 17616. Each of these B. cepacia
isolates express R-LPS. The results obtained in this study suggest that the CCP is the
complement pathway primarily involved in serum killing of B. cepacia.
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Table 17. Serum killing of eight B. cepacia strains by 40% PNHS, 40% PNHS+lOmM
MgCl2 EGTA and HIS at 180 min. Serum killing was calculated as the percent decline in
cell numbers between 0 and 180 min.
Killing of B. cepacia strains (%)




CI 602 0 91 32
C1359 0 96 32
CI 548 5 97 87
CI 409 0 72 37
ATCC 17762 0 100 47
ATCC 17616 17 98 18
C1518 0 4 0
J2395 0 0 0
HIS - heat inactivated serum
PNHS - pooled normal human serum
6.4 Effect of Culture Media on Serum Sensitivity of B. cepacia
To investigate the effect of the culture media on the serum sensitivity of B. cepacia
isolates were cultured overnight at 37°C in either 50% v/v heat inactivated sheep serum
(HISS) or minimal media (MM). B. cepacia isolates were then exposed to PNHS in the
same manner as previously described and the results compared with those obtained
following culture in isosensitest broth (ISTB). Figure 38 shows the percent survival
observed for nine B. cepacia isolates following culture in ISTB, HISS or MM.
The effect of culture media on serum sensitivity of B. cepacia was observed to be strain
dependent. Five of the nine B. cepacia strains investigated were more resistant to the
bactericidal activity of PNHS following culture in HISS whilst culture in ISTB or HISS
appeared to make no difference to the serum resistance or sensitivity of three of the
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isolates (J2395, ATCC 17616, ATCC 25608). Following culture in MM all nine B.
cepacia isolates were less resistant to the bactericidal activity of PNHS than following
culture in HISS or ISTB, with the exceptions of CI394 which was serum-sensitive
(100% kiMing) in HISS and CI359 which exhibited the greatest serum sensitivity
following culture in ISTB. The most marked increases in serum resistance were observed
for CI524 and C1409, the observed differences with the other isolates were not as
marked. The results show that culture medium does have an effect on the serum
sensitivity of B. cepacia isolates. Of interest, the epidemic strain was not observed to be
serum resistant following culture in any of the above conditions examined.
In conclusion, the association of B. cepacia with bacteraemia in CF patients, including
the epidemic strain which expresses R-LPS, cannot be explained by serum resistance and





Three important features of B. cepacia colonisation in CF patients account for current
concern: (1) the organism's characteristic multiresistance to available antimicrobial
agents, which limits possible therapeutic options; (2) the high risk of transmission of
B. cepacia from either person to person or contaminated environmental fomites; and
(3) the life threatening clinical sequelae in which approximately 20% of B. cepacia
colonised CF patients succumb to 'Cepacia syndrome', a rapidly fatal decline in lung
function accompanied by bacteraemia. These features cause major problems for the
management of colonised and non-colonised CF patients in CF clinics and in general
hospital wards; in addition recent reports of social acquisition pose a threat to the
continuation of the adult CF groups in the community which provide great benefit to
both patients and their families (Walters & Smith, 1993). In response to concern and
requests for information guidelines have been issued by national organisations,
including the CF Trust, with the aim of reducing the risk of cross-infection. Such
guidelines will require to be updated as further information becomes available in order
that any recommendations are justified.
Until recently B. cepacia was not considered to be particularly important as a human
pathogen; this is reflected by the fact that literature concerning B. cepacia
pathogenesis is scarce in comparison to the copious literature associated with the
pathogenesis of P. aeruginosa. The recent creation of a new genus, Burkholderia,
with B. cepacia as the type species (Yabuuchi et al., 1992) emphasises that B.
cepacia is distinct taxonomically from P. aeruginosa a fact which is supported by the
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differences in epidemiology and pathogenic potential between the two organisms. In
contrast to B. cepacia, P. aeruginosa in CF is not associated with a rapid decline in
pulmonary function and bacteraemia and, in general, is not readily transmitted
between patients (Tablan, 1993). Furthermore, B. cepacia has not been shown to
produce alginate or express any of the virulence factors classically associated with P.
aeruginosa infection in CF. Nor has B. cepacia been observed to undergo the
phenotypic adaptations, including a transition from S- to R-LPS expression, serum-
sensitivity, development of hypersensitivity to antimicrobial agents and the over
production of alginate, which are observed in P. aeruginosa isolates from chronically
colonised CF patients (Hancock et al., 1983; Penketh et al., 1983; Burke et al.,
1990).
The aim of this thesis was to investigate B. cepacia pulmonary colonisation in CF
patients, particularly the biological properties which may be important in colonisation
by the multiresistant, highly transmissible strain of B. cepacia which was identified
during a survey of antibiotic resistance in B. cepacia strains (Lewin et al., 1993) and
also by improved typing facilities. These studies indicated that the multiresistant
strain of B. cepacia accounted for 75% of the B. cepacia isolates from adult CF
patients in Edinburgh and that it was prevalent amongst CF patients across the UK
(see Introduction). As a result of this outbreak the majority of investigations focused
on the epidemic strain of B. cepacia and the CF patients colonised by this strain.
7.1 The Natural Habitat of B. cepacia and Risk of Environmental
Acquisition
B. cepacia is frequently described in the literature as a ubiquitous saprophyte found in
soil, water and vegetation of diverse geographic distribution (Berkelman et al., 1981).
The use of the word "ubiquitous" may be an overstatement of the organism's
distribution in nature and to clarify this issue an environmental survey was carried out
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using improved selective B. cepacia culture techniques (Nelson et al., 1991) of the
Royal Botanic Gardens in Edinburgh, which provided a range of soil and water
microenvironments. The results of the Botanic Gardens survey demonstrated that B.
cepacia could be isolated from soil, water and plant material from the varied
microenvironments ranging from tropical houses to the outdoor pond. The fact that
B. cepacia was isolated from a relatively small percentage of the sites examined (12 of
55) supported the suggestion that 'ubiquitous' is an exaggeration. Interestingly, it also
confirmed the observation of Palleroni (1984) that despite extraordinary nutritional
and survival capabilities B. cepacia does not appear to predominate in the natural
environment.
Biochemical and genetic analysis of the strains isolated during the microbiological
survey of the Botanic Gardens suggested that B. cepacia strains isolated from the
'natural' environment are distinct from their clinical counterparts confirming the
observations of Gonzalez & Vidaver (1979) and more recently those of Bevivino et
al. (1994). Genotypic characterisation of the Botanic isolates by PFGE demonstrated
that the majority of environmental isolates were clonally distinct from each other and
also from the clinical and CF isolates. With the exception of B. cepacia type strain
ATCC 17616, all the environmental B. cepacia isolates, including those from the
Botanies, expressed S-LPS with a full O-side chain; in addition, environmental
isolates exhibited a lower degree of antimicrobial resistance than strains from CF
patients or B. cepacia from the hospital environment (Mrs C. Doherty, personal
communication).
Increased interest in environmental strains of B. cepacia has emerged because the risk
which such strains present to CF patients is unknown. In the past, the literature has
not clearly differentiated between true environmental strains and contaminating
environmental strains (e.g. strains contaminating hospital equipment after use by
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colonised patients). The improved selection procedures which have been successfully
developed should provide sufficient material to further clarify this issue. Previous
studies, which examined the hospital and home environments of CF patients (Nelson
et al., 1991; Fisher et al., 1993) have shown that B. cepacia colonised CF patients
may contaminate their immediate environment. In contrast, in the report of Pegues &
Tablan (1993) isolates of B. cepacia from the 'natural' environment were distinct from
the B. cepacia isolated from CF patients.
The ability of B. cepacia to survive in conditions of low nutrient availability
undoubtedly contributes to the organism's success as a nosocomial pathogen. Carson
et al. (1973) demonstrated that distilled water may contain high numbers of B.
cepacia (10^ cfu/ml) which are not detected as the small cell size does not result in
turbidity. Commercial products, such as disinfectants, may become contaminated
following dilution with the 'sterile' water resulting in outbreaks of B. cepacia
pseudobacteraemia or tissue infection (Bassett et al., 1970; Berkelman et al., 1981;
Craven et al., 1981; Decicco et al., 1981). Various factors influence bacterial
resistance to disinfectant agents: Vess et al. (1993) proposed that the ability of B.
cepacia strains to attach to surfaces and form cellular masses or biofilms provided
protection from agents active against planktonic populations; alternatively Pyle et al.
(1994) suggested that the mechanism of resistance to iodophor agents involved
physiological mechanisms such as catabolite repression. In contrast to the in situ
resistance of B. cepacia strains to disinfectant agents, a comparable degree of
resistance in vitro could not be demonstrated (Bassett et al., 1970; Craven et al.,
1981); indeed, the six commonly used disinfectants were effective against two strains
of B. cepacia investigated in this study. However, conditions likely to be encountered
in situ, in particular nutrient deprivation which may induce adaptations in B. cepacia
to promote survival, were not accurately reproduced in the assay. The influence of
culture conditions in experimental investigations cannot be ignored; the above
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experiments will be repeated following culture in appropriate conditions as part of a
future project.
In conclusion, the risk environmental strains of B. cepacia present to CF patients
remains unclear. Based on present evidence patients are probably at greatest risk
from person-to-person transmission or indirect acquisition from contaminated fomites
in the hospital or home where the ability of B. cepacia to survive in conditions of low
nutrient availability allows a contaminated reservoir to be a source of infection (Fisher
et al., 1993; Govan et al., 1993; Pegues & Tablan, 1993; Burdge et al., 1993).
7.2 B. cepacia Colonisation of Patients with Cystic Fibrosis
Several studies have proposed that B. cepacia strains may vary in virulence, with
some strains being highly virulent and others essentially avirulent (McKevitt &
Woods, 1984; Goldman & Klinger, 1986; Gilligan, 1991). This issue will be
addressed in the following section.
Extracellular Virulence Factors
In previous studies the virulence factors associated with P. aeruginosa colonisation in
CF (elastase, phospholipase C (PLC), alginate and exotoxin A) have not been
demonstrated in B. cepacia isolates. However, because of the clearly documented
virulence and transmissibility of the epidemic strain (Govan et al., 1993) attempts
were made to investigate putative virulence factors in epidemic strain isolates. In the
present study, investigation of the epidemic strain of B. cepacia confirmed the
previous reports that B. cepacia lacks the classic P. aeruginosa virulence factors
(McKevitt & Woods, 1984; Montie et al., 1985; Nakazawa et al., 1987; McKevitt et
al., 1989; Vasil et al., 1990) and also indicated that the epidemic strain was no
different from other B. cepacia strains. All strains of B. cepacia showed some PLC
activity but no elastase production was observed for any of the B. cepacia strains
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investigated. Melanin production was characteristically associated with the epidemic
strain and has not previously been described in B. cepacia. A pathogenic role for
melanin is unlikely as non-melanin producers have also been associated with fatalities
in CF. However, identifying melanin production is a useful marker for the epidemic
strain. Although exopolysaccharide production was observed in several B. cepacia
strains following culture on the appropriate media, it would seem unlikely that
exopolysaccharide production contributes to virulence as many CF isolates including
the epidemic strain did not produce exopolysaccharide under any growth conditions.
This result agreed with the survey of polysaccharide biosynthesis by Sage et al.
(1990) which indicated that there was no correlation between the ability of B. cepacia
to colonise the respiratory tract and the production of exopolysaccharide. Finally,
Southern hybridisation studies with an exotoxin A gene probe performed by Dr J.
Nelson showed a positive band with the epidemic strain although subsequent
experiments failed to demonstrate biosynthesis of a 66 kDa protein equivalent to P.
aeruginosa exotoxin A. In contrast, Vasil et al. (1986) demonstrated that the gene
encoding exotoxin A was absent in eight B. cepacia strains.
B. cepacia Cell Surface
Bacteria interact with their environment via their cell envelope and therefore the
components of the envelope are important in enabling an organism to adapt and
survive in a susceptible host. The next section of this thesis concerned the
investigation of the major cell surface components of B. cepacia namely fimbriae,
flagella, LPS and OMPs.
Tweedy et al. (1968) first described the fimbriae of B. cepacia and showed them to be
similar to Type 1 fimbriae of E. coli. Investigation of the epidemic strain and other
CF isolates of B. cepacia confirmed this and agree with the majority of subsequent
observations (Fuerst & Hayward, 1969; Sajjan & Forstner, 1992; Kuehn et al., 1992)
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that B. cepacia fimbriae are peritrichous and morphologically similar to Type 1
fimbriae. A further comparison with Type 1 fimbriae is that haemagglutination of
guinea pig red blood cells by some B. cepacia strains was also inhibited by D-
mannose. Only one study has described B. cepacia strains expressing polar fimbriae,
similar to the fimbriae of P. aeruginosa (Saiman et al., 1990). The present study and
that of Tweedy et al. (1968) noted that fimbriation was rare in B. cepacia strains with
only 10% of organisms from solid or liquid culture observed to express fimbriae. In
the present study, electron microscopy (Figures 8-10) indicated that B. cepacia
expressed two different types of fimbriae; one (Figure 9) comparable to Type 1
fimbriae which was associated with mannose sensitive haemagglutination by strains of
B. cepacia; and a second 'crinkly' type (Figure 10) observed on non-
haemagglutinating B. cepacia strains. It is possible that expression of a particular
fimbrial type in any strain of B. cepacia might be associated with the colonising
potential of that B. cepacia strain; for example from available evidence it is not clear
whether the 22 kDa adhesin found on fimbriae of adherent B. cepacia strains (Sajjan
& Forstner, 1992 and 1993) is associated with more than one fimbrial type. Different
fimbrial morphological types have not previously been described for B. cepacia;
interestingly a recent paper presented by Forstner et al. (1994) described seven
different structural classes of B. cepacia fimbriae. Co-expression of two different
fimbrial classes was common, particularly amongst CF isolates. The Toronto and
Edinburgh epidemic strain isolates expressed a 'cable' pilus, so called because of its
rather unusual morphology, assembled from a 17 kDa pilin subunit.
In some Gram-negative bacteria fimbrial-mediated haemagglutination has been
reported to be associated with adherence and colonisation for example Helicobacter
species and Haemophilus influenzae type b (Gilsdorf et al., 1992; Taylor et al.,
1992). B. cepacia strains investigated in this study did not show such an association.
B. cepacia strains which were capable of haemagglutination (those with Type 1 type
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fimbriae) were not particularly adherent to mucin, whilst mucin adherent strains which
were also observed to express fimbriae did not haemagglutinate. As the 22 kDa
adhesin involved in adherence to mucin and BEC has been shown to be located on B.
cepacia fimbriae (Sajjan & Forstner, 1992), it is possible that strains of B. cepacia
which are capable of haemagglutination do not express this adhesin and therefore that
the different adhesins are associated with different fimbriae.
Motility, in association with chemotaxis, enables a bacterium to move towards a more
favourable environment and may promote localisation to the host surface (Finlay &
Falkow, 1989). Motility in P. aeruginosa has been associated with increased
virulence; for example non-flagellate or non-motile mutants of P. aeruginosa show
decreased virulence in a burned mouse model (Montie et al., 1982; Drake & Monde,
1988). Furthermore reduced motility and impaired virulence were observed in strains
expressing R-LPS isolated from chronically colonised CF patients with poor
pulmonary status (Luzar et al., 1985). In this study the B. cepacia strains
investigated exhibited a range of motility. Interestingly, the motility of the epidemic
strain isolates of B. cepacia (which express R-LPS) was significantly less than the
motility of the environmental, clinical and other CF isolates. The lack of motility
observed in a strain associated with transmission and considered to be 'virulent'
indicates that being highly motile may not be as important for B. cepacia as for P.
aeruginosa.
McKevitt & Woods (1984) reported that the majority (54%) of CF isolates of B.
cepacia expressed R-LPS. In their study no typing data was available to confirm that
the CF isolates studied were clonally distinct. In contrast, the results from the present
study showed that the majority of B. cepacia strains investigated (regardless of
source) expressed S-LPS. An explanation for this apparent contradiction may lie in
the transmissibility of B. cepacia and the lack of typing data available for the
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McKevitt & Woods study. For example, 75% of the B. cepacia isolates from CF
patients in the Edinburgh clinic express R-LPS, but these isolates are clonally related.
As discussed earlier, B. cepacia isolated from the 'natural' environment expresses S-
LPS; the epidemic strain would appear to be rather unusual in the consistent
expression of R-LPS. It is interesting to speculate what advantage the expression of
R-LPS could confer on to the epidemic strain as a potential pathogen, as the organism
would have increased susceptibility to the bactericidal activity of serum and would be
more susceptible to phagocytosis due to increased hydrophobicity. In the context of
intracellular survival however, increased uptake by phagocytes might be an advantage.
Increased resistance to antimicrobial agents is associated with reduced expression of
OMPs in B. cepacia (Aronoff , 1988). Godfrey et al. (1984) also observed that in P.
aeruginosa the loss of the LPS O-side chain contributed to resistance to (3-lactam
antibiotics. In this study the CF isolates of B. cepacia were observed to express
fewer OMPs than the isolates from the hospital environment or the soil (Figure 15).
The CF isolates were also found to be less sensitive to a range of antimicrobial agents
(Mrs C. Doherty, personal communication). Expression of R-LPS by the epidemic
strain may contribute to the high levels of antimicrobial resistance observed with this
strain (Simpson et al., 1994). A recent report demonstrated that the expression of
extracellular virulence factors and cell surface components of B. cepacia was
influenced by sub-MIC levels of antibiotics (McKenney et al., 1994). Although B.
cepacia is seldom eradicated by antimicrobial agents, altering the expression of
potential virulence factors may reduce the pathogenic potential of the organism and
enable the host's immune response to control the infection.
B. cepacia Adherence
Adherence to an appropriate host mucosal or epithelial cell surface, mediated via
specific interactions between bacterial adhesins and host receptors, is often a pivotal
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event in bacterial colonisation (Krogfelt, 1992). B. cepacia adherence has recently
been the focus of research for several groups and has been reviewed in the
Introduction.
Evidence suggests that oral colonisation by both Gram-positive and Gram-negative
pulmonary pathogens is a prerequisite for subsequent colonisation of the respiratory
tract (Johanson et al., 1979; Woods et al., 1980; Komiyama et al., 1987). After
colonisation of the oral cavity, aspiration of the contents may lead to colonisation of
the lower respiratory tract. The role of adherence in the pathogenesis of Gram-
negative respiratory tract infection has been investigated largely in association with
BEC; the ability of P. aeruginosa and S. aureus to adhere to BEC in vitro has been
reported to be directly related to the severity of lung infection (Woods et al., 1980;
Schwab et al., 1993). In contrast Paranchych et al. (1986) reported that P.
aeruginosa bound less well in vitro to BEC from CF patients and a prospective in
vivo study showed little evidence of buccal cell adhesion by P. aeruginosa (Dr J.
Govan, personal communication). In the present study B. cepacia was successfully
cultured from various sites within the oral cavity and also from saliva of B. cepacia
colonised CF patients. It seems reasonable to postulate, that these sites could act as a
reservoir for B. cepacia in preceding colonisation of the lower airways as described
for P. aeruginosa (Woods et al., 1980). In addition the relatively high concentrations
of the epidemic strain cultured from saliva may contribute to the transmissibility of
this strain. Since only a small proportion of the patients attending the Edinburgh adult
CF clinic are colonised by other strains of B. cepacia (2 out of 9 in the present study)
it is not clear whether oral carriage of B. cepacia is a general phenomenon or limited
to the epidemic strain.
Binding of B. cepacia to BEC was demonstrated in a small number of unmatched
subjects and clearly showed that the epidemic strain binds to BEC with more affinity
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than other strains of B. cepacia, P. aeruginosa or N. meningitidis. Woods et al.
(1981) proposed that in P. aeruginosa colonisation, serious illness was accompanied
by a marked increase in patient susceptibility to respiratory tract colonisation
associated with increased protease activity of secretions and alterations in epithelial
cell surfaces such as loss of fibronectin. The greater degree of adherence observed
with all the organisms to the BEC of patient I (Table 13), a chronically unwell patient
colonised by the epidemic strain might be due to such alterations in epithelial cell
surfaces.
Reports have suggested that adherence to BEC and respiratory mucin may be
mediated via fimbrial adhesins, for example the B. cepacia 22 kDa fimbrial adhesin
described by Sajjan et al. (1992) or the PAK pilin of P. aeruginosa which mediated
adhesions to respiratory epithelial cells (Doig et al., 1988). Alternatively, Ramphal et
al. (1991) demonstrated that adhesion may be mediated by several classes of non-
fimbrial adhesins including alginate. The study of Sajjan et al. (1992) indicated that
the ability to adhere to mucin may contribute to the virulence of a strain; adherent
isolates were obtained from CF patients with more advanced disease, suggesting that
increased mucin adherence may contribute to morbidity and mortality. An alternative
hypothesis, emphasising the role of the host in colonisation is emerging from the work
of Barasch et al. (1991) who showed that decreased sialylation of epithelial cells in
patients homozygous for AF508 is associated with increased P. aeruginosa binding in
vitro.
In this study mucin adherence of B. cepacia was measured in a microtitre assay
incorporating hyperimmune serum from CF patients colonised with the epidemic
strain to measure binding. The assay had several drawbacks, principally concerning
the use of CF serum; (1) serum obtained from patients colonised by the epidemic
strain might have been less efficient at detecting other strains of B. cepacia and hence
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bias the results; (2) serum from three different patients had to be used, as the first and
second choices unfortunately died during the course of the studies and the
experiments had to be repeated with serum from the next patient.
The trend in results obtained for the adherence of each B. cepacia strain to purified
mucin were consistent for the different sera. Specific adherence to purified
respiratory mucin was observed in only seven of 30 strains investigated, all of these
were CF isolates. In normal healthy lungs mucin serves to protect the underlying
respiratory epithelia from bacterial colonisation as adherent bacteria are removed by
mucociliary clearance (Reynolds, 1989). In CF airways impaired clearance and viscid
stagnant mucus mean that adherent organisms are not removed; thus an enhanced
ability to adhere may be an important virulence factor in some CF isolates of B.
cepacia. Binding of B. cepacia to mucin was approximately ten-fold less than that
observed for P. aeruginosa. B. cepacia binding to the control (no mucin) was
negligible but that for P. aeruginosa was almost as high as binding to mucin which
agrees with previous observations by Sajjan et al. (1992) who reported that P.
aeruginosa adherence to mucin was non-specific. In contrast to the results obtained
for this study, Sajjan et al. (1992) reported that the majority of B. cepacia strains (28
of 30) were adherent to purified mucin. However no typing data was available in this
study and a clonal relationship between strains could not therefore be discounted, an
important oversight considering the potential transmissibility of some B. cepacia
strains. The need for typing was emphasised following collaboration between our
laboratory and that of Dr J. Forstner in Toronto in which strains were exchanged to
be analysed in our respective mucin adherence assays involving ELISA or
radiolabelling. The results for the adherence assays performed in each centre were
consistent for each B. cepacia strain analysed. The collaboration also revealed
important information on the epidemiological background and origin of the Edinburgh
epidemic strain. Genomic fingerprinting of the epidemic strain and also the Toronto
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high binding strain showed similar PFGE profiles. The Toronto strain was a melanin
producer, had R-LPS and was bacteriocin type S3/P0. Although not conclusive, the
data suggest a clonal and epidemiological link between the Edinburgh and Toronto
isolates. This link has recently been confirmed by the multilocus enzyme typing study
of Johnson et al. (1994).
7.3 The Humoral Immune Response to b. cepacia in Colonised Cystic
Fibrosis Patients
Studies of the humoral immune response in P. aeruginosa colonised CF patients have
provided important evidence on the nature of the interaction between the CF host and
the colonising organism and may explain, at least in part, why P. aeruginosa is able to
persist in the CF lung. The occurrence of a specific anti-P. aeruginosa antibody
response has been shown to be useful in diagnosing infection at an early stage and
also in differentiating between infection and harmless colonisation (Brett et al., 1988;
Cordon et al., 1992). Furthermore, measurement of an antibody response against P.
aeruginosa has been found useful in monitoring the progress of infection, as a guide
to therapeutic intervention and also as a prognostic indicator. The present study
identified several similarities between the humoral immune response of CF patients
colonised by P. aeruginosa and the humoral immune response of CF patients
colonised by B. cepacia and therefore it is reasonable to propose that the explanations
may be extrapolated to B. cepacia colonisation and persistence in the lungs of CF
patients.
In chronically colonised CF patients the anti-P. aeruginosa antibodies belong to all
the major immunoglobulin classes and are directed against all the major P. aeruginosa
antigens (OMP, flagella, LPS and alginate) and toxins (exotoxin A, elastase and PLC;
Doring & Hpiby, 1983; Hancock et al., 1984; Pier et al., 1987; Albus et al., 1989;
Pedersen et al., 1990, Fomsgaard, 1990; Nelson et al., 1990; Kronborg et al., 1992;
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Fournier et al., 1993). These studies have demonstrated a strong correlation between
the development of an anti-P. aeruginosa antibody response and the onset of chronic
colonisation. By monitoring the immunological responses of the CF host it is possible
to identify stages in chronic infection: for example, serum antibodies to exotoxin A,
phospholipase C and flagella appear during the initial stages of colonisation indicating
the role of these virulence factors in colonisation. A beneficial role for anti-P.
aeruginosa antibodies has not been established. The antibody response is ineffective
in eliminating P. aeruginosa and high and rising levels of antibodies paradoxically
correlate with a poor prognosis (Wheeler et al., 1984; Hpiby et al., 1990). In
contrast, it has been suggested that the large amount of anti-LPS antibodies protect
against endotoxaemia in CF patients (Fomsgaard, 1990, Kronborg et al., 1992) and
recently Morrin & Reen (1993a and b) demonstrated that specific anti-P. aeruginosa
antibodies could inhibit adherence of some P. aeruginosa strains to BEC.
Furthermore, Pier et al. (1987) and Cryz et al. (1988) reported that
opsonophagocytic antibodies to LPS and alginate are protective, conferring resistance
to colonisation by P. aeruginosa, and forming the rationale behind initiations to
develop vaccine strategies, either actively using a conjugate vaccine (Cryz et al.,
1988) or by passive administration of hyperimmune globulin (Genzyme - personal
communication with Dr J. Govan).
The failure of the antibody response to eliminate P. aeruginosa from CF lungs may be
a consequence of the inappropriate nature of the antibody response with respect to
IgG subclass. Several groups have speculated that the functional capacity of the anti-
P. aeruginosa antibodies is "blocking" rather than opsonising or lysis-promoting (Fick
et al., 1981; Pedersen et al., 1989; Moss et al., 1986). The relative amounts of the
different isotypes present in serum have been correlated with pulmonary function,
degree of opsonophagocytosis and the efficacy of immunoprotection: for example, in
P. aeruginosa colonised cystic fibrosis patients increased levels of IgG2 and IgG3 are
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associated with decreased lung function whilst high concentrations of IgG4 correlate
directly with disease severity (Pressler et al., 1988; Pedersen et al., 1989;
Likavconova & Lagace, 1992). Marked shifts in the IgGl-4 responses to specific P.
aeruginosa antigens are also observed, notably an increase in specific IgG2 coupled
with a lack of IgGl in response to chronic stimulation by LPS (Fick et al., 1986;
Shryock et al., 1986); recently Kronborg et al. (1993) showed that IgG2 anti-lipid A,
IgG3 anti-lipid A and IgG2 anti-polysaccharide correlated with lung deterioration
before the onset of chronic infection was diagnosed. A high concentration of specific
anti-P. aeruginosa IgG2 may inhibit clearance of P. aeruginosa from the CF lung as
pulmonary macrophages are restricted in FC7R expression, with receptors for IgGl
and IgG3 only. Formation of immune complexes may also indirectly inhibit
phagocytosis as IgG2 is the major constituent of immune complexes (Hornick & Fick,
1990). It has been suggested that terminal CF is an immune complex disease
(Fomsgaard, 1990); the high concentration of anti-LPS antibodies observed in the
later stages of infection supports this hypothesis.
The anti-fi. cepacia antibody responses to several B. cepacia envelope components
was investigated by ELISA and immunoblot systems; both of which have been shown
to be sensitive and specific for determining antibodies to P. aeruginosa (Brett et al.,
1986; Shand et al., 1988; Fomsgaard, 1990). The ELISA based system incorporated
purified core R-LPS from the epidemic strain of B. cepacia and was able to
differentiate between non-colonised patients and CF patients colonised by the
epidemic strain or other strains of B. cepacia. The R-LPS preparation was chosen as
a coating antigen for the following reasons:
1. LPS represents a more defined antigenic preparation than a system based on
whole cells and was better able to discriminate CF patients colonised with B.
cepacia from patients colonised with P. aeruginosa;
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2. Available evidence suggested antigenic cross-reactivity between some outer
membrane proteins of B. cepacia and P. aeruginosa (Aronoff & Stern, 1988;
Aronoff et al., 1991);
3. Our own absorption studies demonstrated that the anti-B. cepacia LPS IgG
antibodies are specific and do not react with P. aeruginosa core LPS and vice
versa confirming previous findings that the composition and structure of core-
LPS between P. aeruginosa and B. cepacia are different (Palleroni, 1984;
Nelson et al., 1992);
4. Core LPS is believed to be a relatively conserved component of LPS (Wilkinson,
1983), and therefore is a suitable antigen for the detection of an antibody
response against all serotypes of B. cepacia;
5. Tne majority of B. cepacia isolates from CF patients were reported to express R-
LPS (McKevitt & Woods, 1984).
The ELISA data obtained in both the cross-sectional study and the study of paired
sera clearly show elevated anti-B. cepacia antibody titres, for the three major
immunoglobulin classes IgG, IgA and IgM, in sera from CF patients chronically
colonised by the epidemic strain of B. cepacia. For patients colonised by other strains
of B. cepacia and non-colonised patients the difference was less marked. Similar
observations were made for sputum IgA anti-B. cepacia LPS antibody titres.
Several theories may explain the absence of significant serum anti-B. cepacia IgG (i.e.
a titre < 1600); firstly the CF patient has never been colonised with or exposed to B.
cepacia, secondly the colonising strain of B. cepacia may be non-immunogenic and
finally in patients 'intermittently' colonised by the epidemic strain lack of detection in
sputum and low antibody titres may result from a low concentration of B. cepacia in
the lower respiratory tract rather than an actual absence of the organism (Figure 21;
Dr S. Elborn, personal communication). The detection of a rising antibody titre as
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shown in the longitudinal study (Figure 21), is therefore of more value in confirming
colonisation with B. cepacia than a single measurement. Indeed, in the longitudinal
studies a rise in the level of anti-B. cepacia LPS IgG antibodies was demonstrated in
some of the patients prior to or accompanying the first positive sputum culture of B.
cepacia.
The prognostic value of measuring anti-B. cepacia IgG antibody titres is less obvious
from this limited study. Hopefully, analysis of data from a large ongoing multicentre
study will provide further information. At present, available evidence does not show a
correlation between increased antibody titres and pulmonary decline (Brown et al.,
1993). For example, the index case, who became colonised with B. cepacia in 1989
(see patient 10, Figure 3, Introduction), has had relatively high anti-B. cepacia LPS
IgG titres (12800) for the last four years. In contrast, the last CF patient to contract
the epidemic strain (patient 25, Figure 3) who was severely ill and awaiting heart-lung
transplant at the time of acquisition of B. cepacia, died so rapidly that there was no
time for an anti-B. cepacia antibody response to develop.
Examination of the immunoblots of paired serum from CF patients revealed a strong
response to the R-LPS of the epidemic strain following colonisation with B. cepacia
(Figure 24a) and confirmed the ELISA results. The presence of a serum IgG
response to the O-side chain of the environmental isolate of B. cepacia J2395 in
patients not known to be colonised by this strain was interesting (Figure 24b). There
is no satisfactory explanation for the presence of these antibodies. One possibility is
that the CF patients involved had been co-colonised with an additional strain of B.
cepacia which was never cultured from sputum. However, it is unlikely that so many
patients would be colonised by a strain which was never detected in an efficient
diagnostic laboratory. Alternatively it is possible that the epidemic strain may express
S-LPS in vivo. There is no evidence to indicate that the epidemic strain expresses S-
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LPS in vivo or in vitro, despite investigation of LPS from newly acquired and chronic
isolates of the epidemic strain and also following culture of the organism in a range of
conditions.
Immunoblots obtained with serum from CF patients colonised by various strains of B.
cepacia against the Proteinase K digests of six non-epidemic strains of B. cepacia,
OMPs and also flagella preparations emphasise that the immune response in B.
cepacia colonised CF patients is heterogeneous; for example, CF patients colonised
by the 'same' strain exhibit different degrees of response to antigens of homologous
and heterologous B. cepacia strains. The lack of serum IgG in some of the patients
against antigens from a homologous strain of B. cepacia suggests that strains of B.
cepacia vary in their capacity to stimulate the immune response. The results from this
study indicate that the epidemic strain may be particularly immunogenic. It is
interesting to speculate whether increased immunogenicity of a strain correlates with
increased virulence, and whether the excessive immune response observed in some CF
patients colonised with the epidemic strain contributes to the pathology observed in
these patients.
Respiratory tract infections have been reported to be associated with an IgG2 subclass
deficiency (Bradwell, 1993). In this study however, raised concentrations of at least
one of the IgG subclasses, including IgG2, were observed. Analysis of the IgG
subclasses in CF patients colonised with B. cepacia were consistent with subclass data
obtained for CF patients colonised with P. aeruginosa. The most marked increases in
total IgG concentration were observed for IgGl and IgG4, whilst the greatest
percentage increase in specific antibody against B. cepacia R-LPS was observed for
IgG2 and IgG3 (Shryock et al., 1986; Pressler et al., 1988; Fomsgaard, 1990). A
correlation between the antibody subclass response and clinical status in the B.
cepacia colonised CF patients was observed for some of the CF patients studied (for
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example Patient 1, Figure 32 and 33). Patient 1, colonised by B. cepacia only, had
raised concentrations of all four IgG subclasses; the anti-fi. cepacia antibody response
comprised largely IgG2, which as described earlier has poor opsonic potential and
may inhibit clearance of B. cepacia from the lung. The titre of specific anti-B.
cepacia LPS IgGl was low and for IgG4 not detectable, but total serum
concentrations were markedly increased. Based on the immunoglobulin data obtained
it is tempting to speculate that a combination of hypergammaglobulinaemia and non-
opsonic specific antibody may contribute to the persistence of B. cepacia and immune
mediated damage.
The chemiluminescent opsonophagocytosis assay provides a simple method of
assessing phagocyte function in vitro by measuring oxygen radicals produced by
phagocytes during the respiratory burst following phagocytosis of particles (Blair et
al., 1988). In the absence of serum, P. aeruginosa PAOl was more susceptible to
non-opsonic phagocytosis than B. cepacia or S. aureus. Non-opsonic phagocytosis
of P. aeruginosa has been described by Speert et al. (1984, 1986) who showed that
susceptible strains expressed more fimbriae and were more hydrophobic and
concluded that non-opsonic phagocytosis was facilitated by hydrophobic interactions
mediated by fimbriae. In the present study the epidemic strain, which has been shown
to express peritrichous fimbriae (Figure 10) and to be slighdy more hydrophobic than
either J2395 or C1559 (Figure 17), was more susceptible to non-opsonic
phagocytosis then either of the latter two B. cepacia strains. The results following
incubation with serum are more difficult to interpret. Chemiluminescence was
reduced for the epidemic strain and also P. aeruginosa PAOl in the presence of
serum yet increased for the remaining B. cepacia strains and for S. aureus. Inhibition
of chemiluminescence appeared to be non-specific as all sera, regardless of the
bacterial status of the patient, were capable of inhibiting phagocytosis.
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In summary, analysis of the anti-5. cepacia antibody response in CF patients shows
some parallels with the well documented anti-P. aeruginosa antibody response. CF
patients colonised by B. cepacia may mount a significant and specific antibody
response against the colonising strain. In contrast to P. aeruginosa, the ability of B.
cepacia to stimulate an antibody response was observed to be strain dependent and
some strains, notably the epidemic strain, appeared to be particularly immunogenic.
Serum from patients colonised by the immunogenic strains of B. cepacia contained
antibodies which were cross-reactive with epitopes of other strains of B. cepacia,
whilst serum from patients colonised with some other strains of B. cepacia contained
few antibodies directed even against the homologous strain. Detection of an anti-5.
cepacia antibody response in CF patients may be a useful aid in conjunction with
other available methods for diagnosing colonisation with B. cepacia, and indeed has
been used to confirm colonisation by the epidemic strain in our laboratory. However
the variation in immunogenicity between B. cepacia strains means detecting an
antibody response cannot be relied upon to confirm colonisation with B. cepacia.
In CF patients, a beneficial role for anti-5. cepacia antibodies is not obvious.
Previous studies have shown that specific anti-fi. cepacia antibodies are not
protective (Aronoff & Stern, 1988; Aronoff et al., 1991), and the results of this study
indicate that the antibodies are not effective in eliminating B. cepacia once it is
established in the CF lung. The role of other host defences in controlling B. cepacia
colonisation is not clear. The results from the ongoing multicentre study may indicate
the role of cytokines and some inflammatory markers in vivo. Unrelated studies by
colleagues in the department are currently underway investigating the in vitro
interaction of B. cepacia with cytokines. If B. cepacia is shown to be able to survive
intracellularly, the role of the cell mediated immune response against B. cepacia
would also be important. There is no information available to date on the interaction
of B. cepacia with the cell mediated immune response.
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7.4 Serum Bactericidal Activity against b. cepacia
The ability of Gram-negative bacteria to invade and survive in the bloodstream
correlates strongly with resistance to the complement-mediated bactericidal activity of
serum; serum-resistant bacteria have been shown to be more virulent and less
immunogenic than their serum-sensitive counterparts (Clumeck et al., 1982; Taylor,
1983). Studies with animal models have demonstrated that serum-resistant strains of
E. coli consistently caused infective endocarditis in rabbits whilst serum-sensitive
strains did not (Durack & Beeson, 1977). N. gonorrhoeae associated with localised
infections are serum-sensitive whilst strains associated with disseminated systemic
infection are serum-resistant (Rice, 1989). Similarly, a higher proportion of E. coli
isolated from the blood of bacteraemic patients are serum-resistant compared with
isolates from faeces or urinary tract infections (Taylor, 1983). P. aeruginosa isolates
from the lungs of chronically colonised CF patients are typically serum-sensitive; the
infection remains localised and bacteraemia does not occur (Hpiby & Oiling, 1977).
A number of cell envelope polymers are considered to be important in protecting the
bacterium from complement-mediated serum killing: for example, the acidic
polysaccharides or capsules such as the K antigens of E. coli and K. aerogenes
(Williams et al., 1983), outer membrane proteins such as the Aeromonas A protein
(Munn et al., 1982) and most significantly the role of LPS, in particular the O-side
chain which presents a steric barrier to the stable insertion of the C5b-9 membrane
attack complex and has been well studied in E. coli, K. pneumoniae and P.
aeruginosa (Taylor, 1983; Schiller & Joiner, 1986; Ciurana & Tomas, 1987; Williams
& Tomas, 1990). Additional mechanisms of serum resistance are exhibited by N.
gonorrhoeae and include phenotypic shifting of lipooligosaccharide antigen
expression and addition of sialic acid residues and stimulation of blocking antibodies
directed at outer membrane protein antigens which prevent binding of bactericidal
antibodies to lytic epitopes (Rice, 1989; Smith et al., 1992).
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The lack of standardised methods and definitions of serum resistance and sensitivity
makes accurate assessment of the impact of serum activity in vivo difficult (Crokeart
et al., 1992). DeMatteo et al. (1981) showed that survival of P. aeruginosa isolates
in human serum was highly dependent on in vitro conditions. Expression of cell
envelope components is influenced by both the growth conditions and growth phase
and in vitro susceptibility may not reflect the in vivo situation. Anwar et al. (1983)
reported that nutrient conditions had a profound effect on the susceptibility of B.
cepacia to serum killing. The classification of serum resistance and sensitivity in this
study was initially based on that of Thomassen & Demko for P. aeruginosa (1981)
but was subsequently influenced by the nature of the results obtained; for example
after a 3 h exposure to PNHS, a 90% or greater decline in cell numbers was measured
for all the strains classified as sensitive, whilst a 10% or less decline was typical for
those strains classified as serum-resistant. In the present study only one B. cepacia
strain produced results outwith these limits and was classified as intermediate.
Serum sensitivity was influenced by the time of exposure of the B. cepacia strains to
PNHS. A higher proportion of B. cepacia strains were serum-sensitive after 3 h than
after 90 min, suggesting that serum killing of some of the B. cepacia isolates was
slow or delayed and indicating that stopping the reaction after 1 or 2 h as in some
studies would not identify all serum-sensitive strains (Crokeart et al., 1992). The
major determinant of serum resistance in B. cepacia was expression of S-LPS as the
four serum-resistant isolates of B. cepacia expressed S-LPS with a full O-side chain.
Delayed serum killing of B. cepacia isolates was observed where the O-side chain was
lacking or where the chain length was shorter. The length of the O-side chain has also
been shown to be important in evasion of serum killing by K. aerogenes (Williams et
al, 1983).
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A role for the other envelope components in protecting B. cepacia from serum
bactericidal activity was less clear. As described in Results (Chapter 3), some B.
cepacia strains produce an exopolymer when cultured under appropriate conditions.
This material was observed in both serum-resistant and serum-sensitive B. cepacia
isolates expressing S-LPS, but not with strains expressing R-LPS including the
epidemic strain. Analysis of the outer membrane proteins of the serum-sensitive B.
cepacia isolates C1359 (epidemic strain), C1559, ATCC 17616, C1409 (which
exhibited delayed killing as shown in Figure 32) and the serum-resistant isolate J2395
revealed that only the latter expressed an OMP of between 150-200 kDa (Figure 15).
It is possible that this protein may complement the barrier effect of the O-side chain.
The nutrient conditions under which B. cepacia was grown affected the susceptibility
to serum killing in a strain-dependent manner. Serum sensitivity was increased for
eight of the nine B. cepacia isolates investigated following culture in a minimal
medium compared to that following culture in ISTB or HISS. Five B. cepacia
isolates were more resistant to serum bactericidal activity following culture in HISS
compared to ISTB, and three of the strains were equally susceptible under all culture
conditions. These results agree with observations on the serum susceptibility of
Bacteroides following culture in the same nutrient conditions (Miss E. Allan, personal
communication). The epidemic strain was not serum-resistant following culture in
nutrient rich or deficient media, suggesting that serum sensitivity in this strain is
genuine and not an artefact of the assay or culture conditions.
The bactericidal activity of serum against B. cepacia was observed to be heat-labile
and, as observed with P. aeruginosa, appears to result principally from activation of
the classical complement pathway (CCP) but with some killing resulting from activity
of the alternative complement pathway (ACP: Thomassen & Demko, 1981; Schiller,
1988). Serum treated with 10 mM MgCl2 EGTA had a reduced ability to kill six B.
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cepacia isolates which were serum sensitive in the presence of PNHS. EGTA binds
calcium ions strongly and magnesium ions poorly thus inhibiting the CCP which
requires both ions whilst the ACP requires only magnesium ions (Fine et al., 1979).
The fact that the CCP is of major importance in serum killing of B. cepacia suggests
that antibodies, which initiate the activity of the CCP, may also play a role in the
process. The requirement for specific antibody in the serum killing of B. cepacia is
unclear. PNHS contained negligible amounts of anti-5. cepacia antibodies as shown
by ELISA incorporating both the R-LPS of the epidemic strain or B. cepacia whole
cells as coating antigen and yet was as efficient at killing B. cepacia as the three CF
sera from patients chronically colonised by the epidemic strain. An attempt to remove
the anti-fi. cepacia antibodies from the CF sera by serial absorption with B. cepacia
whole cells was unsuccessful, possibly because of the extremely high concentration of
antibodies present. This problem was also encountered by Thomassen & Demko
(1981) who proposed that in CF patients chronically colonised by P. aeruginosa with
advanced lung disease, autologous strains are protected from serum bactericidal
activity by the presence of blocking antibodies. A similar mechanism may explain the
inability of the sera from patient III (Figure 37) to effectively kill B. cepacia.
The results from this study do not explain why strains of B. cepacia, in particular the
epidemic strain which expresses R-LPS and was serum sensitive in all investigations,
are associated with bacteraemia in CF patients. A number of possibilities exist to
explain the ability of B. cepacia to invade and survive in the bloodstream
circumventing serum bactericidal activity: (1) the in vivo characteristics of the
epidemic strain are not reflected in the in vitro assay; (2) serum from bacteraemic
patients has been reported to be ineffective in killing the homologous organism in vivo
(Taylor, 1983); (3) bacteria with a slower growth rate may be less susceptible than
rapidly dividing cells (the epidemic strain does grow slowly in conditions of poor
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nutrient availability, Results Chapter 3); and (4) bacteria may adopt an intracellular
location in the blood or reticuloendothelial system (Taylor, 1983).
The proposal that B. cepacia may be able to survive in an intracellular location not
only avoiding serum bactericidal activity but also the humoral immune response is
particularly appealing. Taxonomically, the idea is supported by the fact that B.
cepacia is closely related to B. pseudomallei, the causative agent of melioidosis and a
highly virulent intracellular pathogen (Pruksachartvuthi et al., 1990). More recently
intracellular survival has been described for other well known respiratory tract
pathogens, Bordetella pertussis and even P. aeruginosa (Chi et al., 1991; Freidman et
al., 1992) which, in addition to the well known intracellular pathogens, indicates that
such an ability is widespread. Research to determine whether B. cepacia is able to
survive intracellularly is currently underway in several laboratories in the UK and also
in the USA. If B. cepacia is found to be an intracellular pathogen the inability of the
immune response to eliminate the organism and the ability of a serum-sensitive
organism to survive in the blood might be explained. In addition, such an observation
might have important implications for the future treatment of B. cepacia infections
both in terms of antibiotic therapy and in a rational approach to vaccination.
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CONCLUSIONS
Anxiety concerning the transmission of B. cepacia amongst CF patients attending
different regional CF centres continued to grow throughout the duration of this
project. On conclusion of this project, transmission per se appears to have been
brought under control but only at the social and logistical cost of patient segregation.
In the late 1980's, there was some debate as to whether B. cepacia was truly a
pathogen or simply a marker of advanced lung disease. As a result of growing
evidence from CF clinics it is now generally accepted that some strains of B. cepacia
are pathogenic. 'Cepacia syndrome' has been observed in CF patients previously
considered to be in relatively good health and this study has demonstrated that
patients mount a significant humoral immune response against some colonising
strains. Major problems remain with regard to the modes of pathogenesis of B.
cepacia in CF, as the organism has few demonstrable virulence determinants.
Previous studies have clearly demonstrated that environmental and clinical or CF
isolates of B. cepacia are different (Bevivino et al., 1994). This study has elaborated
on these differences and has shown that CF strains differ significantly from each other
with respect to colonising potential, transmissibility and the ability to stimulate the
host immune response and it is proposed that these differences are accompanied by
variable virulence. The evidence suggests that there are clones of B. cepacia which
are particularly virulent and transmissible, for example the Edinburgh 'epidemic strain'.
It will soon be possible to investigate the virulence of the different B. cepacia strains
and verify (or otherwise) this proposal using the CF mouse developed by Drs David
Porteous and Julia Dorin. Preliminary studies with the epidemic strain have confirmed
the pathogenic potential of that strain; pneumonia developed in six out of nine CF
homozygous mice inoculated with the epidemic strain but not in the control mice.
The observation that there are differences between CF isolates of B. cepacia raises the
question that blanket segregation of all B. cepacia colonised CF patients might not be
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necessary. If the different B. cepacia strains are distinct the nomenclature of this
species must be questioned. Should a strain such as the epidemic strain be classified
with the seemingly harmless strains isolated from the Botanic Gardens? This idea is
further supported by the recent studies of Simpson et al. (1994) which showed that
the epidemic strain has a surface fatty acid composition more closely resembling B.
gladioli, an organism previously thought to be harmless in CF (Christenson, et al.,
1989) than B. cepacia. On the other hand, biochemical data clearly identify the
epidemic strain as B. cepacia. This study shows that the epidemic strain is distinct
from other B. cepacia strains and may even be a hybrid!
Finally, the association of B. cepacia with CF is far from understood. This study
reiterates the heterogeneity of both B. cepacia strains and the nature of their
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Abstract: Bacterial strains which are sensitive to the bactericidal activity of serum are generally considered to be less virulent than
serum-resistant strains and are seldom associated with bacteraemia. Burkholderia (Pseudomonas) cepacia is an important pathogen
in cystic fibrosis and is associated with rapid fatal pulmonary decline and bacteraemia in 20% of colonised patients. In this study 19
isolates of B. cepacia expressing either rough or smooth LPS were investigated to determine the degree of serum sensitivity. Strains
expressing rough-LPS were serum-sensitive: these included a highly transmissible strain of B. cepacia isolated from approximately
50 cystic fibrosis patients attending various U.K. regional centres and associated with cases of bacteraemia.
Key words: Burkholderia cepacia; Pseudomonas cepacia; Cystic fibrosis; Bacteraemia; Serum susceptibility; Lipopolysaccharide
Introduction
Burkholderia cepacia, formerly Pseudomonas
cepacia, [1] is an important pulmonary pathogen
in patients with cystic fibrosis (CF). Clinical se¬
quelae of B. cepacia colonisation are variable and
include asymptomatic carriage or a slow decline
in lung function. The third outcome of B. cepacia
colonisation is observed in approximately 20% of
patients and involves a rapidly fatal decline in
pulmonary function accompanied by necrotising
pneumonia and, in some patients, bacteraemia
[2]. B. cepacia is inherently resistant to most
antibiotics [3,4] and is able to persist despite a
'
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specific anti-fi. cepacia antibody response [5,6],
The role of the bactericidal activity of human
serum against B. cepacia has not been extensively
investigated but is of particular importance due
to the association of B. cepacia with bacteraemia.
In a study of a single B. cepacia strain (NCTC
10661) Anwar et al. [7] described killing by serum
factors and polymorphonuclear leukocytes
(PMN).
It is widely accepted that Pseudomonas aerugi¬
nosa isolates from chronically infected CF pa¬
tients exhibit phenotypic changes rarely observed
in isolates of P. aeruginosa from other sources.
This phenotype includes loss of the O-side chain
portion (B-band) of lipopolysaccharide (LPS), al¬
ginate biosynthesis, and susceptibility to serum
killing [8-12]. Longitudinal studies on the pheno¬
typic characteristics of B. cepacia cultured from
SSDI 0928-8244(94)00002-B
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the CF lung have not been carried out and it is
unclear whether B. cepacia undergoes phenotypic
alterations similar to those observed with P.
aeruginosa. Although a mucoid phenotype of B.
cepacia may be observed under appropriate cul¬
tural conditions [13] biochemical characterisation
of the exopolysaccharide indicate that it is not
alginate (S. Butler, unpublished observations).
The absence of alginate biosynthesis in B. cepacia
is supported by PCR studies which showed no
evidence of the alg D gene, encoding the key
enzyme mannose dehydrogenase, in ten strains of
B. cepacia [14]. In addition, there is no evidence
to date to suggest that a change from smooth-LPS
(S-LPS) to rough-LPS (R-LPS), due to loss of
O-antigen, occurs in B. cepacia strains following
colonisation of the CF lung. Indeed, a highly
transmissible strain of B. cepacia cultured in a
number of CF Centres in the U.K. [15] invariably
expresses R-LPS and has never been associated
with a S-LPS phenotype even in newly colonised
patients (S. Butler, unpublished observations).
The aim of this study was to investigate and
compare the susceptibility of clinical and environ¬
mental isolates of B. cepacia to normal human
serum (NHS) and in particular to investigate the
degree of serum sensitivity in isolates from CF
patients.
1 able 1
Serum killing of B. cepacia by 40% PNIIS at 90 min and lxo
min
Strain Source LPS 90 min 180
(RorS)
C1518 CF (sputum) S SR SR
CI 314 CF (sputum) R SS SS
C1524 CF (sputum) S 1 SS
CI 548 CF (sputum) R SS SS
C1559 CF (sputum) S I SS
CI 454 CF (sputum) R 1 SS
CI 409 CF (sputum) S 1 SS
CI 704 CF (sputum) S SR SR
CI 359 * CF (sputum) R 1 SS
CI602 * CF (blood) R I I
ATCC 25609 Bronchial wash S SS SS
ATCC 25608 Wound S SR SS
ATCC 27515 Infected tissue S SR I
ATCC 17762 Urine R SS SS
J162 Wound S SR SS
J2394 Plant S SR SR
SBC 100 Potato S SS SS
ATCC 17616 Soil R I SS
J159 Onion S SR SR
£. coli R3 R SS SS
E. coli 018 S SR SR








Nineteen isolates of B. cepacia were studied
(Table 1). Nine isolates cultured from sputum
and one from the blood of a colonised CF patient
attending the Edinburgh adult CF clinic were
characterised phenotypically and genotypically by
bacteriocin typing [16] and pulsed field gel elec¬
trophoresis (PFGE: CHEF, BioRad Laboratories
Inc.) respectively. The remaining 9 non-CF iso¬
lates were either of clinical or environmental
origin. All strains were identified as B. cepacia by
growth and colonial morphology on Pseudomonas
cepacia Medium (CEP) (Mast Laboratories Ltd.,
Bootle, U.K.) and by API 20NE (bioMerieux,
69280 Marcy l'Etoile, France). Control strains
were Escherichia coli 018 and E. coli R3 ex¬
pressing smooth and rough LPS phenotypes re¬
spectively.
Lipopolysaccharide analysis
LPS was prepared for polyacrylamide gel elec¬
trophoresis (PAGE) analysis by the proteinase K
digestion method [17] and separated on 14% w/v
polyacrylamide gels incorporating the buffer sys¬
tem of Laemmli [18]. The gels were stained with
silver by the modified method of Tsai and Frasch
[19] as described by Hancock and Poxton [20].
Outer membrane protein analysis
Overnight cultures of B. cepacia C1359, C1409
and J2394 grown at 37°C with aeration, were
harvested from Isosensitest broth (1ST) (Oxoid)
and washed twice in sterile phosphate buffered
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saline (PBS; pH 7.2) at 6000 X g for 10 min at
4°C (Sorvall, RC5B). The pellet was resuspended
in 20 ml pyrogen-free water and sonicated at 8
fim (Microson, Ultrasonic Cell Disruptor, Heat
Systems-Ultrasonics Inc., NY, U.S.A.) to break
cells. Unbroken cells were removed by centrifu-
gation at 7000 Xg for 10 min. Outer membranes
were derived by solubilisation in 2% w/v Sarko-
syl (N-lauroyl sarcosinate: Sigma) for 45 min at
room temperature. Outer membranes were col¬
lected and washed by centrifugation at 38000 Xg
for 1 h at 4°C. The crude outer membrane prepa¬
ration was separated on a 12% w/v polyacryl-
amide gel, and OMP's were stained with
Coomassie blue [20].
Serum
Blood was obtained from 2 normal human
volunteers and 3 CF patients colonised by the
same strain of B. cepacia [15]. After incubation at
37°C for 30 min to allow clotting, serum was
separated by centrifugation at 5000 rpm (Heraeus,
Bactifuge) for 20 min. The normal sera were
pooled (pooled normal human serum; PNHS) and
half of the serum pool was immediately aliquoted
in 2-ml volumes and stored at -70°C whilst the
remaining sera was heat inactivated (HIS) for 30
min at 56°C prior to storage. Each CF serum was
treated in the same manner but not pooled. Both
PNHS and CF sera were screened for the pres¬
ence of anti-5. cepacia antibodies by ELISA as
described by Nelson et al. [5]. Complement activ¬
ity (CH50) was determined by the sheep erythro¬
cyte lysis assay [21]. The roles of the classical
complement pathway (CCP) and the alternative
complement pathway (ACP) were investigated by
treating serum with 10 mM MgCI EGTA (200
mM ethyleneglycol-bis (beta-amino-ethyl ether)
V,/V'-tetraacetic acid; Sigma) which specifically
inactivates the CCP by chelating Ca++ ions and
not Mg++ ions as described by Fine et al. [22].
Serum bactericidal assay
Overnight cultures of B. cepacia grown in 1ST
were harvested by centrifugation, and washed
twice in complement fixation test buffer (CFTB,
pH 7.4: Oxoid). Bacterial pellets were resus¬
pended in CFTB to a density of 1 X 10K cfu ml"1,
and diluted 100-fold in CFTB to give a final
suspension of 1 X 10'' cfu ml"1. The assay tube
consisted of 1.0 or 1.6 ml CFTB with 0.8 ml or 0.2
ml PNHS, PNHS + EGTA, or CF sera respec¬
tively. Controls were 1 ml CFTB + 0.8 ml HIS
and 1.8 ml CFTB. To each tube 0.2 ml of bacte¬
rial suspension was added. Assay tubes were in¬
cubated in a shaking incubator at 37°C for 180
min. Samples (100 p\) were removed at T,„ T30,
Tg„ and TIH() min, diluted 1 in 50 in CFTB and
100 p\ was either plated directly onto a nutrient
agar (NA) plate and spread or further diluted
tenfold in CFTB before being added to NA. NA
plates were incubated at 37°C for 24-48 h before
scoring.
For each experiment the percent killing was
calculated from the number of organisms counted
at T0 and those still viable at the end of the
experiment, taking into account any background
decline in cell numbers as observed in the con¬
trols. The results were classified as: resistant (SR)
= < 10% killing of bacteria; intermediate (I) =
10-95 killing; and sensitive (SS) = > 95% killing.
Results
With the exception of C1359 and C1602, which
represent isolates of the epidemic strain of B.
cepacia, PFGE and bacteriocin typing demon¬
strated no clonal relationship amongst the B.
cepacia strains selected for this study.
Serum sensitivity of B. cepacia
The sensitivity of B. cepacia strains expressing
both smooth or rough LPS phenotypes from dif¬
ferent sources to the bactericidal activity of nor¬
mal human serum was investigated.
Sensitivity to PNHS
Serum killing was measured at 90 min and 180
min to detect delayed killing. After 90 min, 7
(58.3%) of the isolates expressing S-LPS were
resistant to serum bactericidal activity, 3 (25%)
showed intermediate serum sensitivity and the
remaining 2 (16.7%) were serum-sensitive. In
contrast, none of the isolates expressing R-LPS
were serum-resistant, 3 (42.8%) were serum-sen-
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sitive and 4 (57.2%) of rough strains showed
intermediate serum sensitivity. There was a
marked increase in the number of B. cepacia
strains which were serum-sensitive at 180 min
(Table 1). All strains which were resistant to
serum killing at 180 min and the majority of
strains in which delayed killing was observed ex¬
pressed S-LPS. After 180 min, 6 (85.7%) of the
rough B. cepacia isolates were serum-sensitive, 7
(58.3%) of the B. cepacia strains expressing S-LPS
were serum-sensitive, only 4 (33.3%) remained
serum-resistant. Typical killing curves for three
B. cepacia strains, serum-resistant (J2394), serum-
sensitive (C1359) and intermediate (C1409) over
180 min are shown in Fig. 1.
Involvement of OMP in serum resistance
B. cepacia strains expressing S-LPS exhibit a
range of responses to the bactericidal activity of
PNHS suggesting that the presence of a full O-
antigen is not the sole determinant of serum
resistance. To examine the role of OMP, crude
Sarkosyl OMP preparations of serum-resistant
and serum-sensitive strains were examined by
PAGE and Coomassie staining (Fig. 2). The two
CF isolates C1359 (R-LPS) and C1409 (S-LPS)
expressed fewer OMPs than the environmental
strain J2394 (S-LPS), which expressed a broad
band of high molecular mass (150-200 kDa) not
observed in CI409 CF smooth strain, which ex¬
hibited intermediate serum sensitivity.
Serum requirement for bacterial killing
The next series of experiments were per¬
formed to confirm that the serum components
required for killing of B. cepacia were consistent
with those described for other bacterial species
[11,27].
All sera used had levels of haemolytic comple¬
ment within normal ranges (20-50 CH50 units).
Serum killing of B. cepacia was similar using both
10% and 40% PNHS, and was proportional to
the serum concentration as killing of serum-sensi¬
tive and intermediate strains was slower and com¬
plete killing was not always achieved with 10%
PNHS.
Role of antibody in serum killing
In contrast to PNHS which contained negligi¬
ble amounts of anti-8. cepacia antibodies (mean
antibody titre, 400), the hyperimmune CF sera
had a mean anti-B. cepacia antibody titre of
25 600. The bactericidal potential of PNHS and
individual serum from two CF patients were com¬
parable in their killing activity against 3 heterolo¬
gous strains of B. cepacia and the autologous B.
cepacia strain from each patient. However, serum
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Fig. 1. Serum killing of B. cepacia strains J2394 (serum-resistant, S-LPS), C1409 (intermediate, S-LPS) and C1359 (serum-sensitive,
R-LPS - 'Epidemic strain') by 40% PNHS over 180 min. Each point is the mean of triplicates.
r
pulmonary exacerbation, whilst equally active
against heterologous strains of B. cepacia was
inactive against the autologous B. cepacia strain.
(Fig. 3).
Little or no reduction of serum killing was
observed in the presence of HIS indicating that
Fig. 2. SDS-PAGE of crude Sarkosyl outer membrane extracts
of B. cepacia stained with Coomassie Blue. (A) and (B)
molecular mass standards, (C) J2394 (S-LPS, serum-resistant
strain) (D) C1409 (S-LPS, serum-sensitive strain) (E) C1359
(R-LPS, serum-sensitive strain).
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Fig. 3. Serum killing of 4 B. cepacia isolates by PNHS and CF
serum. Patients I — 111 were chronically colonised by the same
epidemic strain of B. cepacia, represented by C1359. Serum
from patient III was obtained during an acute pulmonary
exacerbation.
the bactericidal activity of both PNHS and CF
sera was heat-labile (Table 2). To determine
whether the classical complement pathway (CCP)
or the alternative complement pathway (ACP) is
more important in the complement mediated
killing of serum-sensitive B. cepacia, serum killing
was investigated in 10 strains which were incu¬
bated with 40% PNHS containing magnesium
EGTA (in which only the ACP is functional).
Serum killing of 7 of these strains representing
either sensitive or intermediate killing in 40%
PNHS was decreased in the 40% PNHS +
Table 2
Serum requirement for killing of B. cepacia
HIS 40% PNHS Killing of B. cepacia strains (%)










HIS, heat inactivated serum.
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MgEGTA, although the extent of this was strain-
dependent. No alteration in serum resistance was
observed in 2 serum resistant controls (Table 2).
Discussion
Accumulated evidence suggests that bacterial
resistance to serum bactericidal activity is an im¬
portant virulence determinant in Gram-negative
bacteria [23-25]. In 19 B. cepacia isolates, 13
(68.5%) were sensitive to the bactericidal activity
of PNHS after a 3 h period of exposure, 2 (10.5%)
were intermediately sensitive and 4 (21%) were
resistant. After 90 min exposure to PNHS only 5
(26.3%) of B. cepacia strains were serum-sensi¬
tive. The major determinant of serum resistance
in B. cepacia appeared to be possession of a
complete O-side chain. In other Gram-negative
bacilli including E. coli and Salmonella species
[25] the O-side chain is thought to interfere with
serum killing by steric hindrance, preventing sta¬
ble insertion of the membrane attack complex,
and it seems reasonable to speculate that a simi¬
lar mechanism operates in B. cepacia.
There is evidence that resistance to serum
killing does not rely solely on a single factor, for
example LPS, and other cell surface components
including OMPs and capsular polysaccharide have
been implicated [24,25]. Some B. cepacia strains
may produce an extracellular polysaccharide when
grown in appropriate nutrient-deficient condi¬
tions. This material has been observed in both
serum-resistant and serum-sensitive strains ex¬
pressing S-LPS, but has not been observed in
strains expressing R-LPS (S. Butler, unpublished
observations). Analysis of the outer membrane
proteins of three strains of B. cepacia revealed
that neither the rough strain B. cepacia C1359
nor the smooth strain C1409 expressed an OMP
of between 150-200 kDa which was expressed by
the highly serum-resistant strain J2394. It is possi¬
ble that the presence of this protein may comple¬
ment the protective action of the O-side chain in
inhibiting stable insertion of the membrane at¬
tack complex into the outer membrane. Expres¬
sion of cell surface components is influenced by
both growth conditions and growth phase and the
in vitro serum susceptibility observed may not
accurately reflect the in vivo situation [6,26], An¬
war et al. [7] reported that the nutrient conditions
under which a single strain of B. cepacia was
grown had a profound effect on the killing by
serum factors and polymorphonuclear leukocytes.
It was proposed that variation in outer membrane
protein and phospholipid concentration resulting
from growth in nutrient depleted media was re¬
sponsible for varying sensitivity to serum killing.
Serum bactericidal activity against B. cepacia
is heat-labile and, as with P. aeruginosa [11,27],
appears to result from activation of the classical
pathway, since chelation of serum with MgCl2-
EGTA reduces killing activity. A requirement for
specific antibody in the killing of B. cepacia is
unclear. PNHS with negligible amounts of anti-B.
cepacia antibodies, was as efficient at killing B.
cepacia as CF sera with high titres of specific
anti-B. cepacia antibodies. An attempt to remove
the anti-B. cepacia antibodies from the CF sera
by serial absorption with B. cepacia whole cells
was unsuccessful, possibly because of the high
concentration of antibodies present. This prob¬
lem was also encountered by Thomassen and
Demko [11] who proposed that in CF patients
chronically colonized with P. aeruginosa with ad¬
vanced lung disease, autologous strains are pro¬
tected from serum bactericidal activity by the
presence of blocking antibodies [11], A similar
mechanism may explain the data with serum from
patient III in this study. However, this could not
be proven experimentally for the reasons de¬
scribed, and further studies are necessary to clar¬
ify this matter.
In contrast to the well-recognised association
of serum-sensitive P. aeruginosa with chronic pul¬
monary colonization of CF patients, our study
showed no particular association of serum sensi¬
tivity with CF isolates of B. cepacia. McKevitt
and Woods reported that the majority of CF
isolates of B. cepacia express R-LPS [28]; it
seemed reasonable to assume therefore that a
majority of CF isolates would also be serum-sen¬
sitive. In other infections, for example P. aerugi¬
nosa colonisation of CF lungs [11,26] and E. coli
urinary tract infections [26] strains are typically
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serum-sensitive strains, express R-LPS and are
not associated with bacteraemia. Our finding that
rough forms of B. cepacia are associated with
bacteraemia in CF suggests that the in vivo char¬
acteristics of the organism are different from
those observed in vitro, or that B. cepacia resists
serum killing by an as yet unknown mechanism.
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Introduction
Originally named following its identification as
a cause of soft rot in onions, Burkholderia cepacia
has also been known as Pseudomonas multivorans
and Pseudomonas kingae [1,2], and until most
recently, as Pseudomonas cepacia [3], A proposal
for the transfer of 7 species of the genus Pseu¬
domonas RNA Homology group II to a new
genus Burkholderia with the type-species
Burkholderia cepacia has been validated [3]. For
the purpose of this review the name B. cepacia
will be used.
Once considered solely as a phytopathogen, B.
cepacia is now recognized as an important
pathogen in nosocomial infection and in patients
with chronic granulomatous disease and particu¬
larly in those with cystic fibrosis (CF). CF is the
most common autosomal recessive lethal disease
in Caucasian populations with an incidence of
approximately 1 in 2500 live births and a carrier
* Corresponding author. Tel: (031) 650 3162; Fax: (031) 650
6531.
frequency of 1 in 20. The basic cause of the
pathophysiological symptoms of CF is a defect in
epithelial ion transport which results in viscous
dehydrated bronchopulmonary and gastrointesti¬
nal secretions. Build-up of viscid mucus is associ¬
ated with impaired mucociliary clearance and
susceptibility to bacterial colonization which in
turn initiates a vicious cycle of chronic inflamma¬
tory reaction. The susceptibilty of CF patients to
pulmonary colonization has been recognised since
the earliest descriptions of the disease when pa¬
tients seldom survived infancy. Advances in man¬
agement of CF have meant that today most pa¬
tients survive to early adulthood. However, this
increased longevity has in part created its own
problems including the emergence of new oppor¬
tunistic pathogens, including and most notably,
B. cepacia.
The last decade has seen B. cepacia emerge as
a particular problem amongst patients with CF,
where colonization may be symptomless or asso¬
ciated with a slow decline in lung function. A
more serious clinical outcome, not observed with
other CF pathogens, in which some colonized CF
patients experience B. cepacia bacteraemia and/
SSDI 0928-8244193)E0068 -P
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or succumb to an accelerated and fatal deteriora¬
tion in pulmonary function [4-7], is central to the
current concern over B. cepacia in the CF com¬
munity.
Based on nucleic acid homology, B. cepacia is
more closely related to B. pscudomallei, B. mallei
and B. gladioli than to P. aeruginosa and other
fluorescent pseudomonads, and was placed in the
separate subgroup, Pseudomonas RNA homology
group II. B. cepacia is nutritionally versatile, with
minimal growth requirements and the ability to
survive in unfavourable environments: it has been
isolated from disinfectants and antiseptics and
can even use penicillin G as a nutrient [8-11].
The organism is intrinsically resistant to most
antibiotics, and even if individual strains show in
vitro susceptibility to an antibiotic, there is little
clinical response [10,12-15],
In contrast to the large amount of information
on P. aeruginosa virulence factors, knowledge of
the virulence factors and pathogenesis of B. cepa¬
cia is scanty. Animal models have indicated that
B. cepacia is less virulent than P. aeruginosa [16].
The aim of this review is to discuss the main
features and properties of B. cepacia and, in
particular, to focus on those which may con¬
tribute to its ability to colonize patients with CF.
Colonization and adherence
The ability of a potential pathogen to adhere
to the host mucosal or epithelial cell surfaces is
often pivotal in the subsequent establishment of
infection. Few potential adhesins have been de¬
scribed for B. cepacia, and most attention to date
has been focused on the adhesive properties of
fimbriae.
Electron microscope studies have shown that
approximately 60% of B. cepacia strains express
peritrichous fimbriae (see Fig. 1) [17,58]. Other
B. cepacia strains possess polar fimbriae, similar
to those expressed by B. aeruginosa [18], Kuehn
et al. [17] showed that outer membrane protein
preparations of B. cepacia were enriched with 3
proteins (16, 20 and 40 kDa) which were not
present in a non-fimbriated strain. The fimbrial
subunit was identified as the 16 kDa protein; the
protein appeared similar to those seen in other
bacteria and showed homology with PAK fim¬
briae of P. aeruginosa [17]. This data contrasts
with that of Saiman et al. who found minimal
cross-reactivity with anti-P. aeruginosa anti-pilin
monoclonal antibodies and no homology between
P. aeruginosa pilin gene probes and B. cepacia
genomic DNA [18,19], It is possible that sequence
variation exists among the pilin genes of different
B. cepacia strains and that any individual pilin
gene probe from P. aeruginosa may not reveal a
specific B. cepacia gene [17].
The presence of fimbriae increases the ability
of B. cepacia to adhere to pneumocytes in vitro
[17], In vitro binding experiments by Kirvan et al.
[20] demonstrated that both B. cepacia and P.
aeruginosa adhere to the same Gal/31-4GalNAc
sequence present in many asialoglycolipids. The
experiments of Saiman et al. [19] did not demon¬
strate competition for epithelial receptors, indi¬
cating that different epithelial receptors may be
used preferentially by each of the Pseudomonas
species or that the bacteria may bind to each
other. Binding of 2 B. cepacia strains to epithelial
monolayers increased in the presence of P. aerug¬
inosa indicating a possible synergistic relationship
whereby P. aeruginosa exo-products modify ep¬
ithelial cell surfaces, exposing receptors and facil¬
itating increased B. cepacia attachment [19], It
must be stressed, however, that not all CF pa¬
tients are colonized with P. aeruginosa prior to
acquisition of B. cepacia: in the Edinburgh CF
clinic 38% of patients with B. cepacia are not
co-colonized with P. aeruginosa [6].
Sajjan et al. [21] were able to demonstrate
specific binding of B. cepacia isolates from pa¬
tients with CF to both CF and non-CF mucins as
well as to buccal epithelial cells. Unfortunately
no typing data was available to exclude the possi¬
bility of clonal relationships between the strains
[21], The degree of binding observed with B.
cepacia is considerably less than that observed
with P. aeruginosa [58]. Deglycosylation of mucin
indicated that the mucin receptors for B. cepacia
include N-acetylglucosamine and N-acetylgalac-
tosamine. Isolates exhibiting the highest mucin
binding values tended to correlate with those
patients with severe illness leading to speculation
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that variability in the binding of different B.
cepacia isolates to respiratory mucin may con¬
tribute to morbidity and mortality, and may ex¬
plain why some B. cepacia strains colonize pa¬
tients transiently whereas other strains, once ac¬
quired, are never lost. A sparsely distributed 22
kDa pilin-associated protein was identified as a
mucin binding adhesin specific to piliated strains
of B. cepacia [22].
Siderophores
Production of siderophores enables bacteria to
compete for iron with host iron-binding proteins
including transferrin and lactofcrrin and has been
correlated with the ability of various bacteria to
establish and maintain infection. B. cepacia
strains express at least 3 siderophorc-mediated
iron transport systems, including pyochelin,
cepabactin and azurechelin [23-26]. Pyochelin
produced by B. cepacia is chemically unrelated to
the pyochelin siderophore of P. aeruginosa [23,24],
A 14 kDa fcrripyochelin binding protein, present
in increased amounts in the outer membrane of
iron-starved B. cepacia cells, has also been de¬
scribed [23], Morbidity and mortality in infected
CF patients has been correlated to the produc¬
tion of pyochclin. Although such evidence may
point to a role in pathogenicity, half of the clini¬
cal isolates investigated by Sokol [23] were py-
ochelin-negative. Pyochelin may increase the abil¬
ity of B. cepacia to disseminate throughout the
lungs and perhaps induce a greater inflammatory
Fig. 1. Pseudomonas cepacia J135F) in the process of dividing into 2 separate cells which exhibit peritrichous pili. Staining is 2% w/vphosphotungstic acid. Magnification X 25000.
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response due to the increased area of infection in
the lung [27]. Exogenously supplied pyochclin en¬
hanced the virulence of non-pyochelin producing
B. cepacia strains in a chronic pulmonary model
in rats [27]. Meyer et al. [26] showed that B.
cepacia ATCC25416 excreted both pyochelin and
a lower molecular mass compound, cepabactin,
which strongly chelated Fe III and facilitated iron
translocation. Azurechelin. another distinct iron-
binding compound, has been identified in 88% of
B. cepacia strains isolated from the respiratory
tract [25].
Extracellular virulence factors
B. cepacia produces a number of extracellu¬
lar products including protease, gelatinase,
haemolysin and lipase, although no pathogenic
role for these factors has been demonstrated
[28,29]. Unlike P. aeruginosa, B. cepacia does not
appear to produce toxin A, exoenzyme S, or
other detectable extracellular factors capable of
producing a cytotoxic effect in vitro [28], In a
study of putative pathogenic factors of B. cepacia
[30] a number of characteristics were demon¬
strated more frequently in isolates from CF pa¬
tients than control isolates. These factors in¬
cluded production of catalase, ornithine decar¬
boxylase, valine aminopeptidase, C14 lipase, algi-
nase, and trypsin; reduction of nitrate to nitrite;
hydrolysis of urea and xanthine and complete
haemolysis on bovine red blood cells. The role of
any of these factors in respiratory colonization or
infection in CF patients is not clear [30]. Indeed,
an epidemic strain of B. cepacia CF5610 associ¬
ated with fatal clinical outcome in CF does not
produce C14 lipase or haemolysis [6].
Molecular studies of the Pseudomonas exo¬
toxin A gene by Vasil et al. [31] concluded that
the production of exotoxin A and the presence of
the exotoxin A gene are probably limited to P.
aeruginosa and is not found in other Pseu¬
domonas spp. Southern hybridization experi¬
ments under low, medium and high stringency
conditions with an exotoxin A gene probe failed
to produce a positive signal with any of 8 B.
cepacia strains tested. Similar experiments con¬
ducted by ourselves also failed to demonstrate
the presence of the exotoxin A gene in 3 environ¬
mental strains of B. cepacia although a positive
band was obtained with B. cepacia CF5610 strain
isolated from a patient with CF. However, growth
of this strain in both iron replete and depicted
medium and subsequent analysis of the cell free
culture supernate by polyacrylamide gel elec¬
trophoresis and immunoblot analysis with anti-P.
aeruginosa exotoxin A antisera, failed to confirm
production of a 66 kDa protein equivalent to P.
aeruginosa toxin A. (J.W. Nelson, unpublished
results).
The extracellular proteinase of B. cepacia, a
34 kDa protein, has antigenic similarities to P.
aeruginosa elastase and cleaves gelatin, hide pow¬
der, collagen but not human immunoglobulin IgG,
IgM, secretory IgA, or IgA [32], Intratracheal
instillation of purified proteinase into rat lungs
produces a bronchopneumonia characterized by
polymorphonuclear cell infiltration and proteina-
ceous exudation into large airways. Active immu¬
nization of rats with B. cepacia proteinase elicits
an immunological response although this is not
protective against subsequent lung infection with
B. cepacia [32],
There is also evidence that lipases, particularly
phospholipases, may play an important role in
bacterial virulence [33,34], Phosphoplipase C is
an enzyme that cleaves phosphatidylcholine, a
major lung surfactant, to yield phosphorylcholine
and diacylglycerol, and has been associated with
cytopathology of lung tissue. B. cepacia has fre¬
quently been described as being lipolytic [28,33—
35]. McKevitt and Woods [28] reported that 32 of
48 strains of B. cepacia isolated from CF patients
demonstrated lipase activity on egg-yolk agar
whilst Carson et al. [35] showed that B. cepacia
could hydrolyse Tween 20, 40, and 80. In another
study [34] 6 out of 10 clinical strains of B. cepacia
from the sputum of CF patients produced lecithi-
nase by the egg-yolk reaction, whilst lipase activ¬
ity on 4 different Tweens was strain-dependent.
Purified enzyme had a molecular weight of 25000
and was not cytotoxic for Hela cells or for mice
injected intravenously with purified lipase. It has
been reported, however, that lipase adversely af¬
fected the phagocytic function of rat pulmonary
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alveolar macrophages in a dose-dependent man¬
ner [36]. Phagocytosis of B. cepacia by rat pul¬
monary alveolar macrophages was significantlyreduced when the cells were either preincubated
with lipase or when phagocytosis occurred in the
presence of the lipase [36], Scanning electron
microscopy showed that the macrophages ex¬
posed to B. cepacia lipase had fewer pseudopo-dia, microvilli and other projections compared to
untreated macrophages. Thus B. cepacia lipase
may be an important virulence factor which al¬
lows the bacteria to evade the mammalian host
defence system.
B. cepacia produces a heat-labile haemolysinwhich has both phospholipase C and sphin¬
gomyelinase activities [37], Haemolytic and phos¬
pholipase C (lecithinase) expression in B. cepacia
appears to be a complex phenomena. The studyof Nakazawa et al. [29] found that only 4% of
clinical isolates were 0-haemolytic, whilst 67% of
isolates produced lecithinase. Others have found
higher percentages of haemolytic isolates of B.
cepacia if a variety of erythrocyte types were
tested, including a study of clinical isolates of B.
cepacia from CF patients which found that 40%
were haemolytic when erythrocytes from various
animals were tested [37]. Unlike the PLC activityof P. aeruginosa the PLC activity in B. cepaciadoes not correlate with haemolytic activity [29,37].
However, all haemolytic strains produce de¬
lectable lecithinase activity, and strains of B.
:epacia, whether haemolytic or non-haemolytic,
appear to produce detectable amounts of extra¬
cellular PLC activity. In contrast to the consistent
patterns observed in the PLC gene of P. aerugi¬
nosa there is hypervariability in genetic organiza-cion of the PLC gene of B. cepacia [37], The
ariable manner in which a B. cepacia PLC spe¬cific gene probe hybridizes with restricted B.
epacia DNA, the variability in expression of
aaemolytic and PLC activities of different strains,and the association of DNA arrangements with
conversion of an Hly + to an Hly - variant may« related to the relatively large number of dis-
inct insertion sequences (IS) reported for B.
tpacia (> 25) [37,38]: in contrast these elements
cave yet to be discovered in P. aeruginosa. Somef these IS elements of B. cepacia, can be found
in multiple copies and have been shown to bothactivate or inactivate gene expression.
Cell surface antigens
Lipopolysaccharide
B. cepacia strains isolated from patients withCF may express either the rough (R) or smooth(S) lipopolysaccharide (LPS) phenotype, whereasthe majority of B. cepacia strains isolated fromother clinical conditions or from the environment
express S-LPS (S.L. Butler, unpublished results).This is in agreement with the study of McKevittand Woods [28] where 22 strains examined pos¬sessed S-LPS and 26 strains possessed R-LPS.The epidemic strain of B. cepacia isolated from a
number of CF patients in the UK invariably has aR-LPS phenotype and is associated with the ap¬
pearance of dry colonies [6], There is no evidence
to date to confirm that B. cepacia strains undergo
a phenotypic change from S to R LPS within the
CF lung as is observed with P. aeruginosa.
Western blotting and absorption studies
demonstrated that a significant proportion of
serum antibodies from B. cepacia-infected CF
patients which reacted with the core LPS of B.
cepacia did not react with the core LPS of P.
aeruginosa [39]. These observations indicate dif¬
ferences in the structure and composition of core
LPS between B. cepacia and P. aeruginosa con¬
firming previous findings, including the lack of
phosphorus in the core of B. cepacia LPS [40]and the inability of a monoclonal antibody reac¬tive with P. aeruginosa and P. fluorescens coreLPS to react with B. cepacia [41]. Core hetero¬
geneity between different isolates of B. cepacia
may also exist because immunoblotting demon¬
strated that serum from patients colonized with
B. cepacia produced a band reactive with some
but not all core LPS preparations [39].
Initial chemical analysis of B. cepacia LPSindicated the absence of detectable 3-deoxy-D-
manno-2-octulosonic acid (KDO) in LPS from B.
cepacia [42,43], However, Straus et al. [44] re¬
ported the isolation of KDO from the culture
supernate of 2 out of 10 strains of B. cepacia and
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in a further study KDO was demonstrated in 6
clinical isolates of B. cepacia and all 6 LPS
preparations were equally toxic for mice when
injected intraperitoneally [45]. Compared with
LPS from P. aeruginosa that from strains of B.
cepacia has less phosphorus and more heptose.
Glucose and rhamnose were the major saccharide
components of LPS from the organisms tested
[42], An extracellular material isolated from a
clinical B. cepacia consisted of a surface carbohy¬
drate antigen, LPS and protein, the toxicity of
which appeared to be associated with the LPS
portion of the complex [46], It has been proposed
that this extracellular toxic complex produced by
B. cepacia is responsible for the lethality and
extensive pulmonary tissue necrosis associated
with pneumonia produced by this organism.
Outer membrane proteins
B. cepacia produces 5 major outer membrane
proteins A (56 kDa), B (38 kDa), C (37 kDa), D
(28 kDa) and E (21 kDa). The C and D proteins
have been identified as porin proteins [47,48],
and appear to be antigenic in most patients with
CF who are chronically colonized with B. cepacia
[48,49]. In the study of Anwar et al. [55], outer
membrane protein profiles of magnesium-de¬
pleted cells were much simpler than that of iron-
depleted cells and nutrient broth grown cells.
Synthesis of a 66 kDa outer membrane protein
was induced when B. cepacia was grown under
iron depletion. B. cepacia isolates from individual
CF patients may exhibit marked phenotypic vari¬
ability, including manifestation of different pat¬
terns of outer membrane proteins separated on a
polyacrylamide gel: up to 5 OMP patterns have
been identified from B. cepacia isolates derived
from a single strain [50],
Various studies indicate that the outer mem¬
brane of B. cepacia is a major contributing factor
in the /3-lactam resistance of this species, retard¬
ing the diffusion of /3-lactams to their penicillin-
binding protein targets [47,51,52]. Resistance to
aminoglycosides and hydrophobic compounds in
B. cepacia is largely due to the low outer mem¬
brane permeability [51], Loss of the major porin
protein D and decreased expression of protein C
may also be associated with high level /3-lactam
resistance in some CF isolates of B. cepacia [52],
Production of /3-lactamases, including carbape-
nases capable of hydrolyzing the most potent and
broad spectrum of the /Llactam antibiotics
imipenem and meropenem, also contribute signif¬
icantly to the resistance of B. cepacia [53],
Exopolysaccharide
Production of alginate by mucoid strains of P.
aeruginosa is the major virulence determinant
associated with strains which colonize the lungs
of patients with CF. In contrast, B. cepacia does
not appear to produce alginate. PCR studies with
primers of the P. aeruginosa alg D gene, encoding
the essential enzyme GDP mannose dehydroge¬
nase, indicate that this gene was absent in 10 B.
cepacia strains studied and therefore that B.
cepacia is unlikely to produce an alginate-like
polymer (J.W. Nelson, unpublished results). Ad¬
ditional studies in our laboratory and by Sage et
al. [54] showed that some B. cepacia strains do
produce an exopolysaccharide comprising galac¬
tose, glucose, mannose, glucuronic acid and
rhamnose, with lesser amounts of uronic acid: no
mannuronic or guluronic acid was detected. Sur¬
veys of clinical isolates from patients with CF
indicate that there is no correlation between the
ability of B. cepacia to colonize the respiratory
tract and capacity to form exopolysaccharide
[6,54], In contrast, Straus et al. [46] observed that
1 strain of B. cepacia produced an alginate-like
compound containing 72% guluronic acid with
1.75% acetylation.
Evasion of the immune system
Immunological studies on B. cepacia coloniza¬
tion of patients with CF indicate that the organ¬
ism persists despite a considerable antibody re¬
sponse and suggest the possibility of immune-
mediated damage. Aronoff et al. [48,49] demon¬
strated the presence of IgG antibodies to outer
membrane antigens of B. cepacia in serum from
patients with CF colonized with B. cepacia and/
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or P. aeruginosa. These authors concluded that
some B. cepacia outer membrane components
may be antigenically related to those of P. aerugi¬
nosa and that colonization with B. cepacia occurs
in the presence of antibodies specific for the
outer membrane of the organism. Scrum IgG and
sputum IgA antibodies directed towards the core
LPS of B. cepacia have also been described [39],
Investigations into the bactericidal effect of
human serum have shown a large variation in the
responses of the B. cepacia strains investigated.
All strains expressing R-LPS were serum-sensi¬
tive under a variety of test conditions whilst strains
expressing S-LPS exhibit a range of responses
(S.L. Butler, unpublished results). Anwar et al.
[55] showed that a B. cepacia strain grown in
different nutrient depletions in batch culture
showed varying degrees of sensitivity to engulf-
ment and killing by human polymorphonuclear
leucocytes (PMN) and to killing by human serum.
The wide range of sensitivity shown by the organ¬
ism may reflect the phenotypic variation in cell
envelope composition caused by specific nutrient
depletions. Patients with chronic granulomatous
disease (GCD) are at particular risk of infection
with B. cepacia, which is able to resist
neutrophil-mediated non-oxidative bactericidal
killing (D.P. Speert, personal communication).
The ability of B. cepacia to survive a pronounced
humoral response and other immunological de¬
fences is intriguing and requires further investiga¬
tion. Indeed there is a suggestion that B. cepacia
may invade and survive within respiratory epithe¬
lial cells, enabling the organism to persist within
the CF lung [56],
Concluding remarks
Acquisition of B. cepacia is a major concern
among patients with CF although the exact
pathophysiological role of the organism remains
controversial and unsolved. Epidemiological data
and the use of phenotypic and gcnotypic typing
systems for B. cepacia suggest that certain strains
are particularly transmissible, although there is
no evidence at present that some strains are more
virulent. The role of any of the described viru¬
lence factors of B. cepacia relating to its patho¬
genesis in patients with CF remains unclear. En¬
hanced adhesion to mucin of certain B. cepacia
strains may aid initial colonization whilst multi-
resistance to antibiotics and possible intracellular
localization may contribute to persistence of the
organism. Production of anti-B. cepacia antibod¬
ies by the host and subsequent immune complex
mediated damage, is probably responsible for
pulmonary decline. The development of a CF
mouse model carrying precise and clinically rele¬
vant mutations [57] will allow in vivo investigation
of B. cepacia colonisation and virulence factors.
Current concern over B. cepacia colonisation
amongst CF patients has highlighted the urgent
need to identify B. cepacia colonising factors and
the pathophysiological and/or immunological
factors which account for the rapid clinical dete¬
rioration in some CF patients.
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Serum IgG and sputum IgA antibody to core
lipopolysaccharide antigen from Pseudomonas cepacia in
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Summary. The immunological response of cystic fibrosis (CF) patients to lipopolysaccharide
(LPS) antigens of Pseudomonas cepacia was investigated. Enzyme-linked immunosorbent
assays (ELISA) with either P. cepacia whole cells or extracted core LPS from a clinical isolate
of P. cepacia as antigen were used to measure serum IgG and sputum IgA anti-P. cepacia
antibodies. The ELISA with core LPS distinguished nine CF patients colonised by P. cepacia
from nine age- and sex-matched non-colonised CF patients. The rate of increase of anti-P.
cepacia IgG antibodies after bacteriologically proven P. cepacia colonisation varied in
individual patients: in some patients the first isolation of P. cepacia was preceded or
accompanied by a two-to-four-fold rise in anti-P. cepacia LPS IgG titres. Absorption studies
and immunoblot analysis of serum from patients colonised with P. cepacia demonstrated that
a significant component of the anti-P. cepacia core LPS antibodies was specific for P. cepacia
and did not react with the core LPS of P. aeruginosa. Immunoblotting also illustrated that
theremay be a degree of core heterogeneity between different isolates of P. cepacia. Detection
of P. cepacia LPS specific antibodies in serum (IgG) and sputum (IgA) from CF patients is
recommended to assist the identification of P. cepacia colonisation in CF patients.
Introduction
Pseudomonas cepacia is a major pulmonary patho¬
gen in patients with cystic fibrosis (CF).1-3 Originally
considered a phytopathogen, the organism has been
isolated with increasing frequency from patients with
CF3"8 and is also recognised as an important aetio-
logical agent in nosocomial infection.7,8 The pos¬
session of innate and inducible resistance to many
anti-pseudomonal antibiotics9,10 and the ability to
survive under conditions ofminimal nutrition or in the
presence of certain disinfectants contribute to the role
of P. cepacia as a formidable nosocomial pathogen.8,9
Prevention and treatment of pulmonary infections due
to P. cepacia present a major challenge. The as¬
sociation of P. cepacia with the CF lung is complex,
and clinical sequelae include rapidly fatal deterioration
of pulmonary function, long term colonisation ac¬
companied by a slow decline in lung function, and
chronic asymptomatic carriage.11
Although the humoral response ofCF patients to P.
aeruginosa antigens has been investigated extensively,12
there are relatively few reports defining the response to
P. cepacia antigens.13"14 The aim of this study was to
investigate the antibody response of CF patients to P.
cepacia whole-cell and extracted lipopolysaccharide
Received 7 Oct. 1992; accepted 1 Dec. 1992.
(LPS) antigens. The extent to which antibodies cross-




Nine patients (five female and four male, mean age
21-6 years, range 16-27 years) attending the Edinburgh
adult CF clinic, were identified as being persistently
colonised by P. cepacia (PC +) by serial bacteriological
sputum cultures (at least three consecutive samples
positive). For each patient an age- and sex-matched
CF control was selected from whom P. cepacia had
never been isolated (PC — ).
Serum and sputum samples
Serum samples were obtained from CF patients and
from healthy blood donors at the Blood Transfusion
Centre, Edinburgh; all were stored at — 20°C. Sputum
used for antibody analysis was centrifuged at 10000 g
for 15min and the supernate was stored at — 70°C.
Control sputum samples obtained from patients with
chronic bronchitis were processed as for CF samples.
Whenever possible, sputum and serum were obtained
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Fig. 1. Serum IgG anti-P. cepacia core R-LPS antibodies in (A) nine CF patients persistently colonised with P. cepacia (titre range
3200-51200), (B) nine non-colonised CF patients (titre range 200-3200) and (C) nine healthy controls (titre range 200-800) measured by
EL1SA with core R-LPS as coating antigen; bars represent median values. Antibody titres for the PC+ CF patients were from serum samples
obtained after colonisation with P. cepacia was confirmed by bacteriological culture.
from CF patients at the same time. Specimens from
PC + and PC — CF patients, including those with and
without P. aeruginosa colonisation, were subjected to
detailed immunological analysis; these patients were
designated I-IX (see Results).
Bacteriological analysis of sputum
Bacteriological examination was performed on
sputum which had been homogenised in sputalysin
(Calbiochem, La Jolla, CA, USA). After appropriate
dilutions, sputum was cultured quantitatively on blood
agar, horse digest agar, Pseudomonas Isolation Agar
(Difco), and P. cepacia Selective Medium (Mast
Laboratories, Bootle). Bacteria cultured on P. cepacia
selective medium were identified biochemically by the
AP1 20 NE system (API System, La Balme les Grottes,
France).
Bacterial strains
P. cepacia reference strains J1780 (serotype 1), J1680
(serotype 2), J1705 (serotype 3), J1774 (serotype 4),
J1479 (serotype 5), J1772 (serotype 6), J1690 (serotype
7), J1687 (serotype 8), J1758 (serotype 9) and J1745
(non-typable) were obtained from the Centers for
Communicable Disease Control (Atlanta, GA, USA).
The serotype was based on the serotyping scheme
proposed by Heidt et a/.15 P. cepacia strains J1359
(non-typable), SBC21 (non-typable), SBC42 and
SBC29 were isolated from the sputum of CF patients.
P. cepacia SBC8 was an environmental strain isolated
from a plant. Serotyping sera were unavailable for the
typing of strains SBC42, SBC29 and SBC8, but these
were confirmed as distinct strains by ribotyping.16 P.
aeruginosa R-mutant PAC608, defective in the pro¬
duction of LPS, was obtained from Professor P. M.
Meadow (University College, London).
Preparation ofLPS
The aqueous phenol, chloroform, petroleum ether
method of Galanos et al}~ incorporating the diethyl
ether precipitation of LPS described by Qureshi et al.ls
(as described by Hancock and Poxton19) was used to
prepare LPS from P. cepacia strains expressing R-
form LPS. Briefly, LPS was extracted from washed,
freeze-dried bacteria from an overnight culture,
washed and purified by centrifugation at 100000 g for
4 h and freeze-dried. The proteinase K digestion
method'20 was also used to prepare LPS for analysis by
polyacrylamide gel electrophoresis (PAGE) and
immunoblotting.
SDS-PAGE and immunoblotting
LPS was separated on polyacrylamide 14% gels
with the buffer system of Laemmli21 (except that















Fig. 2. Sputum IgA anti-P. cepacia core R-LPS antibodies in (A) nine CF patients persistently colonised with P. cepacia (titre range 200-6400),
(B) nine non-colonised CF patients (titre range 25-100) and (C) nine chronic bronchitics (titre range 25^400) measured by ELISA with core
R-LPS as coating antigen; bars represent median values. Antibody titres for the PC+ CF patients were from sputum samples obtained after
colonisation with P. cepacia was confirmed by bacteriological culture.
sodium dodecyl sulphate was omitted from the stack¬
ing and separating gel buffers in gels used for immuno-
blotting). The LPS separating gels were stained with
silver by the method of Tsai and Frasch.22 For
immunoblotting, separated antigens were transferred
to nitrocellulose membranes (pore size 0-2 /tm,
Schleicher and Schuell, Dassel, Germany) by the
method of Towbin et al.23 Antigens were probed with
serum diluted 1 in 200 and sputum diluted 1 in 100 for
3 h at room temperature, and the immune complexes
were detected with anti-human IgG and IgA horse¬
radish peroxidase conjugates (ICN Biomedicals Ltd,
High Wycombe) and HRP colour development re¬
agent (BioRad Laboratories, Richmond, USA).
Enzyme-linked immunosorbent assay (ELISA)
Antigens used for coating microtitration plates
were: (a) P. cepacia whole cells, serotypes 1-9 and a
non-typable strain; and (b) extracted LPS from a
rough isolate, P. cepacia J1359. For the whole-cell
assay, bacteria were grown overnight in nutrient broth
containing yeast extract 0-5% w/v (NYB), harvested
and washed twice with PBS. Cells were resuspended to
a density of 107 cells/ml in carbonate-bicarbonate
coating buffer (pH 9-6) and 100 p\ was added to the
wells of polystyrene "Polysorb" microtitration plates
(Nunc, Roskilde, Denmark). Plates were centrifuged
at 1365 g for 5 min to sediment bacteria on to the wells.
In the case of the LPS antigen, extracted LPS was
complexed with polymyxin as described by Scott and
Barclay24 and used at a final concentration of
10 ng/ml. LPS-polymyxin complexes were diluted in
coating buffer and added to microtitration plates at
100 pi/well. All plates were coated overnight at room
temperature and washed four times with wash buffer
(PBS, pH 7-2, containing Tween 20 0 05% w/v and
sodium azide 0-02% w/v). All plates were then post-
coated with post-coat buffer consisting of PBS con¬
taining bovine serum albumin (BSA) 5% w/v, at
100 /d/well. After being washed four times with wash
buffer, plates were stored at — 20°C until used.
Serum and sputum samples were serially diluted in
dilution buffer and added to coated microtitration
plates at 100 /d/well in triplicate. Antibody diluent
consisted of PBS (pH 7-2) containing Tween 20 0-05 %
v/v, BSA 0-5% w/v, polyethylene glycol 6000 4%
w/v and sodium azide 0-002% w/v. After incubation
at 37°C for 90 min, plates were washed four times with
wash buffer. Conjugates, including alkaline phosphat¬
ase conjugated to anti-human IgG or anti-human
IgA (Sigma) were diluted 1 in 1000 in dilution buffer
and added at 100 /d/well. Plates were incubated for a
further 90 min at 37°C and then washed and rinsed
before addition of alkaline phosphatase substrate
(Sigma) at 100 /d/well. After incubation for 30 min at
room temperature, the optical density (OD) of wells
was read at 405 nm in a Titertek Multiscan plate
reader (Flow Laboratories Ltd, Irvine). Final results
were expressed as the titre giving an OD >01 after
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Fig. 3. Longitudinal study of serum IgG anti-P. cepacia LPS antibodies in eight CF patients measured by ELISA with core R-LPS as coating
antigen. Patients I (a.—•—) III (a, —X—) IV (a, —G—) and V (b,—•—) were colonised by P. cepacia only; patients II (a, —I—), VI (b,
—I—) and VII (b, —^—) were colonised by both P. cepacia and P. aeruginosa; patient VIII (b,—G—) was colonised by P. aeruginosa only.
The arrows indicate the time when P. cepacia was first isolated from sputum from each patient.
subtraction of the OD of negative controls (wells
coated only with post-coat buffer) for each sample.
Analytical variation of the ELISA, including intra-
plate and day-to-day (inter-plate) variations, was
performed with six serum samples (three determin¬
ations for each), two each with low, medium and high
ELISA titres, and the coefficient of variation was
calculated. The intra- and inter-plate variations of the
ELISA were 5-5% and 13-9%, respectively.
Absorption studies
Serum from CF patients was serially absorbed with
whole cells of P. cepacia J1359 and P. aeruginosa
PAC608. Overnight cultures of bacteria grown in
NYB were harvested by centrifugation, washed twice
in PBS and resuspended to a density of 108 cells/ml.
Bacterial suspensions (1 ml) were placed in Eppendorf
tubes and cells were harvested by centrifugation with a
microcentrifuge. Bacteria were resuspended in serum
diluted 1 in 200 in dilution buffer, incubated for 15 min
at room temperature and re-centrifuged. The super-
nate was then added to another pellet of cells and the
process was repeated. This step was repeated three
times for each absorbing bacterial strain. Serum anti-
P. cepacia and anti-P. aeruginosa core LPS antibodies
were assayed by ELISA and immunoblotting as
described above.
Statistical analysis
Data were not normally distributed and statistical
analysis was by Wilcoxon signed rank tests.
Results
Whole cell ELISA
IgG antibodies directed to P. cepacia whole-cell
antigens were detected in serum from both PC + and
PC — CF patients. A response to each of the serotype
strains was evident although the difference in antibody
titres between PC+ and PC — patients was significant
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Fig. 4. Immunoblots of P. cepacia LPS antigens with serum from two CF patients colonised with P. cepacia and analysed for IgG anti-LPS
antibodies; (a) serum from patient III, (b) serum from patient VII. The P. cepacia LPS antigens preparations were: lane 1. J1780 (serotype
1); 2, J1680 (serotype 2); 3, J1774 (serotype 4); 4, J1690 (serotype 7); 5, J1758 (serotype 9); 6, J1359 (non-typable); 7, SBC21 (non-typable);
8, SBC42; 9, SBC29; 10, SBC8. (c) Silver stained PAGE of isolated core LPS from P. cepacia J1359.
Fig. 5. Immunoblot of P. cepacia LPS antigens with sputum from CF patient III colonised with P. cepacia and analysed for IgA anti-LPS
antibodies. P. cepacia LPS antigens were as in fig. 4.
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Fig. 6. Serum IgG anti-F. cepacia and anti-P. aeruginosa LPS antibodies in CF patients measured by ELISA with (a) core R-LPS from P.
cepacia J1359 and (b) core R-LPS from P. aeruginosa PAC608 as coating antigens before (■) and after absorption with P. cepacia J1359 (0)
and P. aeruginosa (□) whole cells. Patients I, III, IV and V were colonised by P. cepacia only; patients II, VI and VII were colonised by both
P. cepacia and P. aeruginosa; patient VIII was colonised by P. aeruginosa only; patient IX was not colonised by either organism.
only in the case of serotype 5 and the non-typable
whole cells (p < 0-05).
Core R-LPS ELISA
Serum IgG and sputum IgA antibodies. The ELISA
employing extracted LPS from an isolate expressing
core R-LPS was better than the whole-cell ELISA in
discriminating between PC + and PC — patients (fig.
1). In nine CF patients persistently sputum-positive
for P. cepacia, IgG titres were significantly higher
(median 12800, range 3200-51200) than in nine age-
and sex-matched CF PC— controls (median 400,
range 200-3200) (p < 0-01 Wilcoxon signed rank test),
and in nine healthy blood donors (median 400, range
200-800). There was no significant difference in the
IgG titres between the PC— CF patients and the
healthy blood donors. Seven ofnine PC — CF controls
were colonised by P. aeruginosa and six of nine PC +
CF patients were colonised by P. aeruginosa.
The nine PC + CF patients also had significantly
higher titres of sputum IgA antibodies reactive with
core LPS of P. cepacia (median 1600, range 200-6400)
than did the nine PC— patients (median 50, range
25-100) and nine chronic bronchitics (median 50,
range 25-400) (p < 0-01 Wilcoxon signed rank test);
there was no significant difference between the titres of
the non-colonised CF patients and the chronic
bronchitics (fig. 2). None of the chronic bronchitic
patients was colonised by P. cepacia.
Longitudinal analysis of serum IgG and sputum IgA.
Longitudinal analysis of CF serum samples indicated
that the rate of increase in the levels of anti-P. cepacia
IgG antibodies after bacteriological diagnosis of P.
cepacia colonisation varied from patient to patient; in
some cases (e.g., patients III, IV, VI and VII) the first
isolation of P. cepacia was preceded or accompanied
by a two-to-four-fold rise in anti-P. cepacia R-LPS
IgG titre (fig. 3).
Longitudinal analysis of sputum IgA titres from five
CF patients, four of whom were colonised by P.
cepacia, demonstrated the variable IgA antibody
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Fig. 7. Immunoblot of (a) anti-P. cepacia and (b) anti-P. aeruginosa core LPS IgG antibodies in serum from five CF patients before and after
absorption with P. cepacia J1359 or P. aeruginosa PAC608, or both, whole cells. Lanes l, 5. 9, 13 and 17, unabsorbed serum samples; lanes
2, 6, 10. 14 and 18; serum samples absorbed with P. cepacia J1359 whole cells; lanes 3, 7, 11 and 19 serum samples; absorbed with P. aeruginosa
PAC608 whole cells; lanes 4, 8, 12, 16 and 20, serum samples absorbed with both P. cepacia J1359 and P. aeruginosa PAC608 whole cells.
Patients I (lanes 1—4) and IV (13-16) were colonised by P. cepacia only; patients II (lanes 5-8) and III (9-12) were colonised by P. cepacia
and P. aeruginosas and patient VIII (lanes 17-20) was colonised by P. aeruginosa only.
response to core R-LPS of P. cepacia. During a 10-
week study period, the sputum IgA antibody titre
ranged from 400 to 6400 for two of the PC+ CF
patients, and from 800 to 3200 for a third PC +
patient. In a fourth PC+ patient, the IgA antibody
titre was maintained at 100-200, which was similar to
that of the PC — patient included in the study. There
was no correlation between the sputum IgA antibody
titre and the number of P. cepacia isolated by
bacteriological culture from sputum, but there was a
tendency for IgA levels to rise during hospitalisation
for pulmonary exacerbations.
Immunoblot analyses
Isolated core LPS from P. cepacia J1359 is shown
in the silver-stained PAGE gel (fig. 4c). Reactivity of
serum from two PC + CF patients against P. cepacia
LPS antigens is shown in the Western blots (fig. 4a and
b). In both cases, a positive reactive band corre¬
sponding to the low mol. wt core LPS ofmost but not
all of the P. cepacia isolates was observed: reactivity
with nine and six of the 10 core LPS antigens was
observed with serum from patients III and VII,
respectively (fig. 4a and b). In addition, a response
corresponding to higher mol. wt O-antigen subunits of
LPS from strains SBC42, SBC29 and SBC8 was noted.
The serum used for the preparation shown in fig. 4a
was obtained from a CF patient colonised with strain
JI359 (ribotype A); the serum for the preparation
shown in fig. 4b was obtained from a CF patient
colonised with strains J1359 (ribotype A) and SBC42
(ribotype C). Immunoblot analysis of serum from two
PC — CF patients, one ofwhom was colonised with P.
aeruginosa, did not produce a visible response to any
of the P. cepacia LPS antigens used.
Sputum from the same PC+ CF patient whose
serum was used for fig. 4a was used for immunoblot
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analysis of IgA antibodies reactive with P. cepacia LPS
antigens (fig. 5). A strong response to the core LPS of
strain J1359 and a weak response to the O-antigen
subunits of strain SBC8 was observed.
Absorption studies
Serum from CF patients colonised with P. cepacia
or P. aeruginosa, or both or neither, was absorbed
with whole cells from P. cepacia strain J1359 and P.
aeruginosa strain PAC608 and analysed by ELISA (fig.
6) and immunoblotting (fig. 7). With serum from PC +
CF (patients I-VII, fig. 6) antibodies reactive with P.
cepacia core LPS were substantially removed after
absorption with the corresponding P. cepacia whole
cells, but not after absorption with P. aeruginosa whole
cells. Serum from patients colonised with P. aeruginosa
(patients II, VI, VII and VIII, fig. 6) had a relatively
high antibody titre to P. aeruginosa core LPS; these
antibodies were removed by absorption with P.
aeruginosa whole cells but not by absorption with P.
cepacia whole cells. These absorption studies
demonstrated that a significant component of the anti-
P. cepacia core LPS antibodies was specific for P.
cepacia and not reactive with core LPS from P.
aeruginosa; e.g., patient I, colonised by P. cepacia but
not by P. aeruginosa, had a serum IgG titre of 51200
against P. cepacia core LPS and a titre of 200 against
P. aeruginosa core LPS. The antibodies against P.
cepacia core LPS were removed by absorption with P.
cepacia whole cells but not by the P. aeruginosa whole
cells as shown by ELISA (fig. 6) and immunoblotting
(fig. 7). Conversely, serum from a CF patient colonised
by P. aeruginosa but not by P. cepacia (patient VIII)
reacted with P. aeruginosa core LPS but not with P.
cepacia core LPS.
Discussion
Antibodies reactive with P. cepacia whole cells and
extracted core R-LPS were demonstrated in serum and
sputum from patients with CF. A core LPS prep¬
aration was used as a coating antigen because (a) LPS
represents a more defined antigenic preparation than a
system based on whole cells; (b) available evidence
suggests antigenic cross-reactivity between some
outer-membrane protein antigens of P. cepacia and P.
aeruginosa',1314 (c) core LPS is believed to be a
relatively conserved component of LPS25 and, there¬
fore, provides a suitable antigen for the detection of an
antibody response against all serotypes of P. cepacia',
and (d) many strains of P. cepacia isolated from CF
patients produce rough LPS (i.e., lacking O-specific
side-chains)26 (S. Butler, unpublished observations).
The ELISA system based on core R-LPS from a CF
clinical isolate of P. cepacia clearly differentiated
between serum samples from PC+ and PC— CF
patients. However, figs. 1 and 2 showed that a range of
serum IgG and sputum IgA antibody titres were
obtained with serum from both PC + and PC — CF
patients and it is possible that overlap between the two
groups could occur. Thus, detection of a rising
antibody titre between two or more serum samples
would appear desirable. Indeed, in the longitudinal
studies a rise in the level of anti-P. cepacia IgG
antibodies was demonstrated in some patients before
or accompanying the first isolation of P. cepacia. An
ELISA based on core R-LPS from P. aeruginosa has
also been reported to be useful for the diagnosis of
chronic P. aeruginosa infection in CF.27
Measurement of anti-P. cepacia antibodies to
identify P. cepacia colonisation may prove useful.
Although the value of selective media for P. cepacia is
well recognised,1'6 problems may still be encountered,
including growth of Xanthomonas maltophilia and P.
acidovoransi, and the fact that some clinical isolates of
P. cepacia, on initial isolation from sputum, may take
up to 7 days to grow. In view of the considerable
concern relating to pulmonary colonisation of CF
patients by P. cepacia,4-5'28 the ability to identify P.
cepacia colonisation early and accurately is important,
especially in clinics where segregation of colonised and
non-colonised patients is practised.
Recent studies13'14 have demonstrated the presence
of IgG antibodies to outer-membrane antigens of P.
cepacia in serum from CF patients colonised with P.
cepacia or P. aeruginosa or both. These authors
concluded that some P. cepacia outer-membrane
components may be related antigenically to those of P.
aeruginosa. Similarly, in our study, serum antibodies
reactive with P. cepacia whole cells were found in CF
patients colonised with P. cepacia or P. aeruginosa or
both. In terms of LPS antigens however, the Western
blotting and absorption studies demonstrated that a
significant proportion of the antibodies that reacted
with core LPS of P. cepacia did not react with core
LPS of P. aeruginosa. These observations indicate
differences in the structure and composition of core
LPS between P. aeruginosa and P. cepacia, confirming
previous findings, including structural differences29
(e.g., the lack of phosphorus in the core LPS of P.
cepacia and the inability of a monoclonal antibody
reactive with P. aeruginosa core LPS to react with P.
cepacia30). Furthermore, there is unlikely to be cross-
reactivity with core LPS of X. maltophilia because of
the structural differences reported by Neal and
Wilkinson.30 There may be some core heterogeneity
between different isolates of P. cepacia because West¬
ern blotting demonstrated that serum from patients
colonised with P. cepacia produced a band reactive
with some but not all P. cepacia core LPS preparations.
Although anti-core IgA antibodies were
demonstrated in sputum from chronically colonised
patients, the levels of these antibodies may have been
underestimated because of the possibility of immune-
complex formation and fragmentation of antibody by
elastases derived from neutrophils or P.
90 QQ
aeruginosa. '
Our data suggest that, in CF patients colonised by
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P. cepacia, antibodies reactive with P. cepacia are
unable to eliminate the organism from the lungs.
Indeed, this study and those ofAronoff et a/.1314 have
shown that P. cepacia colonisation occurs in the
presence of antibodies specific for outer-membrane
components of the organism. However, a relatively
high titre of IgG antibodies against P. cepacia was
observed in one of the PC— patients from whom P.
cepacia has never been isolated despite contact with
members of the PC-F group. It is interesting to
speculate on the possible protective effect of antibodies
in a subset of PC— CF patients.
Measurement ofanti-P. cepacia antibodies currently
forms part of a prospective longitudinal study on a
larger number of CF patients from different regional
centres. Such investigation will provide important
information regarding the diagnostic applicability and
usefulness of the antibody assay for detection of P.
cepacia in patients with CF.
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Human hydatid disease: evaluation of an ELISA for
diagnosis, population screening and monitoring of control
programmes
ANNE H. B. BIFFIN, M. A. JONES* and S. R. PALMER
PHLS Communicable Disease Surveillance Centre (Welsh Unit), Abton House, Wedal Road, Roath, Cardiff CF4 3QX
and * Cardiff Public Health Laboratory, University Hospital of Wales, Heath Park, Cardiff CF4 4XW
Summary. The routine use of ELISA and complement fixation tests in the diagnosis of
suspected clinical cases of hydatid disease was evaluated. In the ELISA test, dialysed and
filtered sheep cyst fluid was used as antigen and two positive cut-off points I-3SD and
+ 2SD of the mean absorbance values of the control sera—were evaluated. The predictive
values of ELISA tests were 82 % and 90 % for positive tests, and 86 % and 82 % for negative
tests, respectively with the two cut-off points. In a population survey of blood donors and
veterinary workers in Powys, 4% and 8%, respectively, had ELISA values above the lower
cut-off point. However, it would not be appropriate to use the same test for diagnostic
population screening in Wales since the predictive value of the test is likely to be very low in
this setting. Serological surveys with the ELISA may be of use in monitoring the progress of
the South Powys Hydatid Control Programme. The use of cumulative percentages was found
to be a useful method of comparing whole distributions of results in different populations.
Introduction
Hydatid disease in man is caused principally by
infection with the larval stage of the dog tapeworm
Echinococcus granulosus. It is acquired by ingestion of
the eggs of the tapeworm which are excreted in the
faeces of infected dogs. In the UK, the intermediate
host for Echinococcus granulosus is sheep, and the
sheep farming areas of Mid-Wales and Herefordshire
have the highest incidence of hydatid disease in the
UK.1 Serological tests developed for routine use in the
diagnosis of human infection include an enzyme-
linked immunosorbent assay (ELISA) and comple¬
ment fixation tests (CFT).2-4 In this study, the use of
these methods for the diagnosis of clinically suspected
cases was evaluated. The value of the ELISA test for
monitoring the population prevalence of infection in






Hydatid antigen was obtained from hydatid cyst
fluid aspirated from fertile sheep cysts, dialysed and
filtered through a 0-45-^m acetate membrane.6-7 The
filtered dialysate was stored in small volumes at — 20°C
for use in both ELISA and CFT tests.
Received 23 Sept. 1992; accepted 2 Dec. 1992.
ELISA. An indirect ELISA was performed by a
modification of the method described by McLaren
et al.s The antigen was diluted to its optimum con¬
centration (1 in 500) in carbonate buffer, pH 9 6, and
150 p\ was placed in each well of amicrotitration plate.
After overnight incubation in a moist chamber at
room temperature, the plates were washed four times
in phosphate-buffered saline (PBS), pH 7-2, containing
Tween 20 0-05 % to remove excess antigen before use.
Test serum samples and control sera (150 p\ of each)
diluted 1 in 200 in PBS-Tween were added to duplicate
wells. The standard positive control, similarly diluted,
was added to four wells on each plate. The plates were
incubated for 2 h in a moist chamber at room
temperature and washed with PBS-Tween.
Rabbit anti-human IgG peroxidase conjugate
(Dako) was diluted to its optimum concentration (1 in
7000) in PBS-Tween and 150 p\ was added to all wells
of the tray. The tray was incubated for 3 h at room
temperature in a moist chamber, then washed in PBS-
Tween.
The reporter substrate—orthophenylene diamine
(OPD 0-01%; 150/d)—was added to each well im¬
mediately after preparation and the plates were in¬
cubated in a moist chamber at room temperature. The
reaction was stopped in one of the standard control
wells at intervals to enable the rate of reaction to be
monitored. The reaction was stopped by the addition
of 25 p\ of 2-5 M H,S04 to all wells when the standard
positive control had attained an absorbance value o:
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